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“I may not have gone where I intended to go, but I think I’ve ended up where I 











“For a scientist must indeed be freely imaginative and yet skeptical, creative and yet 
a critic. There is a sense in which he must be free, but another in which his thought 
must be very precisely regimented; there is poetry in science, but also a lot of 
bookkeeping.” 
 
Peter B. Medawar 
The Strange Case of the Spotted Mice: And Other Classic Essays on Science
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Neuroblastoma is a cancer of early childhood and the most frequently 
diagnosed malignancy in the first year of life. Tumors can arise anywhere in the 
sympathetic nervous system, predominantly in the adrenal medulla, and metastatic 
disease is detected in approximately 50% of patients at diagnosis. Neuroblastoma is a 
biologically and clinically heterogeneous disease ranging from spontaneously 
regressing to highly aggressive therapy-resistant tumors. Despite intensive 
multimodal therapy, 50% of high-risk patients are refractory to treatment or relapse 
within two years. Novel therapeutic approaches are warranted to support existing 
therapies, improve patient survival, and reduce therapy-related late effects. The 
tumor microenvironment, a complex and intricate interplay between tumor, immune, 
and stromal cells as well as the extracellular matrix, constantly evolves to support 
tumor growth. Inflammatory processes in the tumor microenvironment are an 
essential part of anti-tumor immunity but can also promote tumor growth. In 
neuroblastoma, several inflammatory mediators and pathways have already been 
identified that support tumorigenesis and a deeper understanding of inflammatory 
processes in the neuroblastoma microenvironment may enable alleviation of tumor-
promoting inflammation while preserving anti-tumor immune responses. 
This thesis aims to identify novel inflammatory mediators and pathways in 
neuroblastoma to contribute to a better understanding of neuroblastoma biology, a 
prerequisite for novel therapeutic approaches. The first study describes a functional 
chemerin/CMKLR1 axis in neuroblastoma. Chemerin, a multifunctional 
chemoattractant protein and its receptors CMKLR1 and GPR1 are expressed in 
neuroblastoma cell lines and tissue. Chemerin promoted pro-tumorigenic signaling 
pathways in neuroblastoma and blockade of the chemerin/CMKLR1 axis impaired 
neuroblastoma growth. 
The second study demonstrates the presence of spleen tyrosine kinase in 
neuroblastoma, a non-receptor tyrosine kinase with diverse functions. Inhibition of 
SYK with commercially available small molecule inhibitors impaired the cell viability of 
SYK-expressing neuroblastoma cells and potentiated the effect of commonly used 
chemotherapeutic drugs.  
The interleukin 17 family has important functions in host defense but has also 
been implanted in inflammatory diseases and cancer. The third study describes the 
expression of interleukin 17 family members and the functionally-related 
interleukin 23 in neuroblastoma. The interleukin 17 receptors RA, RB, and RC are 
present in neuroblastoma cell lines and tumor tissue. Their stimulation with 
recombinant interleukin 17 proteins affected the cell viability of neuroblastoma cells 
only marginally but modulated HGF and Dkk-1 secretion and in vitro migration. 
Interleukin 23p19 was detected in neuroblastoma cell lines and tissues and the 





“Cancer is a collection of many diseases with common principles, and each disease will 
have to be understood and more effectively controlled on its own terms.” 
Harold E. Varmus [1] 
In 1989 Harold E. Varmus fittingly described cancer cells as “a distorted version 
of our normal selves” [2]. During tumorigenesis, the strictly regulated and coordinated 
processes that govern normal cells and tissues are disturbed. Tumor cells multiply 
uncontrolled and co-opt non-malignant cells to form a partnership that supports 
tumor growth and spread to adjacent and distant tissues. 
Cancer is a collective term for a heterogeneous group of diseases and despite 
the fact that cancers are exceptionally diverse and each tumor is unique, advances in 
cancer research have led to the identification of common biological capabilities that 
enable and promote tumorigenesis. In 2000 Douglas Hanahan and Robert Weinberg 
introduced the term “hallmarks of cancer” to conceptualize six characteristics of 
tumor development: self-sufficiency in growth signals, insensitivity to anti-growth 
signals, evading apoptosis, limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis [3]. These hallmarks have since been extended to 
include deregulation of cellular energetics and avoiding immune destruction and the 
enabling characteristics of genome instability and tumor-promoting inflammation [4]. 
In a 2017 review, Yousef Fouad and Carmen Aanei suggested a condensed and revised 
version of the hallmarks defining seven capabilities that support neoplastic growth: 
selective growth and proliferative advantage, altered stress response, metabolic 
rewiring, immune modulation, an abetting microenvironment, vascularization, and 
invasion and metastasis [5].  
Our increased knowledge of cancer biology has led to remarkable advances in 
cancer therapy. Today, physicians can employ an arsenal of targeted drugs, “magic 
bullets”, a concept already described in the late 19th/early 20th century by Paul Ehrlich, 
the founder of chemotherapy [6]. However, cancer remains a global health problem 
as worldwide 1 in 6 deaths are attributed to cancer (estimated 9.6 million deaths in 
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2018), making it the second most common cause of death [7]. A deeper understanding 
of the complex processes of tumorigenesis, invasion, metastasis, and drug resistance 
can improve the utilization of existing treatments and form the basis for the 
development of novel therapies. 
2 THE TUMOR MICROENVIRONMENT 
“Cancers are not just masses of malignant cells but complex “rogue” organs.” 
F.R. Balkwill, M. Capasso & T. Hagemann [8] 
With the increasing understanding of tumor biology, cancer is now considered 
an “ecological disease” [9] characterized by complex and dynamic interactions 
between malignant cells, supporting immune and stromal cells, and non-cellular 
factors (Figure 1) [8, 10]. This intricate tumor microenvironment (TME) is not static 
but evolves to adapt to the needs of the growing tumor, enable invasion into adjoining 
tissues, and metastatic spread to distant organs.  
 
Figure 1: The tumor microenvironment. 
The complex interactions of tumor, immune, and stromal cells resemble to some extent the organized 
structures within tissues and organs. Reproduced/adapted from Journal of Cell Science [8] with 
permission from The Company of Biologists Ltd. 
Solid tumors display commonalities with healthy tissues as they are comprised 
of the parenchyma, consisting of neoplastic cells, and the stroma that contains 
 3 
specialized connective tissue cells, blood and lymphatic vessels, immune cells, and the 
extracellular matrix (ECM) [11].  
The cell types described in the following chapters are important contributors 
to the TME and of prognostic value in different cancer types but do not encompass 
the entirety of the TME. 
2.1 THE TUMOR IMMUNE ENVIRONMENT 
The term “tumor immune environment” indicates the complexity of immune 
cell infiltration in cancer [12]. The composition of the immune infiltrate can vary 
greatly among tumors and undergo dynamic changes during tumorigenesis. 
Furthermore, the immunological composition can be an important prognostic factor 
and affect the response to cancer treatment [13-15]. The increasing knowledge in the 
field of tumor immunology has led to the classification of “tumor immune 
environment subclasses” or “immune subtypes” that can inform predictions on 
disease outcome and response to therapy [12, 16].  
Table 1 provides an overview of immune cells that can be present in the TME 
and have potent tumor supporting and tumor suppressing abilities. 
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Function Reviewed in 
CD8+ T cells    
Cytotoxic T cells 
 
Memory T cells 
IFN-γ, TNF-α 
• Selectively target tumor cells, induce cell death through perforin and granzyme release and FasL and 
TRAIL signaling  
• Functional T cell memory mediates a fast response to a reoccurring antigen 
• Associated with favorable prognosis in different cancers  
• CD8+ cells are often dysfunctional in response to suppressive signals in the TME 
[17, 18] 
CD4+ Helper cells    
Th1 IFN-γ, IL-2, TNF-β 
• Promote inflammation 
• Recruit cytotoxic T cells, NK cells, and macrophages  
• Regulate the activity of cytotoxic T cells 
• Mainly associated with favorable prognosis in different cancers  
• Their contribution to chronic inflammation can also have pro-tumor effects 
[19] 
Th2 IL-4, IL-5, IL-13 
• Regulate activity of different immune cells through cytokine release 
• Immunosuppressive and immunostimulating effects depending on cytokine secretion pattern 
• Pro- or anti-tumorigenic effects dependent on cancer type 
• Th2 cytokines can contribute to immune evasion and escape 
[19] 
Th9 IL-9 
• Anti-tumorigenic functions in some cancers 
• Promote the recruitment of DCs and cytotoxic T cell function 
• IL-9 and Th9 also linked to pro-tumorigenic functions particularly in hematological malignancies 
[19] 
Th17 IL-17, IL-21, IL-22 
• Mainly pro-inflammatory and pro-angiogenic 
• Pro- or anti-tumorigenic effects dependent on cancer type 
[19, 20] 
Th22 IL-22 
• Th22 infiltration linked to poor prognosis in some cancers 
• Pro-tumorigenic functions mainly linked to increased levels of IL-22 that can promote proliferation, 
invasion, and angiogenesis 




IL-21, IFN-γ, IL-4, 
IL-9 
• Provide help for B cells, different subclasses have been identified 
• Infiltration of Tfh cells correlates with patient survival in different solid tumors 
• Positive effects have been attributed to their ability to organize tertiary lymphoid structures and 
decrease immune suppression although the detailed mechanisms are so far little understood 
[20, 22] 
Tregs IL-10, TGF-β, IL-35 
• Mainly anti-inflammatory and immunosuppressive 
• Can effectively impair T cell effector functions  
• Can contribute to impairment of immunosurveillance 
• Mainly associated with unfavorable prognosis in different cancers 
[23] 
γδ T cell 
IL-17, IFN-γ, 
TGF-β, IL-10 
• Potent anti-tumor activity (MHC-independent tumor cell killing, phagocytosis) 
• Positive prognostic marker in different cancers 
• Pro-tumorigenic functions that have been linked to IL-17 secretion and recruitment of 
immunosuppressive cells  
[24, 25] 
Macrophages 
IL-1, IL-6, IL-12, 
IL-23, 
IL-10, TGF-β 
• Versatile cells with potent pro-tumorigenic and anti-tumorigenic abilities 
• Anti-tumorigenic: antigen presentation and activation of effector immune cells 
• Pro-tumorigenic: promote tumor cell proliferation and survival, angiogenesis, metastasis, and 
immunosuppression  
[26, 27] 
MDSCs TGF-β, IL-10 
• Heterogeneous population of myeloid cells found in peripheral blood and the TME 
• Potent immunosuppressive cells 
• Can impair anti-tumor immune responses and immunotherapy 
[28, 29] 
NK cells IFN-γ, TNF-α 
• Potent anti-tumor abilities (tumor cell killing, release of inflammatory mediators) 
• Important contributor to immunosurveillance 
• NK cell presence and activity is a positive prognostic factor in different cancers 
• Their function is often impaired in cancer 
[30, 31] 
NKT cells  
• Recognize lipids and glycolipids 
• Various subsets have been identified 
[32] NKT1 IFN-γ 
• Contribute to immunosurveillance  
• Activate DCs, cytotoxic T cells, NK cells but also support Tregs 
• Can mediate tumor cell lysis 
NKT2 IL-13 
• Immunosuppressive  





• Important antigen presenting cells 
• Various subsets 






• Pro- and anti-tumorigenic functions that greatly depend on mediators/signals in the TME 
• Neutrophil infiltration is mainly a negative prognostic marker but a correlation with good prognosis 
has also been observed in some cancers 






• Potent anti-tumor functions (production of antibodies, antigen presentation, tumor cell killing) 
• Also pro-tumor functions (suppression of T cell differentiation and function) 
• Different subpopulations have been identified with potentially distinct behavior (e.g. Bregs) 
[35] 
Innate lymphoid cells   • Functions dependent on cytokine environment 
[36] 
ILC1 IFN-γ 
• Anti-tumorigenic functions observed in presence of IL-15 
• Pro-tumorigenic functions observed in presence of TGF-β 
ILC2 IL-4, IL-13 
• Considered mainly immunosuppressive and pro-tumorigenic but anti-tumorigenic functions have 
also been described 
ILC3 IL-17, IL-22 
• Heterogenic population with pro-tumorigenic (Treg and MDSC recruitment, pro-metastatic) and 
anti-tumorigenic (NK cell recruitment) functions  
Mast cells  
Context 
dependent 
• Heterogeneous and plastic cell population with differences in morphology, surface receptors, and 
production of specific mediators 
•  tumor promoting, tumor suppressing or inert bystander dependent on tumor type and context 
• Pro-tumorigenic: promote angiogenesis (VEGFs), ECM remodeling (MMPs), EMT and stem cell 
features (IL-8), immunosuppression (TGF-β, IL-13, adenosine)  




2.1.1 T lymphocytes 
Different T lymphocyte populations can be present in the tumor bed, the invasive 
margins, in draining lymph nodes, and lymphoid organs [8]. Both tumor-supportive and 
tumor-suppressive abilities have been described for different T cell populations that are often 
highly context-dependent [19]. Furthermore, the assessment of tumor-infiltrating T cell 
subsets, called the “immunoscore”, is a potent prognostic tool in colorectal tumors and other 
cancers [38-40]. 
Cytotoxic T cells (CTL) 
Cytotoxic (CD8+) effector T cells can induce granzyme-, perforin-, FasL (Fas ligand)-, and 
TRAIL (TNF-related apoptosis-inducing ligand) -mediated apoptosis in target cells and their 
presence has been correlated to a good prognosis in various cancers, such as melanoma, 
colorectal, and breast cancer [13, 18, 41]. However, different mechanisms in the TME can 
limit/prevent the infiltration of cytotoxic T cells and/or impair their function [17, 42, 43]. 
Among these mechanisms, the up-regulation of immune checkpoint receptors, such as 
programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), 
on CD8+ T cells and their ligands PD-L1, PD-L2 and cluster of differentiation 80 (CD80), CD86 
on other immune cells, tumor, and stromal cells has been studied intensely in cancer [44]. In 
health, immune checkpoints are important regulators of immune responses supporting the 
maintenance of self-tolerance and the prevention of autoimmunity [45]. Among other 
markers, such as LAG-3 (Lymphocyte-activation gene 3) and TIM-3 (T-cell immunoglobulin and 
mucin-domain containing-3), PD-1 expression is one of the characteristics of “exhausted”, 
dysfunctional T cells, a condition observed during infections and in cancers [43, 46]. These 
findings have led to the development of checkpoint inhibitors, antibodies targeting checkpoint 
receptors or their ligands [44, 47]. Anti-CTLA-4 and anti-PD-1/PD-L1 checkpoint inhibitors have 
been evaluated in a broad variety of solid tumors as well as hematological malignancies and 
displayed remarkable therapeutic benefits for some portion of patients with advanced 
cancers, such as metastatic melanoma, non-small cell lung cancer, and Merkel cell carcinoma 
[48, 49]. As of September 2018, 2250 clinical trials evaluate the efficacy of PD-1/PD-L1 
checkpoint inhibitors in combination with other therapies or as monotherapies in different 
cancers [50]. Of note, the expression of checkpoint receptors is not limited to cytotoxic T cells. 
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PD-1 is expressed on different subsets of activated T cells, myeloid cells, and B cells [48]. 
CTLA-4 expression is restricted to T cells but differs among subsets, as CD4+ T cells show a 
higher expression than CD8+ T cells [51]. 
Helper T cells 
The world of CD4+ helper T cells (Th cells) is highly complex. So far, seven subsets of Th 
cells have been identified: Th1, Th2, Th17, Th9, Th22, Tfh, and Treg [20]. Each T helper subset 
differentiates in response to specific cytokines and transcription factors, produces a 
characteristic cytokine signature and displays distinct functions [20]. However, specific helper 
cell subsets can react to environmental changes by acquiring characteristics of a different 
subset. This plasticity contributes to a fine-tuned balance between the different subsets that 
regulates their functions in health and disease [20]. 
Th1 cells differentiate in response to interleukin 12 (IL-12) and target CD8+ cytotoxic 
T cells, natural killer (NK) cells, and macrophages through the pro-inflammatory cytokines 
interferon gamma (IFN-γ) and IL-2 [13, 52]. In contrast, Th2 cells differentiate in response to 
IL-4 and target B cells, eosinophils, basophils, and mast cells through the anti-inflammatory 
cytokines IL-4, IL-5, and IL-13 [13, 52]. Both, Th1 and Th2 cells have shown prognostic value in 
different cancers. While Th1 cells generally display anti-tumorigenic functions and correlate 
with good prognosis, Th2 cells can support tumorigenesis and have mainly been associated 
with poor prognosis [13, 19].  
IL-6, IL-21, and transforming growth factor beta (TGF-β) promote the differentiation of 
pro-inflammatory Th17 cells that secrete IL-17A, IL-17F, IL-21, and IL-22 and recruit 
neutrophils and macrophages [53]. Additionally, the presence of IL-23 can maintain 
differentiated Th17 cells long-term [54]. Th17 cells play a dichotomous role in cancer as they 
can both promote and suppress tumorigenesis [20]. Furthermore, Th17 cells display great 
plasticity and in response to changes in their environment they can acquire Th1 properties 
and gain the ability to secrete IFN-γ while no longer secreting IL-17 [55, 56]. This capability 
may be one of the reasons for the dichotomy of Th17 cells in cancer. 
Regulatory T cells (Tregs) are important for the maintenance of tissue homeostasis. 
Tregs differentiate in the presence of TGF-β and IL-2 and they suppress lymphocyte effector 
functions through, among others, TGF-β, IL-10, prostaglandin E2 (PGE2), idoleamine 2,3-
dioxygenase (IDO) and adenosine secretion, sequestration of IL-2, and engagement of 
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immune checkpoint receptors, such as CLTA-4 and PD-1 [23, 57]. The role of Tregs in the TME 
is diverse and their presence has been associated to both good and poor prognosis in different 
cancers [13, 23]. This may be attributed to Treg plasticity as they can display Th17 
characteristics when exposed to IL-6 with or without additional IL-23 and IL-1β presence [58]. 
Furthermore, the presence of cytotoxic CD4+ cells (CD4 CTL) with the ability to kill 
target cells MHC class II-dependent by secreting perforin and granzyme has also been 
described in cancers, for example melanoma [59]. 
γδ T cells 
γδ T cells are a potent T cell subset with pleiotropic functions. They can recognize cell 
surface molecules, such as phosphoantigens, whose expression varies between stressed cells, 
including malignant cells, and healthy tissue without co-stimulation and MHC-restriction [60]. 
Tumor cell death can be induced by perforin and granzyme release but also via FasL and TRAIL 
[24]. There are at least three different human γδ T cell subtypes that differ in their γ- and δ-
chain composition, tissue localization and the type of antigens they recognize [60]. The 
presence of γδ T cells has been observed in different cancer types and their role in 
tumorigenesis is likely context-dependent [24, 61]. Although γδ T cells have been identified as 
a good prognostic factor in different cancer types [62] and anti-cancer functions have been 
observed in vitro and in vivo [63, 64], pro-tumorigenic functions have also been described [65-
67]. Their dichotomous role in cancer may be attributed to the plasticity of γδ T cells. Human 
γδ T cells are functionally immature and differentiate into IFN-γ-secreting type 1 effector cells 
with cytotoxic activity in the presence of IL-2 or IL-15 [68]. However, under highly 
inflammatory conditions γδ T cells can produce IL-17 and display a Th17-like profile [69, 70]. 
Furthermore, Treg-like profiles, characterized by the production of IL-10 and TGF-β, have also 
been observed in γδ T cells [71, 72]. 
2.1.2 Tumor-associated macrophages (TAMs) 
TAMs are abundant in different cancer types and function as important regulators of 
tumorigenesis as they can promote angiogenesis, invasion, and metastasis [26, 73, 74]. In 
response to environmental factors, macrophages can display different phenotypes along a 
phenotypic continuum with M1 and M2 being the extremes [27]. M1 or “classically activated” 
10 
macrophages secrete pro-inflammatory cytokines, such as IL-6, IL-12, IL-23, and tumor 
necrosis factor alpha (TNF-α), and have antigen-presenting, phagocytic, and cytotoxic 
functions [75]. They are activated by IFN-γ, lipopolysaccharide (LPS) or toll-like receptor (TLR) 
ligands and promote a Th1 type immune response [76]. In contrast, IL-4 and IL-13 activate M2 
or “alternatively activated” macrophages, which secrete the anti-inflammatory cytokines 
IL-10 and TGF-β, vascular endothelial growth factor (VEGF), and matrix metalloproteinases 
(MMPs), and support a Th2 type immune response [75, 76]. Although the phenotype of TAMs 
is typically closer to the M2 end of the functional spectrum, TAMs that do not resembles 
alternatively activated macrophages have also been described [77, 78]. Furthermore, 
macrophages display great diversity and plasticity, and phenotypic changes of TAMs during 
tumorigenesis have been observed suggesting that the plasticity of TAMs may be utilized to 
re-educate TAMs as a therapeutic approach [79, 80].  
2.1.3 Myeloid-derived suppressor cells (MDSCs) 
MDSCs are immature and immunosuppressive cells that develop in the bone marrow 
from myeloid progenitor cells and are actively recruited to the tumor and metastatic sites by 
a variety of chemokines and other factors [28]. Their ability to promote tumor cell survival, 
angiogenesis, invasion, metastasis, and immune evasion is well established and MDSCs are 
frequently observed in different cancers [28, 81, 82]. Two large subgroups of MDSCs have 
been described: granulocytic or polymorphonuclear MDSCs (phenotypically similar to 
neutrophils), in most cancers the majority of MDSCs, and monocytic MDSCs (phenotypically 
similar to monocytes) [29]. MDSCs can disrupt immunosurveillance by inducing Tregs [83] and 
inhibiting dendritic cell (DC)-mediated antigen presentation, NK cell cytotoxicity, M1 
polarization, and T cell recruitment, activation, and function through production of reactive 
oxygen and nitrogen species, IDO, Arginase, IL-10 and TGF-β [10, 84]. Furthermore, hypoxia 
up-regulates PD-L1 expression on MDSCs [85]. MDSCs are a mixed population of various 
myeloid cells that display different levels of plasticity and can differentiate into multiple cell 
types, for example macrophages [82, 86]. Therefore, the re-education of MDSCs is an 
attractive therapeutic approach [87]. 
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2.1.4 Natural killer (NK) cells  
NK cells can recognize stressed, infected, foreign, and also tumor cells, through a 
variety of receptors in absence of antigen presentation, non-MHC restricted, and mediate cell 
killing via granzyme B, perforin, FasL, and TRAIL [31]. Furthermore, NK cells can regulate 
immune responses through secretion of cytokines (e.g. IFN-γ, TNF-α, IL-10 and granulocyte-
macrophage colony-stimulating factor (GM-CSF)) and chemokines (e.g. macrophage 
inflammatory protein-1a (MIP-1α=CCL3), C-X-C motif chemokine 8 (CXCL8=IL-8) and 
chemokine (C-C) motif ligand 2 (CCL2=MCP-1)) [31]. NK cells are not a homogenous group as 
distinct NK cell subsets have been described, which differ in localization and function [88]. This 
is also the case in cancer, as functionally different NK cell phenotypes have been described in 
different malignancies [30]. Potent anti-tumor and anti-metastatic functions have been 
demonstrated for NK cells and intratumoral NK cell presence has been associated with good 
prognosis in various cancers [89-91]. However, tumor, stromal and immune cells can release 
factors, such as TGF-β, PGE2, IL-4, and IDO, that impair NK cell infiltration, activation and 
function, resulting in NK cell anergy [92]. Consequently, restoration of NK cell function by 
adoptive NK cell therapy or reprogramming of the immunosuppressive TME to harness their 
full anti-tumor potential are attractive therapeutic approaches that are evaluated in different 
cancer types [91]. 
2.1.5 Dendritic cells (DCs) 
Dendritic cells are professional antigen presenting cells with important functions in 
immunosurveillance [33]. They capture antigens from the microenvironment and present 
them to cells of the adaptive immune system. In addition, they provide important 
costimulatory signals [93]. Different subsets of DCs have been described that differ in their 
localization and specific function [33]. DC function is often impaired in the TME as different 
tumor-derived factors can inhibit their maturation (IL-6, IL-10, VEGF and colony stimulating 
factor 1 (CSF-1)), activation (PGE2, IL-10, VEGF), and function (hypoxia, low pH, and high levels 
of adenosine and lactate) [33, 94]. Additionally, expression of inhibitory molecules, such as 
PD-L1, TIM-3, and LAG-3, can contribute to the dysfunction of DCs in tumors [95]. PD-1 and 
PD-L1 blockade has been demonstrated to restore DC function [96]. 
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2.1.6 Tumor-associated neutrophils (TANs) 
Different subsets of neutrophils, the most abundant leukocytes in human circulation, 
have been described in cancer [97]. Neutrophils are multifunctional cells with remarkable 
plasticity that can both support and suppress tumor growth [34]. They can contribute to an 
inflammatory TME and immune suppression, support extracellular matrix (ECM) remodeling, 
and promote angiogenesis and metastasis through, among others, the release of reactive 
oxygen and nitrogen species, MMPs, arginase-1, cytokines and growth factors, such as TGF-β 
and VEGF-A, and the expression of PD-L1 [34, 98-100]. Moreover, reactive oxygen species can 
promote point mutations and genome instability, a hallmark of cancer [101]. In contrast, 
neutrophils can also effectively kill tumor cells (phagocytosis, degranulation, and release of 
cytotoxic proteins), promote anti-tumor responses through recruitment and activation of 
T cells, and inhibit metastasis [102-104]. 
2.1.7 B lymphocytes 
B lymphocytes, important mediators of humoral immune responses, can be present in 
the tumor margins but are more commonly found in tumor-adjacent tertiary lymphoid 
structures and draining lymph nodes [8, 12]. Both tumor-promoting and -suppressing 
capabilities have been attributed to B cells in different cancers [35]. In particular, different 
subsets of regulatory B cells (Bregs) display tumor promoting functions as they can disrupt 
cancer immune surveillance through secretion of immune suppressive cytokines, such as 
IL-10, and expression of the inhibitory molecules PD-L1, CD80 and CD86 [105]. 
2.2 NON-HEMATOPOIETIC CELLS IN THE TME 
In addition to various immune cells, the TME is comprised of blood vessels, lymphatic 
vessels, and specialized connective tissue cells, such as fibroblasts and mesenchymal stem 
cells [8]. Furthermore, adipocytes, and other cell types can be present in the 
microenvironment of specific tumors [42]. Their role in tumorigenesis will be briefly described 
in the subsequent paragraphs. 
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2.2.1 Vascular endothelial cells and pericytes 
Angiogenesis and neovascularization are important steps in tumorigenesis as a 
sufficient supply with oxygen and nutrients is needed to enable a tumor to grow beyond a 
certain size [106]. In response to pro-angiogenic growth factors, such as VEGFs (particularly 
VEGF-A), platelet-derived growth factors (PDGFs), fibroblast growth factors (FGFs), and 
angiopoietin 2, vascular endothelial cells form new blood vessels with structural support from 
pericytes [107, 108]. This tumor vasculature is exceptionally chaotic, leaky, and characterized 
by an uneven blood flow resulting in varying oxygenation and nutrient supply and potentially 
impairments of drug distribution and immune cell extravasation [107]. The majority of cells 
present in the TME have the ability to influence angiogenesis through pro- or antiangiogenic 
factors. For example, TANs, MDSCs and cancer-associated fibroblasts (CAFs; see 2.2.3) can 
produce a variety of proangiogenic factors that promote proliferation and migration of 
endothelial cells and ECM remodeling [108]. However, various cell types, such as B cells, 
T cells, and macrophages, can display pro- as well as antiangiogenic functions depending on 
their subtype and microenvironmental factors [108]. In return, vascular endothelial cells are 
also known to affect cells in the TME. They can express immune checkpoint ligands, such as 
PD-L1 and PD-L2, as well as TRAIL and FasL, ligands that induce T cell apoptosis [42]. 
Consequently, angiogenesis, and by extent vascular endothelial cell proliferation, is a 
promising therapeutic target and multiple drugs have been evaluated in clinical trials with 
varying results [109]. Of note, there is increasing evidence that not all tumors dependent on 
angiogenesis and it furthermore has been demonstrated that some tumors can co-opt existing 
blood vessels [110, 111]. This underlines the complexity of the TME and has to be taken into 
consideration when targeting angiogenesis. 
2.2.2 Lymphatic endothelial cells 
Lymphangiogenesis, the formation of new lymphatic vessels by lymphatic endothelial 
cells, is promoted by VEGF-C and VEGF-D and contributes to the dissemination of tumor cells, 
a prerequisite for metastasis [112]. Furthermore, lymphatic endothelial cells display 
immunomodulatory functions, such as tumor antigen cross-presentation, that can promote 
apoptosis of antigen-specific cytotoxic T cells and thereby supports tolerance [42]. 
Additionally, the heightened interstitial flow, resulting from an increase in lymphatic vessels, 
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can cause changes in the tumor stroma, such as a stiffening of the ECM, that can contribute 
to immune suppression [113]. 
2.2.3 Cancer-associated fibroblasts (CAFs) 
Cancer-associated fibroblasts are myofibroblasts (activated fibroblasts) and a 
dominant cell type in the microenvironment of many tumors [8]. CAFs are a heterogeneous 
population of multifunctional cells that can in principle support all stages of cancer 
development and progression by promoting malignant cell growth, invasion, metastasis, 
angiogenesis, drug resistance, inflammation, and immune suppression [114]. In contrast to 
quiescent fibroblasts in healthy tissue, CAFs resemble activated wound healing-associated 
fibroblasts but display even more pronounced proliferative, secretory, and migratory abilities 
[114]. While normal fibroblasts can suppress the growth of cancer cells, CAFs have been 
coerced by the tumor and can display potent tumor promoting functions [115]. CAFs can 
secrete a variety of factors with tumor-promoting (e.g. epidermal growth factor (EGF), insulin-
like growth factor (IGF), hepatocyte growth factor (HGF) and IL-6), immune modulatory (e.g. 
TGF-β, IL-4, IL-6, PGE2, CCL2, CXCL12 and GM-CSF), angiogenic (e.g. VEGFA, PDGFα, and TGF-β) 
and ECM remodeling functions (e.g. MMPs, TIMPs (tissue inhibitors of metalloproteinases), 
collagens and fibronectin) [116]. Due to their well-established tumor-promoting role, CAFs are 
considered attractive therapeutic targets and different drugs are under evaluation that target 
receptors present on or factors secreted by CAFs or aim to normalize or re-educate them to a 
quiescent or tumor-suppressive state [114]. However, CAFs are functionally heterogeneous 
and anti-cancer functions have also been observed [116].  
2.2.4 Mesenchymal stem cells (MSCs) 
Mesenchymal stem cells are multipotent stromal cells, recruited from the bone 
marrow that can differentiate into, among others, fibroblasts, adipocytes, osteoblasts and 
chondrocytes [117]. They are rare, migratory cells that support wound healing by regulating 
the immune response and tissue regeneration [118]. MSCs can be recruited to the TME where 
they have the potential to promote immune suppression comparable to a wound healing 
setting [42, 118]. Furthermore, MSCs can promote EMT and bone metastasis by secreting 
chemokines and attracting tumor cells to the bone marrow [117, 119].  
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2.3 EXTRACELLULAR MATRIX (ECM) 
The ECM, a collection of extracellular molecules, is an important component of healthy 
organs, but also tumors, as it ensures tissue integrity by providing a structural scaffold for the 
cells [120]. In the TME, as in any other organ, the ECM undergoes constant remodeling. 
Proteases, such as MMPs and cathepsins, are secreted by tumor cells, CAFs, and TAMs and 
degrade ECM components as new components are produced by CAFs [8]. Furthermore, 
extracellular vesicles released by tumor cells and other cells in the TME have been 
demonstrated to support tumor growth, angiogenesis, metastasis, immunomodulation, and 
drug resistance [121, 122]. By no means a bystander in the TME, the ECM can suppress 
tumorigenesis in early stages but also support cancer progression [10]. The ECM can promote 
tumor cell proliferation, migration, and invasion, support angiogenesis and simultaneously 
suppress infiltration, activation, and function of immune cells and contribute to therapy 
resistance [123]. 
3 CANCER IMMUNOEDITING 
“In the enormously complicated course of fetal and post-fetal development, aberrant cells 
become unusually common. Fortunately, in the majority of people, they remain completely 
latent thanks to the organism's positive mechanisms” Paul Ehrlich [124] 
Several safety control systems can prevent tumor growth when cells are subjected to 
malignant transformations. Intrinsic control and repair mechanisms, involving tumor 
suppressor proteins, aim to restore normal cell behavior or induce apoptosis [4]. Furthermore, 
the immune system constantly recognizes and eliminates malignant cells. This hypothesis of 
“immunosurveillance” was developed by Macfarlane Burnet [125] and Lewis Thomas [126] 
and later extended to the concept of immunoediting [127].  
Cancer immunoediting encompasses three phases: elimination, equilibrium, and 
escape (Figure 2) [127, 128]. During the elimination phase, the innate and adaptive arm of the 
immune system recognize tumor antigens and danger signals present on, or released by, 
malignant cells in response to oncogenic stress, leading to the eradication of the emerging 
tumor [128, 129]. In the equilibrium phase, the tumor is controlled by the immune system and 
kept functionally dormant [128, 129]. A reduction in tumor immunogenicity, for example 
through loss of tumor antigens and/or MHC class I expression and the development of an 
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immunosuppressive TME, can upset the equilibrium leading to immune escape and renewed 
tumor growth [128, 129]. Importantly, cancer-related inflammation can promote immune 
escape through various mechanisms [130]. 
 
Figure 2: Cancer immunoediting. 
Cancer immunoediting engages after the intrinsic cellular mechanisms that prevent malignant growth have 
failed. The immune system recognizes malignant cells and controls tumor growth (elimination phase) but might 
fail to eliminate all tumor cells leading to a phase of functional dormancy (equilibrium) in which the immune 
system prevents progression but cannot eliminate the tumor. In the escape phase, tumor cell populations 
emerge that evade immune destruction resulting in tumor progression. From [128] reprinted with permission 
from AAAS, an adapted version from [131] with permission from Annual Reviews, Inc.  
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4 INFLAMMATION AND CANCER 
“Tumors appear to the host in the guise of wounds or, more correctly, of an unending series of 
wounds that continually initiate healing but never heal completely” Harold F. Dvorak [132] 
Inflammation is an essential defense mechanism of the body against harmful stimuli, 
such as injury, pathogens and other biological or chemical irritants. An acute inflammatory 
response is characterized by a rapid infiltration of innate immune cells into the damaged tissue 
and their activation [133]. Depending on type and severity of the damage, adaptive immune 
cells may also be recruited. Subsequently, coordinated innate and adaptive immune 
responses lead to the elimination of the harmful stimulus, followed by resolution of 
inflammation and re-establishment of tissue homeostasis [133]. In contrast, chronic 
inflammation is the response to a persistent harmful stimulus with continuous recruitment of 
immune and stromal cells, resulting in lasting immune responses and tissue remodeling [134].  
The first observations linking inflammation to tumor growth were made by Rudolf 
Virchow in 1858 when he observed “lymphoreticular infiltrates” within tumors [135]. Over a 
century later, in 1986, Harold F. Dvorak compared tumorigenesis to wound healing in his 
seminal work “Tumors: wounds that do not heal” [132]. Today, the link between inflammation 
and cancer is firmly established. Approximately 16% of all cancers can be attributed to 
infections [136] and cancers arise at a higher rate in chronically inflamed tissues [137, 138]. 
Persistent inflammation can affect every step of tumorigenesis and is recognized as an 
enabling characteristic for multiple cancer hallmarks [4, 139]. Cytokines and other 
inflammatory mediators can induce epigenetic changes and genome instability, support cell 
survival, and proliferation, promote angiogenesis, and contribute to immunosuppression 
[137, 139, 140]. Inflammatory mediators can contribute to the development of “pre-
metastatic niches” in distant organs thereby providing a receptive microenvironment “soil” 
for the malignant cells “seed” in accordance with Stephen Paget’s hypothesis from 1889 [141, 
142].  
However, inflammation is also an important factor of antitumor immunity and it has 
been demonstrated that therapy-induced acute inflammation (by specific chemotherapeutic 
agents, radiation, and targeted therapies) can re-educate the TME and promote antitumor 
responses [140, 143, 144]. 
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Two cross-talking pathways connect inflammation and cancer: the intrinsic and the 
extrinsic pathway (Figure 3) [145].  
Figure 3: The molecular links between cancer and inflammation 
Intrinsic (oncogene activation) or extrinsic (inflammation, infection) factors lead to activation of pro-
inflammatory transcription factors, such as NF-κB and STAT3, regulating the expression pro-inflammatory 
mediators, among others, cytokines and chemokines, promoting the recruitment of inflammatory cells. The 
resulting inflammatory TME supports various cancer hallmarks, such as angiogenesis and metastasis. Reprinted 
and adapted by permission from Springer Nature Customer Service Centre GmbH: Springer Nature, Nature 
Reviews Clinical Oncology [146].  
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The intrinsic pathway is oncogene-driven and imparts tumor cells with pro-
inflammatory characteristics, such as recruitment of inflammatory cells and promotion of 
angiogenesis [130]. For example, oncogenic Ras induces IL-6, IL-1β, and IL-8 expression in 
ovarian epithelial cells [147] as well as the expression of GM-CSF in pancreatic epithelial cells 
[148] and promotes COX-2 expression [149]. In contrast, the extrinsic pathway is driven by 
inflammatory conditions (e.g. infection or chronic inflammation) and the resulting 
inflammatory and environmental factors [130]. For example, danger signals (damage-
associated molecular patterns or DAMPs) are released in injured/stressed tissues and 
recognized by the innate immune system initiating the release of pro-inflammatory 
mediators, such as TNF-α, IL-6, and IL-1 [150]. 
4.1 INFLAMMATORY MEDIATORS 
In the inflammatory TME, chronically activated immune cells, stromal cells, and tumor 
cells secrete growth factors, cytokines, proteolytic enzymes, chemokines, and other 
chemoattractant factors, that can promote tumor and stromal cell proliferation and 
migration, ECM remodeling, metastasis, and immune suppression (Figure 3) [137, 145]. 
Various therapeutic approaches (examples of which are listed in Table 2) have been developed 
to either target tumor-supporting inflammatory mediators or promote anti-tumorigenic 
inflammation and immune responses, with the aim to re-educate the TME and promote anti-
cancer functions [47, 130, 138, 146, 151, 152]. 
Table 2: Examples of therapeutic approaches to alleviate pro-tumorigenic inflammation while promoting anti-
tumorigenic immune responses. Based on information from [47, 130, 138, 146, 151-154] 
Target Drugs (examples) 
Diverse anti-inflammatory/ immunomodulatory functions 
Steroids (Dexamethasone, 
Prednisolone), Statins, Chemotherapy, 
Radiotherapy 
COX/PGE2 axis 
COX1/2 Aspirin, Ibuprofen 
COX2 Celecoxib 
Omega-3 fatty acids 
Inflammatory cytokines and 
chemokines 
TNF-α Infliximab, Etanercept 
IL-6/IL-6R Siltuximab, Tocilizumab 
IL-1R Anakinra 








Ruxolitinib, AZD9150, NCT02646748, 
Curcumin, Resveratrol 
NF-κB signaling Bortezomib (proteasome inhibitor) 
Myeloid cells 
M-CSF/CSF-1R BLZ 945, PLX7486, AMG820, 
Diverse functions Tasquinimod 
Anti-CD47 Hu5F9-G4 
TLR agonists Motolimod, CMP-001 
Arginase inhibitors CB-1158 
IDO antagonists Indoximod, Epacadostat 
PI3Kγ inhibitors TG100-115 















T cell activation, proliferation 
IL-2, Pegilodecakin (Pegylated IL-10) 
IFN-α 
The following inflammatory mediators are merely representatives of an extensive and 
complex network and will only be described briefly. 
4.1.1 Tumor necrosis factor alpha (TNF-α) 
TNF-α is a multifunctional inflammatory cytokine with both, pro- and anti-tumorigenic 
functions [155]. Secreted by tumor and/or stromal cells TNF-α is frequently detected in the 
tumor tissue and serum of patients with different cancer types and has been identified as a 
prognostic factor in, among others, breast cancer and prostate cancer [156]. TNF-α can 
promote tumor cell proliferation and survival, angiogenesis, metastasis, and the recruitment 
of inflammatory cells [155]. 
4.1.2 Interleukin 1 (IL-1α and IL-1β) 
IL-1α and IL-1β, members of the IL-1 family, are master regulators of inflammation as 
they promote the expression of other inflammatory mediators (cytokines, chemokines, 
COX-2, MMPs, etc.) as well as their own expression thereby amplifying the inflammatory 
response [157, 158]. While the IL-1α precursor is constitutively present and active in cells 
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under homeostatic conditions, IL-1β expression is stimulated by inflammatory signals and 
activation of the IL-1β precursor is required for its functionality [158, 159]. 
IL-1β is an important cytokine in carcinogenesis as it can exert anti-tumorigenic effects 
but also potent pro-tumorigenic functions by promoting angiogenesis, the development of 
cancer stem cells, invasion, metastasis, and immune suppression [157, 160]. Furthermore, 
IL-1β promotes Th17 expansion and in concert with IL-23 the secretion of IL-17 in γδ T cells 
[161, 162]. 
4.1.3 Interleukin 6 (IL-6) 
Tumor and/or stromal cells can produce IL-6 whose elevated levels are a prognostic 
marker in different cancers [163]. IL-6 function is often mediated by JAK (Janus kinase)/ STAT3 
(signal transducer and activator of transcription 3) signaling supporting proliferation, survival, 
and invasiveness of malignant cells [164]. Furthermore, IL-6/JAK/STAT3 signaling can 
modulate immune cell function by exerting negative regulatory effects on, among others, 
NK cells and effector T cells and positive effects in Tregs and MDSCs [164]. In addition, IL-6 is 
an adipokine affecting various metabolic processes and has been demonstrated to contribute 
to cachexia in preclinical models [165]. 
4.1.4 Interleukin 23 (IL-23) 
IL-23 is a pro-inflammatory cytokine consisting of the IL-23p19 and the IL-12p40 
subunits that signals through the IL-23R/ IL-12Rβ1 complex activating JAK and STAT signaling 
pathways [166, 167]. IL-23, and the related cytokine, IL-12, share the p40 subunit and are both 
secreted in response to microbial pathogens by dendritic cells and macrophages [168]. 
However, there is a clear functional distinction. While IL-12 promotes Th1 differentiation, 
IL-23 stabilizes and maintains Th17 populations [54, 169, 170]. In addition to Th17 cells, IL-23 
also regulates the function of other IL-17 producing cells, such as γδ T cells, ILCs, and NKT cells 
[171]. IL-23 has been implicated in different inflammatory diseases, such as psoriasis and 
Crohn’s disease [172, 173]. Furthermore, the efficacy of IL-23-specific antibodies for the 
treatment of psoriasis has been demonstrated in multiple clinical trials [173]. 
IL-23 is frequently overexpressed in human cancers [174] and both pro-tumorigenic 
and anti-tumorigenic functions have been described [175]. IL-23 displays cancer-promoting 
effects in, among others, colorectal cancer [176-178] and prostate cancer [179]. In contrast, 
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cancer-suppressing effects of IL-23 have been observed in, for example glioma [180, 181] and 
melanoma [182]. Tumor- or immune cell- (e.g. MDSCs) derived IL-23 can directly drive 
tumorigenesis by promoting tumor cell proliferation and survival [179, 183, 184], maintain 
stemness [185], and promote EMT, migration, and metastasis [178, 186-188]. In addition, 
IL-23 can support the inflammatory microenvironment and impair immune surveillance 
(Figure 4) [189].  
 
Figure 4: IL-23 functions in tumorigenesis.  
Myeloid cells produce IL-23 in response to a variety of signals, such as DAMPs, PAMPs, and PGE2. IL-23 signals 
through IL-23R present on a variety of innate and adaptive immune cells resulting in the secretion of IL-17 and 
IL-22. IL-17 and IL-22 can promote the proliferation of tumor as well as epithelial cells and induce the production 
of inflammatory mediators thereby contributing to an immunosuppressive TME. Furthermore, IL-23 can directly 
promote proliferation and invasion of tumor cells expressing IL-23R. Reprinted by permission from Springer 
Nature Customer Service Centre GmbH: Springer Nature, Nature Medicine [189].  
IL-23 can suppress NK cell and CD8+ cell function and contribute to the recruitment of 
macrophages, neutrophils, and Tregs, thereby affecting cytokine secretion [174, 190-192]. 
Furthermore, IL-23 produced by pulmonary squamous cancer cells can convert ILC1 to ILC3 
cells promoting tumor cell proliferation in an IL-17-dependent manner [193].  
Opposing effects have been described for IL-23 and IL-12 in carcinogenesis [194]. In a 
fibrosarcoma mouse model, for example, outgrowth of dormant tumors was reduced 
following IL-23p19 depletion, whereas inhibition of IL-12/23p40 promoted tumor growth 
[195]. This suggests a delicate balance between these two cytokines that might influence the 
immunoediting process. Furthermore, a complex interaction between cervical cancer cells 
and stromal cells has been described where cancer-instructed CAFs stimulate IL-23 expression 
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in DCs and thereby Th17 expansion. Concomitantly, a decreased expression of IL-12p35 in DCs 
was observed that was linked to tumor cell-derived IL-6 [196]. Based on these findings, 
therapeutic approaches targeting IL-23 (alone or in combination with other targeted 
therapies) to restore the IL-23/IL-12 balance have demonstrated great potential for promoting 
anti-tumor responses in murine models [197-199].  
4.1.5 Interleukin 17 family 
The IL-17 family consists of six cytokines (IL-17A-F) and five receptors (IL-17RA-IL-17RE) 
and plays an important role in host defense against pathogens, inflammation, and 
inflammatory diseases [200]. Functional cytokine/receptor combinations have been 
established for the majority of the IL-17 family members and the knowledge on their 
expression in different cell and tissues is constantly expanding (Figure 5).  
Figure 5: The IL-17 family.  
The IL-17 family consists of six cytokines and five receptors. To date, the receptor for IL-17D remains unknown. 
While some family members are widely expressed in different cell types and tissues, the expression of others is 




The best-studied family members IL-17A (often called IL-17) and IL-17F are signature 
cytokines of the Th17 helper cell subset [208]. Homodimers of IL-17A and heterodimers of 
IL-17A and IL-17F signal through IL-17RA/RC [206, 209], and overlapping but also specific 
functions have been described for IL-17A and IL-17F in immune response and host defense 
[210]. More recently, an additional IL-17F/IL-17RC signaling axis has been established [211]. 
The major IL-17A/F producing cells (Th17 cells, γδ T cells, ILC3, and NKT cells) express IL-23R 
and respond to IL-23 stimulation (alone or in concert with other cytokines) with secretion of 
IL-17A and IL-22, thereby promoting local inflammation [162, 212]. However, IL-23-
independent IL-17 expression has also been observed in γδ T cells and NKT cells [213-215]. 
IL-17A is a potent immune modulator as it can induce/enhance the secretion of pro-
inflammatory cytokines (e.g. IL-1β, TNF-α, and IL-6), chemokines (e.g. CXCL9 CXCL10, and 
CCL2) and other factors, such as MMPs and PGE2, that promote and facilitate the recruitment 
of immune cells [212]. IL-17A has been implicated in different autoimmune diseases including 
psoriasis, inflammatory bowel disease, and multiple sclerosis [200]. Several drugs targeting 
the IL-23/IL-17 axis have recently been approved for the treatment of psoriasis based on their 
superior performance in clinical trials [216]. 
Both tumor-promoting and tumor-suppressing functions have been described for 
IL-17A, IL-17F, and their producing cells, indicating versatile and context-dependent functions 
of IL-17A in the TME [20, 60, 217]. Tumor-suppressing functions of IL-17A are often associated 
with promotion of anti-tumor immune responses through increased recruitment and function 
of specific immune cells, such a CD8+ T cells and NK cells [218-220]. However, IL-17A-mediated 
immune cell recruitment can also promote tumorigenesis as has been demonstrated for 
neutrophil recruitment in breast cancer [221, 222]. Additionally, IL-17A can, among others, 
inhibit CD8+ T cell infiltration, increase MDSC presence [223], promote tumor cell proliferation 
[224-226], migration and invasion [227, 228] , angiogenesis [229-231], and metastasis [232, 
233] (Figure 6).  
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Figure 6: IL-17 functions in tumorigenesis.  
IL-17 producing lymphocytes are recruited in response to chemoattractant factors released from the tumor. IL-17 
can support anti-tumor immune responses through vasodilation effects and by enhancing immune cell 
recruitment. However, vasodilation may also support metastasis and IL-17-mediated recruitment of, among 
others, neutrophils that can support immune suppression. Reprinted by permission from Springer Nature 
Customer Service Centre GmbH: Springer Nature, Nature Immunology [212]. 
IL-17B 
IL-17B is secreted as a non-disulfide-linked dimer and binds IL-17RB [234, 235]. The 
IL-17B/IL-17RB axis has been implicated in embryonic development, tissue regeneration, 
inflammation, inflammatory diseases, and cancer [236]. Furthermore, IL-17B was found to 
inhibit IL-25-mediated IL-6 production in colon epithelial cells indicating antagonistic functions 
of both cytokines [237]. IL-17B/RB has been implicated in gastric, pancreatic, breast, and lung 
cancer where it supports tumorigenesis by promoting tumor cell survival, chemokine 
expression, migration, and metastasis [238-243]. 
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IL-17C 
IL-17C signals through IL-17RA/IL-17RE heterodimers, stimulates epithelial immune 
responses and contributes to mucosal immunity and barrier maintenance but has also been 
implicated in various inflammatory diseases, such as psoriasis, rheumatoid arthritis, and 
inflammatory bowel disease [244-246]. Pro-tumorigenic effects of IL-17C have been observed 
in colorectal cancer where it promotes cell survival [247] and in lung cancer where it promotes 
the recruitment of TANs [248]. 
IL-17D 
Although the receptor for IL-17D remains unidentified, several IL-17D functions have 
been previously been observed. IL-17D can promote the expression of pro-inflammatory 
cytokines (IL-6, IL-8 and GM-CSF) in endothelial cells [249]. Furthermore, the stress-sensing 
protein Nrf2 (nuclear factor erythroid 2-related factor 2) induces IL-17D in virus-infected cells 
and tumors where it contributes to the control of the viral infection or tumorigenesis as IL-17D 
deficient mice displayed a higher tumor incidence rate and exacerbated viral infections [250]. 
IL-17D expression is decreased in metastatic prostate cancer compared to primary prostate 
tumors and advanced grade glioma [251]. Furthermore, IL-17D-mediated NK cell recruitment 
promotes tumor rejection in preclinical cancer models [251]. 
IL-17E (IL-25) 
IL-17E (also known as IL-25) function is mediated by a heterodimer of IL-17RA and 
IL-17RB [252, 253]. Important roles in barrier maintenance and the defense against parasites 
have been demonstrated for IL-25 [254]. It promotes Th2-type inflammations characterized 
by, among others, high levels of eosinophils and increased expression of IL-4, IL-5, and IL-13, 
and has been linked to chronic allergies, particularly asthma [255-258]. Furthermore, IL-25 can 
suppress Th17 responses by up-regulating PD-L1 expression in mesenchymal stromal cells and 
by inducing IL-13 secretion thereby inhibiting IL-23, IL-1β, and IL-6 expression in DCs, key 
regulators of Th17 cells [259, 260]. Anti-tumorigenic effects of IL-25 have been demonstrated 
in breast cancer [261, 262], gastric cancer [263], and colon cancer [264]. However, pro-
tumorigenic and pro-metastatic functions of IL-25 have also been observed in breast cancer 
[265, 266] indicating diverse functions of IL-25 in carcinogenesis. 
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4.1.6 CXCL12/ CXCR4  
Chemokines are chemotactic cytokines with versatile functions in the TME, where they 
not only regulate immune cell migration but can also affect tumor cell proliferation, 
angiogenesis, and metastasis [267]. For example, the chemokine CXCL12 and its receptor 
CXCR4 exert diverse pro-tumorigenic functions in various cancers [268]. In tumor cells, the 
CXCL12/CXCR4 axis promotes proliferation, stemness [269-272], and metastasis [273-275]. Its 
effect on endothelial cells drives angiogenesis in synergy with VEGF [276, 277]. Furthermore, 
the CXCL12/CXCR4 axis is involved in DC recruitment and Treg homing to the TME and bone 
marrow, respectively [278, 279]. 
4.1.7 Chemerin/ CMKLR1 axis 
Chemerin is a multifunctional chemoattractant factor and adipokine [280, 281] 
implicated in, among others, obesity and metabolic disorders [282, 283], cardiovascular 
diseases [284], leukocyte trafficking [285], host defense [286], angiogenesis [287], and 
inflammation [288].  
Furthermore, chemerin has been identified as a biomarker/ prognostic factor in gastric 
cancer [289], colorectal cancer [290], and non-small cell lung cancer [291]. Although chemerin 
serum levels are higher in patients with aggressive adrenocortical tumors compared to benign 
tumors, high chemerin levels correlate with improved overall survival [292].  
Secreted as prochemerin with low activity, chemerin’s function is regulated by its 
environment, as it can be further processed by extracellular proteases into different chemerin 
isoforms with varying activity (Figure 7) [280, 283, 293]. 
To date, three G protein-coupled receptors (GPCRs) have been identified that bind 
chemerin: CMKLR1 (Chemokine-like receptor 1), GPR1 (G protein-coupled receptor 1), and 
CCRL2 (C-C chemokine receptor-like 2) [294-296]. CMKLR1 is expressed by a variety of immune 
cells, such as macrophages, DCs, and NK cells as well as endothelial cells, adipocytes, and 
smooth muscle cells [297]. The chemerin/CMKLR1 axis can promote but also suppress 
inflammation, as functionally different chemerin isoforms may be present at different stages 
of inflammation and thereby, to some extent, control the severity of the immune response 
[288, 298]. Serine proteases secreted by, for example neutrophils, during early stages of 
inflammation generate active chemerin that contributes to recruiting different innate immune 
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cells, and promoting angiogenesis [288]. Proteases present at a later stage of inflammation, 
such as mast cell tryptase or cysteine proteases, produced by macrophages can generate 
chemerin variants with low or no activity promoting phagocytosis and regulating immune cell 
trafficking [288]. This diverse functionality may form the basis for the complex role of the 
chemerin/CMKLR1 axis in cancer, as both pro- and anti-tumorigenic effects have been 
described [299]. While pro-tumorigenic functions have been demonstrated in glioblastoma 
[300], squamous esophageal cancer [301, 302], gastric cancer [303], oral squamous cell 
carcinoma [304], and neuroblastoma [305] anti-tumorigenic functions have been observed in 
hepatocellular carcinoma [306-308], melanoma [309], and adrenocortical tumors [310]. 
 
 
Figure 7: Chemerin processing. 
Chemerin can undergo complex post-secretory processing by different proteases resulting in chemerin isoforms 
with varying activity determined predominantly by chemotaxis and intracellular calcium mobilization assays. 
While ChemerinR125 does not promote chemotaxis in CMKLR1-postive cells, antimicrobial activity has been 
demonstrated. Based on [280, 283, 293, 311]. 
Although most of the known chemerin functions are mediated by CMKLR1, roles for 
CCRL2 and GPR1 are emerging. In cutaneous squamous cell carcinoma, fibroblast-derived 
chemerin promotes migration of tumor cells through CCRL2 and GPR1 [312]. Furthermore, 
CCRL2 has been linked to migration and invasion in glioblastoma [313] and metastasis in 
colorectal cancer [314]. However, also the function of CCRL2 is complex and context-
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dependent, as it has been demonstrated to suppress migration and invasion in breast cancer 
[315]. 
Originally cloned in 1994 [316], GPR1 was identified as a chemerin receptor in 2008 
[295]. GPR1 mRNA has been detected in different human cell types and tissues, such as the 
adrenal cortex, smooth muscle cells of blood vessels, kidney tubules, and skin [317]. Although 
the role of GPR1 in health and disease is so far only partly understood versatile functions are 
emerging. While GPR1 is a co-receptor in human immunodeficiency virus replication [318], it 
has also been linked to the regulation of glucose homeostasis [319] and atherosclerosis [320]. 
Furthermore, pro-tumorigenic effects of chemerin in gastric cancer were recently linked to 
both CMKLR1 and GPR1 [321]. 
4.1.8 COX-2/ PGE2  
While normally absent in the majority of cells, cyclooxygenase 2 (COX-2) is upregulated 
during inflammation and also in various tumors [322]. COX-2 is one of the enzymes that 
mediates the synthesis of prostanoids, such as PGE2, a potent pro-inflammatory factor [322]. 
The COX/PGE2 axis can promote proliferation, survival, and migration of tumor cells, support 
angiogenesis, advance immunosuppression through impairment of effector T cells, NK cells, 
and DCs, and enhance suppressive MDSCs and Treg functions [322-324]. Furthermore, PGE2, 
in synergy with IL-23, can promote Th17 expansion in vitro [325]. 
4.2 INFLAMMATORY CELL SIGNALING 
Pro-inflammatory cell signaling pathways, such as the JAK/STAT3 pathway or NF-κB 
(nuclear factor kappa-light-chain-enhancer of activated B cells) signaling, are frequently 
upregulated in cancer and among the most attractive drug targets for cancer therapy [130, 
138, 152]. 
NF-κB activation occurs in tumors cell and other cells of the TME and can regulate, 
directly or through cross-talk with other signaling pathways, all known cancer hallmarks [326]. 
Cytokines and danger signals, such as DAMPs and PAMPs (Pathogen-associated molecular 
patterns), can among others, activate NF-κB signaling [326]. Similar to NF-κB, the JAK/STAT3 
pathway can regulate various cancer hallmarks, such as cell proliferation and survival, invasion 
and metastasis, inflammation, and immune suppression [327]. Members of the IL-6 family, 
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TLRs, various GPCRs, and microRNAs can modulate JAK/STAT3 signaling in tumor cells and 
other cells present in the TME [327]. 
Spleen tyrosine kinase (SYK) is a non-receptor tyrosine kinase widely expressed in 
hematopoietic cells mediating signaling by immune receptors, integrins, C-type lectins, and 
others [328]. Activated SYK can directly interact with VAV and PLCγ family members, 
phosphoinositide 3-kinase (PI3K) and SLP (Scr homology 2 domain containing leukocyte 
protein) 76 or 65 activating a broad variety of downstream signaling molecules, such as 
extracellular signal-regulated kinase (ERK), Akt, c-JUN-NH2 terminal kinase (JNK), the mitogen-
activated protein kinase p38, and transcription factors like NF-κB (Figure 8) [328]. 
 
Figure 8: SYK signaling. 
In the immunoreceptor-signaling context, SYK is recruited upon ITAM (immunoreceptor tyrosine-based 
activation motif) phosphorylation leading to SYK activation by phosphorylation (not shown). Active SYK can bind 
to a variety of signaling molecules that activate various downstream pathways thereby regulating different 
cellular responses. Feedback mechanisms can further mediate SYK signaling. Reprinted by permission from 
Springer Nature Customer Service Centre GmbH: Springer Nature, Nature Reviews Immunology [328]. 
SYK has been implicated in different inflammatory conditions [329] and recently, with 
fostamatinib, the first SYK inhibitor has been approved for the treatment of immune 
thrombocytopenia [330]. Both, pro- and anti-tumorigenic SYK functions have been described 
in hematological cancers and solid tumors indicating SYK’s multifunctionality [331]. For 
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example, SYK inhibits breast cancer tumor growth and lung metastasis formation in vivo [332] 
and functional involvement in cell-cell adhesion has been described in vitro [333]. However, 
SYK has recently been implicated in breast cancer metastasis, where it supports mesenchymal 
to epithelial transition and metastatic outgrowth [334]. Although SYK expression decreased 
following TGF-β-mediated EMT its activity increased considerably, indicating that the 
expression level of the kinase is not necessarily an indicator of its activity [334]. Pro-tumor 
functions of SYK have been described in Ewing sarcoma where it promotes tumor growth by 
upregulation of c-Myc and MALAT1 [335]. Furthermore, SYK is expressed in retinoblastoma 
and inhibition of SYK impairs cell survival in vitro and tumor growth in vivo [336]. In ovarian 
cancer, SYK promotes cell migration, invasion, and paclitaxel-resistance [337, 338]. Recently, 
pro-inflammatory functions of SYK have been described in the glioma TME [339]. Moncayo et 
al. demonstrated that SYK inhibition not only impaired tumor cell proliferation and invasion 
but also reduced infiltration of B cells and leukocytes [339]. Furthermore, SYK is present in 
neuroblastoma tissues and SYK-inhibition potentiates the neuroblastoma cell killing effects of 
chemotherapeutic drugs in vitro [340]. 
5 PEDIATRIC CANCER 
“Children are not just small adults”- saying in pediatrics 
Although the common principles of tumorigenesis described above apply to both, 
pediatric cancers and adult cancers differ in many aspects. The occurrence of malignancies in 
children and adolescents is rare in comparison to adults. Overall, childhood cancers account 
for 1.4% of malignancies worldwide [341]. While the risk to develop a childhood cancer is 
about 1 in 500, adult cancers occur with an approximate risk of 1 in 3 [342]. About 35000 
children and adolescents are diagnosed with cancer each year in Europe [343]. The 5-year 
survival of childhood cancer patients in high-income countries has remarkably improved from 
30% in the 1960s to approximately 80% in the 2000s [341]. However, despite improving 
survival rates, 6000 pediatric cancer patients die every year in Europe, making it the primary 
cause of disease-related deaths in children above one year of age [343]. 
While carcinomas are the most frequently occurring cancer type in adults, childhood 
cancers are more diverse, and carcinomas account for less than 5% of all cases [341]. In 
children, hematologic malignancies (leukemia and lymphoma) are predominant (40%), 
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followed by tumors of the central nervous system (25%) and other solid tumors (35%) [342]. 
However, the distribution varies between different age groups (Figure 9) [341]. 
 
Figure 9: Proportions of pediatric tumor groups in Europe.  
The distribution of the 12 main tumor types is displayed according to their occurrence in different age groups. 
Reprinted from The Lancet Oncology, Vol. 14, [341], an adapted version from The Lancet, Vol. 364 [344] with 
permission from Elsevier. 
Tumor development in adults is a multistep process based on an accumulation of 
mutations and microenvironmental changes over a long period of time. Many pediatric 
malignancies, particularly solid tumors, are considered developmental diseases, as they are 
closely associated with defects in normal organ and tissue development and/or maturation 
[345, 346]. Cells in developing immature tissues often display a high proliferation rate, 
prolonged survival, and increased migration ability, typical characteristics of malignant cells. 
Therefore, it has been suggested that many pediatric solid tumors arise when cells and tissues 
fail to complete development to mature tissues and organs [345, 346]. Consequently, this 
poses a challenge for childhood cancer therapy since tumors can be surrounded by normal 
but equally fast growing developing tissue that will be affected to some extent by 
chemotherapy and radiation [345]. 
The repeated observation that the mutation frequency and mutational load is 
significantly lower in pediatric compared to adult tumors (Figure 10) [347, 348] supports the 
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notion that fewer defects are necessary to promote pediatric tumorigenesis thereby 
accelerating cancer development [345, 346]. 
 
Figure 10: Somatic mutations in pediatric and adult cancers. 
Frequency of somatic mutations in 11 pediatric (n=879 primary tumors) and 11 adult (n=3281) cancer types. The 
solid black lines represent the median mutation load for each cancer type, the solid purple and solid green line 
the median mutation load across pediatric and adult cancers, respectively. Reprinted from [347] under the 
Creative Commons Attribution License (CC BY 4.0). 
The treatment of pediatric malignancies is particularly challenging considering the 
young age of the patients and the fact that the majority of the survivors will develop chronic 




“Few tumours have engendered as much fascination and frustration for clinical and laboratory 
investigators as neuroblastoma” Garrett M. Brodeur [351] 
Neuroblastoma is a malignancy of early childhood, with 90% of cases being diagnosed 
within the first 5 years of life and less than 5% in children over 10 years of age [352, 353]. The 
median age at diagnosis is 18 months [354]. Neuroblastomas account for 6-10% of childhood 
cancers [355]. It is the most common embryonal cancer, accounting for 44% of embryonal 
malignancies in Europe [356], and the most frequently diagnosed cancer during the first year 
of life [357].  
Tumors can occur anywhere in the sympathetic nervous system with the majority 
arising in the adrenal gland (47%) and from paraspinal or other sympathetic ganglia (24% 
abdominal/retroperitoneal, 15% thoracic, 3% pelvic, 3% in the neck and 8% at other sites) 
[358]. Approximately 50% of patients present with metastatic disease at diagnosis with the 
major metastatic sites being the bone marrow and bone (>50%) and to a lesser extent lymph 
nodes, liver, and intracranial and orbital sites. Metastases are rarely observed in the lung and 
CNS [357, 359]. 
6.1 EPIDEMIOLOGY 
The annual incidence rate of NB in Europe (1995-2002) is 1.78 per million persons of 
the general population with a slightly higher occurrence in boys (2.02 per million) than girls 
(1.56 per million) [356]. The age-standardized incidence rate is 10.9 cases per million children 
(age 0-14) in Europe (1988–1997) [360]. Although cases of neuroblastomas in adults have 
been reported, they are exceedingly rare with an incidence rate of fewer than 0.3 cases per 
million people per year (1973-2002) [361].  
In the Nordic countries (Norway, Sweden, Denmark, Finland, and Iceland) 
neuroblastomas account for 8% of pediatric cancers (Figure 11) [362].  
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Figure 11: Distribution of pediatric cancer diagnoses in the Nordic countries from 1985-2014. 
The proportions of cancer types in children <15 years of age at diagnosis. The Nordic countries include Norway, 
Sweden, Denmark, Finland, and Iceland. LCH = Langerhans Cell Histiocytosis; HLH = Hemophagocytic 
Lymphohistiocytosis; Reprinted from [362] with permission from Göran Gustafsson, Solid Tumor Registry Group, 
NOPHO Annual Report 2016. 
Owing to advances in diagnosis and therapy, the 5-year survival has increased from 
56% to 74% in the past 30 years (Table 3) representing the most prominent improvement 
among childhood cancers in the Nordic countries [362]. 
Table 3: Neuroblastoma 5-year survival estimates over three time periods in the Nordic countries.  
OS= overall survival, * p-values between time periods; ** OS at 5 years-whole time period. Adapted and reprinted 
from [362] with permission from Göran Gustafsson, Solid Tumor Registry Group, NOPHO Annual Report 2016.  
 N Survival at 5 years-Kaplan-Meier (± SD) OS at 5 years 
  1985-1994 1995-2004 2005-2014 p-value* 1985-2014** 
Sweden 420 0.61±0.04 0.66±0.04 0.74±0.04 0.045 0.67±0.02 
Denmark 268 0.39±0.05 0.68±0.05 0.71±0.06 <0.01 0.59±0.03 
Norway 233 0.51±0.05 0.83±0.05 0.88±0.04 <0.01 0.73±0.03 
Finland 279 0.68±0.05 0.67±0.05 0.68±0.06 0.93 0.67±0.03 
Iceland 11 0.67±0.27 0.75±0.21 0.75±0.21 0.92 0.72±0.14 
All countries 1210 0.56±0.02 0.70±0.02 0.74±0.03 <0.01 0.66±0.01 
 
However, despite advances in treatment, neuroblastoma accounts for 12-15% of 
cancer-related deaths in children [353]. Particularly the treatment of high-risk patients 
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remains a challenge as approximately 50% of high-risk patients do not respond to therapy or 
relapse within two years despite intensive treatment regimen [363]. 
6.2 BIOLOGY AND HISTOLOGY 
Neuroblastoma is a neuroendocrine tumor originating from neural crest cells of the 
sympathoadrenal lineage [364, 365]. The neural crest is a tightly controlled, migratory, and 
transient cell population during embryogenesis that gives rise to different tissues including 
the sympathetic nervous system [366]. During this highly complex process,s de-regulated 
expression of factors that promote proliferation and stemness (e.g. N-Myc, FGF/Stat3, Lin28B, 
ALK), migration (Wnt, BMP, Rho), and differentiation (e.g. BMP, Phox2b, FoxD3) may lead to 
the development of malignant neuroblasts that give rise to neuroblastoma [366, 367]. 
The majority of neuroblastomas are sporadic with familial cases of neuroblastoma 
accounting for only 1-2% of all neuroblastoma cases [357]. As a major predisposition factor in 
familial neuroblastoma, mutations in the ALK gene, encoding the anaplastic lymphoma 
receptor tyrosine kinase (ALK) were identified [368].  
Several genetic alterations have been identified in neuroblastoma [357]. While whole 
chromosome gains (triploid and hyperdiploid DNA content) indicate a favorable clinical 
behavior, segmental chromosome aberrations are connected to clinically unfavorable tumors 
(Table 4) [369, 370].  
Table 4: Prognostic value of genetic alterations in neuroblastoma 
Analysis based on 505 patients without MYCN-amplification; EFS=event-free survival, OS=overall survival; 
Reprinted from [370] under the Creative Commons Attribution License (CC BY-NC-SA 3.0). 
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The gain of 17q and loss of 1p or 11q are the most common segmental alterations 
associated with a poor prognosis [371-373]. Recently, distal loss of 6q has been described as 
a marker of poor prognosis in high-risk neuroblastoma patients [374]. 
The best-characterized genetic alteration in neuroblastoma is the amplification of the 
MYCN oncogene, a potent genetic marker for aggressive clinical behavior. MYCN amplification 
is observed in approximately 20% of neuroblastomas and more intriguingly in about 40% of 
high-risk patients, underlining its importance as a prognostic factor [375-379]. N-Myc is a 
powerful transcription factor that can affect the majority of cancer hallmarks driving tumor 
progression and metastasis [380, 381]. 
Neuroblastomas, as the majority of pediatric cancers, are characterized by a low 
mutational frequency [347, 348, 382]. The most frequently observed changes are activating 
mutations in ALK, PTPN11, MYCN, and the NRAS oncogene and in addition, inactivating 
mutations in ATRX and ARID1A/B [382-385]. However, an increase in mutations and 
segmental alterations has been observed in relapse neuroblastomas [386, 387] including 
mutations in the RAS/MAPK pathway, p53, and ALK [388-390]. Recently, a “high” mutational 
burden (>3) was identified as a prognostic marker independent of age, stage, histology, and 
MYCN-amplification [391]. 
Neuroblastoma is known for its remarkable ability to spontaneously regress, despite 
metastatic disease, in infants with only numerical chromosome aberrations and without 
segmental chromosome aberrations or MYCN amplification [392, 393]. Several molecular 
mechanisms have been suggested to underlie/contribute to spontaneous regression, such as 
TrkA/NGF-mediated apoptosis or differentiation, immune recognition and tumor elimination, 
telomere shortening, and epigenetic alterations [393]. However, the exact mechanisms of 
spontaneous regression still remain uncertain [394].  
Histologically, neuroblastoma is a small round blue cell tumor composed of 
neuroblasts and Schwann cells at different proportions. Neuroblastic tumors display different 
levels of differentiation and maturation that form the basis for a morphology-based, 
prognostic classification system [395, 396]. Based on this system neuroblastic tumors can be 
categorized into four morphologic categories [395-397]: 
• Neuroblastoma (Schwannian stroma-poor) with undifferentiated, poorly 
differentiated or differentiating subtype (Figure 12A) 
• Ganglioneuroblastoma, intermixed (Schwannian stroma-rich) 
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• Ganglioneuroma (Schwannian stoma-dominant) with maturing or mature subtype 
(Figure 12B) 
• Ganglioneuroblastoma, nodular (composite Schwannian stroma-rich/stroma-
dominant/stroma-poor) with favorable and unfavorable subtype 
 
Figure 12: Histology of neuroblastoma and ganglioneuroma. 
Typical examples of neuroblastoma (A) and ganglioneuroma (B), H&E, magnification 900x. A poorly 
differentiated neuroblastoma (A) is characterized by neuroblasts with relatively small nuclei showing salt and 
pepper chromatin pattern, and a limited quantity of neuropil. Necrosis and calcification are often observed 
(insert). (B) Ganglioneuroma with maturing and mature ganglion cells embedded in Schwannian stroma. Images 
were kindly provided by Andrey Valkov (Department of Clinical Pathology, University Hospital of Northern 
Norway, Tromsø, Norway). 
6.3 NEUROBLASTOMA TME AND IMPLICATIONS OF INFLAMMATORY 
MEDIATORS 
There is increasing evidence that the neuroblastoma TME is characterized by complex 
interactions between tumor cells, immune cells, other stromal cells, and non-cellular 
components [398]. 
Lymphocyte infiltration was established as a positive prognostic marker in neuroblastoma 
already 50 years ago [399, 400]. In addition, high levels of CD3+ T cell proliferation and 
organization correlate with positive clinical outcome [401] and a T cell-poor 
microenvironment and reduced interferon pathway activity have been linked to MYCN 
amplification [402]. Moreover, the presence of a cytotoxic T cell RNA signature corresponds 
to increased infiltration of T cells and NK cells and a better prognosis in a subgroup of non-
MYCN-amplified high-risk patients [403]. Furthermore, infiltration with CD8+ T cells with an 
effector memory phenotype was observed in a panel of neuroblastoma tissues [404]. 
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However, it has been demonstrated that neuroblastoma cells apply different strategies, such 
as downregulation of MHC class I (HLA-1) expression, upregulation of checkpoint inhibitors 
(e.g. PD-L1), and secretion of immunosuppressive factors (e.g. TGF-β, IL-10, and arginase-2), 
to create an immunosuppressive microenvironment and impair T cell function [405-407]. Of 
note, differentiation of neuroblastoma cells can lead to an upregulation of MHC class I 
expression increasing sensitivity to CTL- and NK cell-mediated lysis [408].  
Great potential for NK cell-mediated neuroblastoma cell killing has been 
demonstrated in vitro and in vivo [409]. However, different mechanisms have been described 
that impair NK cell-mediated immunosurveillance, such as downregulation of MHC class I, 
downregulation of activating receptors and/or their ligands, and the presence of 
immunosuppressive NK cell receptor isoforms [409-411]. 
The importance of myeloid cells in the neuroblastoma TME has been demonstrated in 
different studies. TAM infiltration correlates with clinical stage, risk classification, and 
metastasis [412, 413]. Furthermore, a genetic signature representing TAMs was identified as 
a prognostic marker in children with neuroblastoma at the age of ≥ 18 months without MYCN 
amplification [412]. TAMs can promote neuroblastoma proliferation in vitro and in vivo in an 
IL-6-dependent manner [414]. Furthermore, in a murine model lacking MYCN amplification 
TAMs upregulate c-Myc expression and STAT3 activation in neuroblastoma cells in an IL-6-
independent manner [415].  
MDSCs promote tumor growth in neuroblastoma and contribute to an 
immunosuppressive TME [416]. The presence of CSF-1R+ myeloid cells correlates with poor 
survival in neuroblastoma patients and blockade of CSF-1R significantly impaired tumor 
growth and reduced splenic MDSC and TAM numbers in an aggressive murine model of 
neuroblastoma [417].  
As professional antigen presenting cells, DCs play an important role in 
immunosurveillance [33]. Neuroblastoma cells can impair DC generation, maturation, and 
function and interestingly, neuroblastoma cell-derived gangliosides have been identified as 
contributing factors [418, 419]. 
CAFs play an important role in the neuroblastoma TME by producing mPGES-1, a key 
enzyme for PGE2 synthesis, thereby supporting tumor growth and angiogenesis [420, 421]. 
Additionally, a new subtype of CAFs has recently been described in neuroblastoma that 
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displays phenotypical and functional similarities with mesenchymal stromal cells and 
stimulates neuroblastoma growth in vitro and in vivo [422]. 
Sufficient vascularization ensures the supply of oxygen and nutrients in growing 
tumors [108]. Several angiogenic factors, such as VEGF, PDGF, and FGF, contribute to 
angiogenesis in neuroblastoma [398]. Moreover, N-Myc and ALK can promote VEGF 
production in neuroblastoma [423, 424]. Furthermore, effective VEGF-blockade (VEGF-Trap) 
in neuroblastoma causes regression of coopted host vasculature [425]. Interestingly, MYCN 
amplification has been observed in microvessel-forming endothelial cells in neuroblastoma, 
indicating that they may originate from tumor cells [426].  
Of note, ECM components, such as reticulin fibers and exosomes, have also been associated 
with high risk and pro-tumorigenic functions [427, 428]. 
Various inflammatory mediators have been identified in the neuroblastoma TME. 
Table 5 presents a selection of inflammatory mediators and their function in neuroblastoma. 
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Promotes cell proliferation, survival, and drug resistance through activation of STAT3 
[429] 
[430] 
IL-6 elevated in blood and bone marrow of patients with high-risk disease compared to low and intermediate risk patients [431] 
COX/mPGES/ PGE2 
IL-1β upregulates COX-2 and the release of PGE2 in the neuroblastoma cell line SK-N-SH [432] 
COX-2 is upregulated in neuroblastoma cell lines and tumor tissue; COX inhibition induces cell death in vitro and inhibits 
tumor growth in vivo 
[433] 
NSAIDs induce apoptosis of neuroblastoma cells in vitro and inhibit neuroblastoma growth in vivo [434] 
Combination of low-dose chemotherapy and COX inhibitors potentiates neuroblastoma cell apoptosis and promotes p53 
function 
[435] 
Selective COX-2 inhibition (Celecoxib) potentiates efficacy of chemotherapeutic drugs in vitro and in vivo  [436] 
PGE2 receptors are expressed in neuroblastoma cell lines and tumor tissue; PGE2 promotes cell viability and Akt signaling, 
PGE2 receptor antagonists reduce cell viability 
[437] 
Low dose Aspirin (dual COX-1/ COX-2 inhibitor) reduces tumor burden, infiltration with MDSCs, TAMs, DCs, and TGFβ 
levels 
[438] 
β-catenin stabilization is involved in PGE2-mediated increase in neuroblastoma cell viability [439] 
11q-deleted neuroblastomas display elevated levels of mPGES and PGE2, high mPGES expression is associated with poor 
overall survival in stage 4 neuroblastomas, COX-inhibition reduces tumor growth in an 11q-deletion xenograft model 
[421] 
mPGES inhibition reduces CAF-derived PGE2 production, tumor growth, and angiogenesis [420] 
CXCR4/CXCR7/CXCL12 
CXCR4 is expressed in neuroblastoma cells and CXCL12 promotes migration of SH-SY5Y cells [440] 
CXCR4 expression correlates with high clinical stage and metastases in the bone and bone marrow [441] 
CXCL12 does not stimulate chemotaxis of primary neuroblastoma cells or cell lines [442] 
CXCR4 promotes growth of primary tumor and liver metastases in an orthotopic tumor model [443] 
Multiple CRXR4 isoforms are expressed in neuroblastoma cells and CXCR4 downregulation is independent of CXCL12 but 
correlates with increasing confluency 
[444] 
CXCR4 and CXCR7 mediate neuroblastoma cell migration towards mesenchymal stromal cells [445] 
CXCR7 reduces neuroblastoma growth in vitro and in vivo and impairs CXCL12/CXCR4 chemotaxis [446] 
In a tumor cell implantation model CXCR4 or CXCR7 promote neuroblastoma cell dissemination to the liver or adrenal 
gland and liver, respectively; co-expression of CXCR4 and CXCR7 promotes dissemination to the bone marrow 
[447] 
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M-CSF (CSF-1)/ CSF-1R 
Neuroblastoma cells express CSF-1R and CSF-1 at varying levels; targeting CSF-1 using siRNA reduces tumor growth, TAM 
infiltration, and angiogenesis in vivo 
[448] 
Neuroblastoma cell-derived M-CSF promotes suppressive functions of myeloid cells; CSF-1R inhibition, alone or in 
combination with checkpoint blockade limit tumor growth in a transgenic neuroblastoma model 
[417] 
CSF-1R inhibition in combination with PD-1 blockade increases T cell infiltration in transgenic neuroblastoma model; 
correlation between PD-L1 expressing myeloid cells and tumor burden was determined 
[449] 




TNF-α promotes neuroblastoma cell proliferation in the presence of insulin [451] 
TNF-α activates NF-κB in neuroblastoma cell lines, NF-κB activation does not promote differentiation or proliferation [452] 
TNF-α induces NF-κB-mediated upregulation of Fas in a subset of neuroblastoma cell lines, TNFα sensitizes those cells to 
FasL-, cisplatin-, etoposide-induced cell death 
[453] 
TNF-α upregulates PD-L1 and HLA-1 in SH-SY5Y and SK-N-FI cells but not MYCN-amplified cell lines  [454] 
Cell supernatants from neuroblastoma cell lines can decrease TNF-α and IL-12 production from mature DC’s [455] 
Macrophage-derived TNF-α and IL-1β induce upregulation of arginase-2 in neuroblastoma cells promoting proliferation; 
high levels of TNF-α and IL-1β in stage 4 tumors are associated with a worse prognosis 
[456] 
 43 
6.4 STAGING AND RISK CLASSIFICATION 
Neuroblastoma is a highly heterogeneous disease with its clinical behavior 
spanning from spontaneously regressing to highly aggressive, metastatic and therapy-
resistant tumors [351]. 
First published in 1988 and revised in 1993, the International Neuroblastoma 
Staging System (INSS), based on tumor resectability and the extent of metastases, was 
until recently the most widely used neuroblastoma staging system [457, 458]. 
However, INSS has the disadvantage that tumor assessment is made after the initial 
surgery. Therefore, the International Neuroblastoma Risk Group (INRG) developed a 
pretreatment classification system (INRGSS) to update and replace the INSS in 2009 
[459, 460]. The system was developed to enable the comparison of clinical trials 
conducted at different sites by defining four pretreatment risk groups (very low-, low, 
intermediate- or high-risk) [459]. The INRGSS is based on image-defined risk factors to 
determine the extent of the disease at the time of diagnosis (Table 6) and clinically 
relevant criteria (Table 7) [459, 460]. 
Table 6: International Neuroblastoma Risk Group Staging System (INRGSS).  




Table 7: INRG Consensus Pretreatment Classification schema.  
GN, ganglioneuroma; GNB, ganglio-neuroblastoma; Amp, amplified; NA, not amplified. For the 
definition of L1, L2, M, and MS see Table 6. All blank fields represent any value. Reprinted from [459] 
with permission. ©2009 American Society of Clinical Oncology. All rights reserved.  
 
6.5 TREATMENT 
The treatment of neuroblastoma is as heterogeneous as the disease itself 
ranging from observation only to intensive multimodal therapy [357]. The INRGSS 
pretreatment risk groups serve as important guides for clinicians to decide the best 
treatment plan (Figure 13). 
 
Figure 13: Overview of neuroblastoma treatment based on risk classification.  
Surgical resection or observation only is the standard treatment for low risk patients. The treatment of 
intermediate risk patients includes chemotherapy and surgery while the therapy regimen for the high-
risk patients includes chemotherapy, surgery, myeloablation and stem cell transplantation, radiation, 
immunotherapy, and treatment with a differentiation-inducing agent. Reprinted by permission from 
Springer Nature Customer Service Centre GmbH: Springer Nature, Cell and Tissue Research [461].  
 45 
The treatment for patients with very low- and low-risk disease includes 
observation or surgical resection and intermediate-risk disease is managed with 
chemotherapy and surgical resection [461]. Increasing evidence supports that 
observation alone as an appropriate treatment for low-risk patients with favorable 
histologic and genomic features [462, 463]. Furthermore, several studies demonstrate 
the possibility to reduce treatment in patients with low- and intermediate-risk disease 
while maintaining a high overall survival rate (>90%) [464-466]. 
Although the 5-year overall survival has increased in high-risk neuroblastoma 
patients from 29% (patients diagnosed between 1990 and 1994) to 50% (patients 
diagnosed between 2005 and 2010), treatment of high-risk disease remains a 
challenge [467]. The current therapeutic regimen lasts approximately 18 months and 
consists of the induction phase (5-8 cycles of intensive chemotherapy and surgical 
resection), the consolidation phase (myeloablative chemotherapy followed by 
autologous stem cell transplantation and radiation therapy) and the maintenance 
phase (treatment with the differentiating agent isotretinoin and anti-GD2 therapy 
combined with IL-2 and with or without GM-CSF) [468]. 
The prognosis for patients with refractory or relapsed neuroblastoma remains 
poor and although partial or complete responses can be achieved these patients are 
rarely cured [461]. Common salvage therapy includes chemotherapy or 131I-MIBG 
radiotherapy [461, 469]. 
The increasing understanding of neuroblastoma biology has led to the 
identification of various druggable targets, such as ALK, PI3K/mTOR (mammalian 
target of rapamycin)/Akt, Aurora A kinase, EGFR, Ras/MAPK, histone deacetylase, 
Wnt/β-catenin, checkpoint kinases 1 and 2 (CHK1/2), Bromodomain and extra-
terminal motif (BET) proteins, and VEGF, and the development of targeted therapies 
[363, 470, 471]. Several targeted drugs have been evaluated or are currently under 
evaluation in neuroblastoma clinical trials [363, 470, 471]. 
The inclusion of monoclonal antibodies targeting the disialoganglioside GD2 
(known as dinutuximab or ch14.18) in combination with IL-2 and GM-CSF into 
maintenance therapy has significantly improved event-free survival in high-risk 
neuroblastoma patients [472]. In addition, the efficacy of anti-GD2 therapy as part of 
consolidation therapy has also been demonstrated [473]. This has led to the 
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development of humanized anti-GD2 monoclonal antibodies and different 
approaches targeting GD2, such as bispecific antibodies or CAR-T cells [474]. 
Furthermore, combination therapy of anti-GD2 with chemotherapy, NK cells or PD-1 
blockage has displayed great promise in clinical trials or pre-clinical studies [475-477]. 
Intense neuropathic pain is one of the major adverse effects related to anti-GD2 
therapy and modifications in the treatment regimen, such as long-term antibody 
infusion, aim at reducing toxicity [478]. 
Other immunotherapy approaches, among others, immune checkpoint 
blockage (anti-CTLA-4 and anti-PD-1), NK cell therapy, and ALK CAR (chimeric antigen 
receptor) T cell therapy, have been investigated in neuroblastoma with mixed results 
or are currently under investigation [479-483]. Recently, Parihar et al. demonstrated 
that genetically modified NK cells target MDSCs and improve the activity of GD2 
CAR-T cells in a neuroblastoma xenograft model [484]. Furthermore, antibodies 
targeting CD105+ cells (MSCs, monocytes, and endothelial cells) improved 
immunotherapy with dinutuximab and activated NK cells in a neuroblastoma murine 
model [485]. These findings underline that a thorough understanding of the 




AIMS OF THE THESIS 
The overall aim of this thesis was to investigate novel inflammatory mediators and 
inflammatory pathways in neuroblastoma and evaluate their therapeutic potential. 
 
The specific aims were: 
 
Paper I: To assess the functional significance of the Chemerin/CMKLR1 axis in 
neuroblastoma tumorigenesis. 
 
Paper II: To evaluate spleen tyrosine kinase (SYK) as a potential therapeutic target in 
neuroblastoma. 
 
Paper III: To investigate the role of the IL-17 family and the associated cytokine IL-23 




This section aims to give a general overview of the methods used in this thesis, 
the rationale for choosing them, and their limitations. The specific materials and 
conditions used in this work are described in detail in papers I-III. 
1 BIOLOGICAL MATERIAL 
Cancer cell lines are an extremely useful tool to study diverse biological 
processes and the efficacy of therapeutic agents. A broad variety of neuroblastoma 
cell lines with specific morphological and genetic characteristics is available that can 
represent different aspects of neuroblastoma biology, such as presence or absence of 
MYCN-amplification, ALK mutations, and segmental chromosome aberrations [486]. 
Neuroblastoma cell lines are a convenient tool as their handling is uncomplicated and 
their relatively short doubling times allow extensive experimental set ups. However, 
one has to keep in mind that cancer cell lines have undergone many passages that 
unavoidably have caused changes in the cells. They should, therefore, be considered 
a useful model that can however not replace patient material and in vivo studies.  
Primary cell cultures can be a valuable alternative to established cell lines as 
they display a more native phenotype. However, primary cell cultures are difficult to 
obtain for rare diseases, such as neuroblastoma with 233 registered cases in Norway 
between 1985 and 2014 [362]. Furthermore, specific ethical guidelines apply for the 
work with primary cells. 
1.1 CELL LINES (PAPER I-III) 
To confirm the identity of the cell lines used in this work STR (short tandem 
repeat) profiling was performed at the Centre of Forensic Genetics, University of 
Tromsø. The cell lines were routinely grown without antibiotics as it has been 
demonstrated that antibiotics can affect the proliferation and gene regulation of 
cultured cells [487, 488]. Furthermore, the use of antibiotics can hide low level 
contaminations and mycoplasma infections [489]. Mycoplasma tests were performed 
regularly.  
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1.2 HUMAN TISSUE SAMPLES (PAPER I-III) 
Neuroblastoma tumor tissues were obtained in accordance with the ethical 
approval from the Stockholm Regional Ethical Review Board and the Karolinska 
University Hospital Research Ethics Committee (approval ID 2009/1369-31/1 and 03-
736) at the Astrid Lindgren Children’s Hospital, Karolinska University Hospital. 
Informed consent (written or verbal) for the use of tumor samples in research was 
provided by the parents or guardians. 
1.3 IN VIVO STUDIES (PAPER I AND III) 
All animal studies were conducted at the Department of Comparative 
Medicine, Karolinska University Hospital in accordance with the local guidelines and 
the European Directive 2010/63/EU. The studies were approved by the regional ethics 
committee (ethical permits N231/14 and N42/12). The 3R’s (replacement, refinement, 
and reduction) were considered while planning and conducting all experiments 
involving animals. 
2 GENE EXPRESSION STUDIES  
2.1 SCREENING OF PUBLICALLY AVAILABLE GENE EXPRESSION 
DATABASES (PAPER I-III) 
The R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl) was 
used to screen different neuroblastoma datasets for the expression of relevant genes 
and their prognostic implications (comparison of high and low expression in relation 
to overall or event-free survival), and to examine correlations between genes. Both 
microarray-based data sets (paper I-III) and RNA-sequencing-based data sets 
(paper III) were used. Furthermore, the MegaSampler feature was utilized to compare 
gene expression between neuroblastoma cohorts, the neural crest, and neurofibroma 
(benign tumors of the peripheral nervous system) to determine differences in 
expression levels. Since neuroblastoma is a rare disease, an advantage of employing 
the R2: Genomics Analysis and Visualization Platform is access to data from a greater 
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number of patients. In addition, the availability of a variety of neuroblastoma datasets 
enables comparisons between the data sets.  
2.2 ENDPOINT RT-PCR (PAPER I-III) 
Endpoint reverse transcription (RT-) PCR was used to detect the presence or 
absence of gene transcripts. Endpoint PCR is not a quantitative method and does, at 
most, allow for semi-quantitative estimations if normalization to a housekeeping gene 
is performed. If the quantification of gene expression would have been the aim, a 
different method, such as quantitative real-time PCR or Droplet Digital PCR, should 
have been chosen. One advantage of endpoint PCRs is the ability to estimate PCR 
product sizes following agarose gel electrophoresis. For the majority of genes 
examined in this study, intron-spanning primers were used to ensure that 
amplification of residual genomic DNA is clearly distinguishable from the amplification 
of transcript-based cDNA based on the PCR-product size. 
3 PROTEIN DETECTION 
Most methods for protein detection depend on the availability of reliable and 
thoroughly validated antibodies. For extensively studied proteins, such as 
housekeeping proteins like GAPDH (Glyceraldehyde-3-phosphate dehydrogenase) or 
cell signaling proteins like Akt and ERK1/2, this poses no problem since a variety of 
verified antibodies are available. However, it can be difficult to find reliable antibodies 
for less extensively studied proteins. The availability of thoroughly validated 
antibodies in particular for members of the IL-17 family and CMKLR1/chemerin was a 
major challenge in this work. Commercially available antibodies frequently do not 
perform as promised even on suggested positive controls. For paper III we tested 
seven different antibodies for IL-17RB alone for the use in western blot and/or IHC to 
find one that works satisfactory for each method. Our difficulties are mirrored in two 
recent publications demonstrating the challenge to find reliable IL-17A and IL-17B 
antibodies [490, 491].  
Fortunately, the problem of antibody reliability has gained increasing attention 
in the past years [492] and there are several initiatives, such as the Human Protein 
Atlas (www.proteinatlas.org) [493] aiming to improve validation and reliability of 
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antibodies. Furthermore, guidelines on antibody validation are emerging [494, 495]. 
However, antibody validation remains largely the responsibility of the researcher and 
antibody suppliers could provide better support to enable a more effective validation 
by the researcher. Greater transparency of antibody origins would help to select 
antibodies and prevent the purchase of the same antibody from different suppliers. 
In addition, suppliers could provide more detailed information concerning their 
validation practices, to enable the researcher to evaluate the antibodies for their 
specific needs more time- and cost-effectively.  
3.1 WESTERN BLOT (PAPER I-III) 
Western blot is a common method used to detect specific proteins in cell or 
tissue lysates. Briefly, protein lysates are separated according to their size by SDS-
PAGE (sodium dodecyl sulfate–polyacrylamide gel electrophoresis) and transferred to 
a membrane. Unspecific binding sites are subsequently blocked and the membranes 
are incubated in the primary antibody solution, with the primary antibody being 
directed against the protein of interest. Following washing steps to remove unbound 
antibodies, the membranes are incubated in a secondary antibody solution containing 
antibodies directed against the species of the primary antibody. The secondary 
antibody is conjugated with an enzyme, for example horseradish peroxidase (HRP), or 
a fluorescent dye. If an enzyme-conjugated secondary antibody is used, the addition 
of, for example a chemoluminescent substrate, leads to substrate conversion and a 
chemoluminescent signal that can be detected. A marker containing proteins of a 
known size allows for size estimation of the obtained signal/protein band. This is a 
major advantage of western blotting because information can be gained concerning 
antibody specificity based on the number of visible bands and size estimations. 
Western blotting is a semi-quantitative method allowing comparisons of band 
strength, corresponding to protein amounts, between samples on the same 
gel/membrane. The amount of the protein of interest should be normalized to the 
amount of a housekeeping protein (ideally in the same size range) to ensure equal 
sample input and even protein transfer and blocking. 
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 Western blot analyses were used in this work to determine the presence of 
different proteins in neuroblastoma cell lysates and to evaluate the specificity of 
antibodies. 
3.2 IMMUNOCYTOCHEMISTRY AND IMMUNOHISTOCHEMISTRY 
(PAPER I-III) 
Immunocytochemistry (ICC) and immunohistochemistry (IHC) are methods 
that determine the localization of proteins in cells (ICC) or tissues (IHC). The use of 
different fluorescent dyes or chromogens allows for multiplexing and colocalization 
studies. Either primary (direct detection) or secondary antibodies (indirect detection) 
can be conjugated to a fluorescent dye or chromogen. Indirect detection has the 
advantage of greater sensitivity since multiple secondary antibodies can bind to a 
primary antibody leading to an amplification of the signal. The use of isotype control 
antibodies (same species as the primary antibody) instead of primary antibodies is 
important to control for unspecific binding. A crucial step in IHC is the use of the 
optimal antigen retrieval approach (heat induced or enzymatic) to unmask epitopes, 
as cross-linking of proteins during fixation can mask antigens.  
ICC and IHC are commonly used to determine the subcellular location of a 
specific protein (ICC/IHC) and to study protein expression pattern in different cell 
types and areas of tissues (IHC). A prerequisite for successful ICC and IHC is the 
availability of high quality antibodies to avoid false positive staining (lack of specificity) 
or false negative staining (lack of sensitivity). In this work, ICC and IHC were used to 
determine the presence/absence and localization of specific proteins in 
neuroblastoma cell lines and tissues. 
3.3 ELISA (PAPER I AND III) 
Enzyme-linked immunosorbent assay (ELISA) is a method to quantify proteins 
in cell supernatants, plasma, serum, and tissue lysates. In this work, commercially 
available, validated sandwich ELISAs were used to determine the concentration of 
chemerin, Dkk-1, and HGF in cell supernatants of stimulated neuroblastoma cell lines. 
In typical sandwich ELISAs, plates are coated with an antibody directed against the 
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protein of interest. Unspecific binding sites are blocked followed by addition of the 
samples. An additional antibody specific to the protein of interest is added that is 
either directly enzyme-conjugated (e.g. HRP) or tagged (e.g. biotin). If a tagged 
antibody is used, an enzyme-conjugated antibody targeting the tag is added. 
Thorough washing between each step is essential to remove unbound sample and 
antibodies. Finally, the appropriate substrate, such as TMB (3,3′,5,5′-
tetramethylbenzidine), for HPR is added and after sufficient color development, the 
reaction is stopped. Absorbance measurements at the appropriate wavelength (e.g. 
450nm for TMB) are performed to quantify the amounts of the reaction product. A 
dilution series of known protein concentrations is included in each run to draw a 
standard curve, allowing for the extrapolation of the concentration of the protein of 
interest in the samples. 
3.4 IMMUNOPRECIPITATION (PAPER II) 
Immunoprecipitation was used in paper II to concentrate neuroblastoma cell-
derived SYK to enable the detection of specific phospho-sites. Phospho-specific 
antibodies are raised against a specific phospho-residue, a very small antigen. This can 
result in very weak signals particularly if no prior stimulation of phosphorylation took 
place as not all copies of the protein may be phosphorylated at the same time. In this 
work, we wanted to determine the phosphorylation state of SYK under normal growth 
conditions. Through immunoprecipitation, we were able to concentrate and purify 
total SYK protein enabling us to detect the phosphorylation of specific sites and in 
addition, reduce unspecific background staining observed for some of the phospho-
specific antibodies. 
3.5 FLOW CYTOMETRY (PAPER III) 
Flow cytometry was used in paper III to evaluate the presence of IL-23p19 in 
tumors, sera, spleen, liver, and lung of TH-MYCN mice. Multi-color flow cytometry is 
a common technique to determine the presence of specific cell populations in more 
or less heterogeneous samples (e.g. tissue lysates, cell cultures, sera) and to 
determine the presence/absence of a specific target in different cell populations. High 
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quality antibodies and the inclusion of extensive controls are, among others, 
important factors that determine the quality of flow cytometry analyses. 
4 REGULATION OF CELL SIGNALING PATHWAYS 
4.1 PHOSPHO-SPECIFIC WESTERN BLOTS (PAPER I-II) 
Phospho-specific western blots were used in paper I and II to determine the 
activation or inhibition of specific cell signaling pathways in response to specific stimuli 
or inhibitors. Normalization to the corresponding total protein and/or a house keeping 
protein are important to ensure equal loading and consequently that the differences 
observed are in fact due to stimulation or inhibition and not a result of unequal protein 
input. During our work on paper II, we experienced difficulties to completely remove 
phospho-antibodies prior to re-probing with the total-protein antibodies. This can 
lead to signals from the remaining phospho-antibodies or can impair the binding of 
the total protein antibodies. Incomplete antibody removal is a well-recognized 
problem for relative phospho-protein quantification [496]. We, therefore, chose an 
approach to circumvent this problem, which was running separate gels for phospho- 
and total protein and to normalize each to its loading control before calculating 
phospho/total protein ratios.  
4.2 CALCIUM MOBILIZATION (PAPER I) 
Calcium is an important second messenger connected to GPCR signaling. In 
paper I, calcium mobilization from intracellular compartments was detected by live 
cell imaging. The cells were loaded with a calcium sensitive fluorescent dye and 
probenecid to ensure the retention of the fluorescent dye within the cells. Calcium 
mobilization in response to GPCR activation resulted in an increase of fluorescence 
that was detected with a confocal laser scanning microscope.  
We also attempted to establish a protocol for plate-reader based calcium 
mobilization measurements but observed that the automated injection of media 
(without stimuli) to the cells caused an increase in calcium mobilization by itself. This 
may be attributed to the high pressure of the injection causing mechanical stress in 
the cells, as the same effect was not observed when media was carefully added 
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manually to the control cells in the microscopy based set up. Intracellular calcium 
mobilization has previously been linked to mechanical stimulation in a variety of cell 
types [497]. 
5 MTT CELL VIABILITY ASSAY (PAPER I-III) 
The MTT assay was used to determine cell viability in response to stimuli, 
inhibitors or drugs. The cell viability was determined in comparison to control cells 
that were set as 100% viable cells. There are a variety of colorimetric or fluorescence 
based cell viability assays. We chose the MTT assay because it is inexpensive, widely 
used, and a well-established method in our lab. MTT is tetrazolium dye that is reduced 
to a purple insoluble formazan by nicotinamide adenine dinucleotide phosphate 
(NADPH)-dependent cellular oxidoreductase enzymes (mainly mitochondrial 
dehydrogenases present in living cells) [498]. Therefore, the production of formazan 
is a measure of metabolic activity/cell viability. The MTT assay can also be used as a 
proliferation assay as an increase in cell numbers correlates with an overall increase 
in cellular activity. However, it is important to note that more specific assays are 
available to determine proliferation directly, such as the BrdU assay or the 
3H-thymidine incorporation assay, whose measures of DNA synthesis are more 
specific to determining proliferation.  
6 CLONOGENIC ASSAY (PAPER I) 
The clonogenic assay also known as colony formation assay is a cell survival 
assay that assesses the ability of a cell to divide without restrictions. In paper I we 
used this assay to determine whether CMKLR1 inhibition affected the ability of 
neuroblastoma cells to form cell colonies (>50 cells) from a single cell.  
7 PARP-1 CLEAVAGE (PAPER II) 
PARP-1 is a nuclear protein with important functions in DNA damage repair but 
also in, among others, cell death and inflammation. In the context of cell death, PARP 
is an in vivo target for caspase-3- and caspase-7-cleavage resulting in fragments of 
89 kDa and 24 kDa [499]. It has been observed that other cell-death related proteases 
can also cleave PARP-1 resulting in different fragment sizes. Therefore, the size of 
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PARP-1 fragments can give an indication towards which form of cell death the cells 
are undergoing [499]. In paper II, PARP-1 cleavage, represented by the presence of 
the 89 kDa fragment, was detected using western blot to supplement MTT cell viability 
data. A reduction in cell viability in combination with an increase in cleaved PARP-1 
indicated that SYK-inhibition in combination with chemotherapy induced cell death 
rather than reducing cell proliferation. However, further studies would be required to 
determine the extent and type of cell death or the extent of proliferation inhibition. 
8 SCRATCH ASSAY (IN VITRO MIGRATION ASSAY) (PAPER III) 
The scratch assay also called wound healing assay is a well-established method 
to assess two dimensional cell migration in vitro [500]. In paper III we utilized the 
scratch assay to determine whether recombinant IL-17 proteins affect the migration 
of neuroblastoma cell lines in vitro. However, additional studies using specific 
chemotaxis assays are required to investigate if the migration of the cells is directed 
towards the recombinant proteins. Chemotaxis assays are based on creating a 
gradient of the respective stimulus to examine if the cells migrate towards the highest 
concentration of the stimulus. 
9 KNOCKDOWN/ KNOCKOUT STUDIES 
9.1  SIRNA MEDIATED DOWNREGULATION OF GENE EXPRESSION 
(PAPER II) 
Transient downregulation of SYK expression was achieved using small 
interfering RNA (siRNA). siRNAs are specifically designed to complementary bind to 
transcripts from genes of interest promoting their degradation and preventing 
translation. In paper II, cells were transfected with SYK mRNA-targeting siRNAs using 
liposome-based transfection. High transfection efficiency is the prerequisite for 
substantial downregulation of gene expression. In both SYK-positive cell lines, we 
observed a pronounced reduction in SYK protein following siRNA transfection. 
However, we did not achieve a complete knockdown of SYK expression, which can be 
attributed to the sub-optimal transfection efficiency we previously observed in these 
cell lines with liposome-based transfection methods.  
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Alternative transfection methods, such as electroporation, could improve 
transfection efficiency and consequently result in complete knockdowns. 
Alternatively, gene knockout using CRISPR/Cas9 or stable gene knockdown through 
genome-integrated shRNA mediated by, for example lentiviral transduction, can be 
used to permanently downregulate target gene expression. 
9.2 CRISPR/CAS9 GENE KNOCKOUT (PAPER I) 
In paper I we attempted CRISPR/Cas9 (clustered regularly interspaced short 
palindromic repeats/CRISPR-associated protein 9)-mediated CMKLR1 knockout in the 
neuroblastoma cell line SK-N-AS. CRISPR/Cas9 has revolutionized the field of genome 
editing and many additional applications beyond genome editing have been described 
[501]. In our work, we used commercially available sgRNA/Cas9 plasmids. 
Modifications to the supplied protocol were necessary as one of the difficulties we 
encountered was achieving sufficient transfection efficiency while maintaining cell 
viability. We, therefore, changed the transfection reagent from the supplied 
EndoFectin™Max (GeneCopoeia) to jetPRIME® (Polyplus-transfection®) since it 
resulted in higher transfection efficiency. Furthermore, SK-N-AS cells were very 
sensitive to mechanical stress and flow cytometry-based single cell sorting could not 
be utilized. Therefore, manual serial dilutions were made to establish clones derived 
from a single cell.  
10 MMP ACTIVITY ASSAY (PAPER I) 
Real-time zymography was used to study the degradation of gelatin by MMP-2 
and MMP-9. The use of fluorescent (2-methoxy-2, 4-diphenyl-3(2H)-furanone (MDPF)-
labeled) gelatin in the acrylamide gel allowed us to follow the degradation of gelatin 
by MMP-2 and MMP-9 in real time without additional staining of the gel. Areas of 
gelatinase activity (degradation of gelatin) were apparent as dark bands against the 
bright fluorescent background of undegraded gelatin. 
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11 IN VIVO STUDIES 
11.1  XENOGRAFT MODEL (PAPER I) 
Immunodeficient nude mice were used to investigate the effect of the CMKLR1 
inhibitor α-NETA on the growth of SK-N-AS xenografts. This was an appropriate model 
to evaluate the effect of CMKLR1 inhibition on tumor cell growth in vivo. Nude mice 
are deficient of T cells due to a mutation in the transcription factor FOXN1 required 
for thymus development [502-504]. T cells are important contributors to the TME, 
therefore, an immunocompetent mouse model would be more appropriate to study 
the effect of chemerin/CMKLR1 axis on the neuroblastoma microenvironment. 
11.2  TH-MYCN TRANSGENIC MODEL (PAPER III) 
The transgenic TH-MYCN model overexpresses human MYCN under the 
control of the rat tyrosine hydroxylase promoter (TH) in neuroectodermal cells 
causing tumors that resemble human neuroblastomas [505]. The tumors express 
neuronal markers (e.g. synaptophysin) and display neuronal differentiation at varying 
degrees. As an immunocompetent model, TH-MYCN mice are frequently used in 
immunological studies of neuroblastoma [417, 438]. Macroscopic metastases are 
occasionally observed in liver, lung, and ovaries of the TH-MYCN mice [505]. However, 
bone marrow involvement or bone metastases, which are frequently observed in 
neuroblastoma patients are rarely seen in TH-MYCN mice [359, 505]. A murine 
neuroblastoma model with pronounced secondary tumors in the bone marrow was 
recently developed [506]. Additional murine neuroblastoma models have been 
developed in the past years to extend the knowledge on neuroblastoma biology, 
among others, models expressing mutated ALK and a model resembling MYCN non-
amplified tumors [415, 507-509]. 
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SUMMARY OF MAIN RESULTS 
PAPER I: Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells 
reduces clonogenicity and cell viability in vitro and impairs tumor 
growth in vivo 
A correlation between high CMKLR1 and GPR1 expression and a reduced 
overall survival probability was observed in two neuroblastoma gene expression 
cohorts. Chemerin, CMKLR1, and GPR1 protein were detected in a panel of 
neuroblastoma cell lines and tumor tissues. IL-1β, TNF-α, and serum increased the 
secretion of chemerin in SK-N-AS cells. Chemerin induced calcium mobilization, 
promoted phosphorylation of Akt and ERK1/2, and stimulated MMP-2 synthesis. The 
CMKLR1 antagonist α-NETA reduced the cell viability and clonogenicity of 
neuroblastoma cell lines. Furthermore, early and prolonged treatment of nude mice, 




PAPER II: SYK inhibition potentiates the effect of chemotherapeutic 
drugs on neuroblastoma cells in vitro 
SYK expression was elevated in neuroblastoma compared to neural crest and 
benign neurofibroma. SYK and phosphorylated SYK were observed in the majority of 
examined neuroblastoma tissues. SYK mRNA and less frequently SYK protein were 
detected in neuroblastoma cell lines. Phosphorylation at tyrosine 525/526, 
tyrosine 352, and tyrosine 323 was observed in SYK-expressing SH-SY5Y cells. The cell 
viability of SYK-positive neuroblastoma cells was reduced by siRNA-mediated SYK 
downregulation or SYK inhibition. In addition, Akt and ERK1/2 phosphorylation was 
reduced by SYK inhibition. The selective SYK inhibitor BAY 61-3606 enhanced the 
effect of chemotherapeutic drugs on SYK-expressing neuroblastoma cells illustrated 
by decreased cell viability and increased PARP cleavage. Furthermore, the cell viability 
of neuroblastoma cells was increased following transient expression of a constitutive 
active SYK variant independent of endogenous SYK levels. 
  
 61 
PAPER III: Interleukin 17 family and interleukin 23 in the 
neuroblastoma microenvironment 
High expression of IL17A, IL17B, IL17C, IL25 (IL17E), and IL17F and the 
receptors IL17RA, IL17RB, and IL17RD correlated with a reduced overall survival 
probability in a neuroblastoma expression cohort. IL-17RA, IL-17RB, and IL-17RC 
proteins were detected in neuroblastoma tissues and neuroblastoma cell lines. 
Recombinant IL-17A, IL-17A/F, IL-17B, and IL-25 stimulated the cell viability of 
neuroblastoma cell lines at varying degrees. Of note, high concentrations of IL-25 
impaired the cell viability of neuroblastoma cell lines. In addition, IL-17A and IL-17B 
promoted in vitro migration of SK-N-BE(2) cells. IL-17A, IL-17B, and IL-25 modulated 
HGF secretion in SK-N-AS cells. Moreover, IL-25 increased Dkk-1 secretion in SK-N-AS 
cells while decreasing Dkk-1 secretion in SK-N-BE(2) cells. Furthermore, IL-23p19 was 
detected in neuroblastoma cell lines and tumor tissue. Additionally, different splice 




In the past decades, great advances in the treatment of pediatric malignancies 
led to current 10-year survival rates of above 80% [350]. According to estimates, 
approximately 1 in 1000 individuals of the general adult population in high-income 
countries is a childhood cancer survivor [341, 342]. By 2020 the number of childhood 
cancer survivors in Europe may be as high as 500000 [343]. However, most childhood 
cancer survivors suffer from severe chronic health conditions and by the age of 45, 
the cumulative burden of chronic health conditions is twice as high as in the general 
population [350].  
Neuroblastomas are tumors arising from the developing sympathetic nervous 
system and the most common malignancies during the first year of life [461]. As a 
biologically and clinically highly heterogeneous disease, the treatment of 
neuroblastoma is equally heterogeneous ranging from observation and surgery for 
low-risk tumors to intensive multimodal therapy for high-risk disease [461]. In 
consequence, a broad variety of late effect (therapy-related morbidities) is observed 
in neuroblastoma survivors, with severe chronic health conditions, such as heart, 
pulmonary and gonadal dysfunction, hearing loss, and secondary malignancies, 
occurring in patients that underwent intensive treatment protocols [510]. This 
underlines the necessity for improved and novel therapy approaches to reduce late 
effects and enable childhood cancer survivors to live a high-quality life.  
Among the most promising new therapeutic approaches for neuroblastoma 
treatment are targeted therapies, among other, inhibitors of ALK, Aurora A and B, 
PI3K/Akt, and BET [471]. However, intrinsic or acquired resistance to targeted 
therapies is a well-established challenge and various combination strategies are 
emerging to utilize the full potential of targeted therapies [511]. A recent phase II 
clinical trial of the Aurora A kinase inhibitor alisertib in combination with irinotecan 
and temozolomide demonstrated antitumor activity especially in patients with MYCN 
non-amplified tumors [512]. Spleen tyrosine kinase (SYK) is a non-receptor tyrosine 
kinase and a promising therapeutic target in pediatric retinoblastoma and Ewing 
sarcoma [335, 336]. Recently, the first SYK inhibitor Fostamatinib was approved by the 
US Food and Drug Administration for use in chronic immune thrombocytopenia [330]. 
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In paper II we evaluated the efficacy of SYK inhibition in combination with 
chemotherapeutic drugs in neuroblastoma cell lines. We observed a more 
pronounced inhibitory effect on cell viability when SYK inhibition was combined with 
chemotherapy. Combinations of targeted therapies, conventional therapy, and 
immunotherapy may allow the use of lower doses and lead to a reduction in late 
effects. Furthermore, targeted therapies hold great promise for patients that cannot 
be treated with conventional therapies. This was recently observed in a 
neuroblastoma patient with DNA repair defects that resulted in severe toxicities in 
response to chemotherapy. The identification of a gain-of-function ALK mutation 
allowed the successful treatment of the patient with the ALK inhibitor ceritinib [513]. 
In paper II, we established the presence of SYK in neuroblastoma cell lines and 
tumor tissue and demonstrated that SYK inhibition reduces neuroblastoma cell 
viability and Akt- and ERK-phosphorylation. Furthermore, we observed that 
chemotherapeutic drugs affect SYK levels in neuroblastoma cells. SYK is a 
multifunctional kinase that can support but also suppress tumor growth in different 
cancers [331]. Novel functions of SYK in tumor cells and also other cells present in the 
TME are constantly emerging. Recently, SYK has been implicated in mesenchymal to 
epithelial transition and metastatic growth in breast cancer [334]. SYK participation 
has also been described in the regulation of energy metabolism as SYK inhibition 
promoted a shift from glycolysis to oxidative phosphorylation (anti-Warburg effect) in 
glioma stem cells [514]. Yu et al. previously linked SYK function to migration and 
invasion of ovarian cancer cells as it phosphorylates the actin binding proteins 
cortactin and cofilin, which are involved in actin assembly and the formation of 
invadopodia [338]. Interestingly, a chemerin/CMKLR1/SYK signaling axis has 
previously been described in macrophages in connection to actin polymerization and 
phagocytosis [515]. In paper I we investigated the chemerin/CMKLR1 axis in 
neuroblastoma, but a potential link between chemerin/CMKLR1 and SYK remains to 
be investigated. Furthermore, there is increasing evidence that inhibition of SYK in 
tumor-supporting immune cells, can contribute to the overall tumor-suppressing 
effects of SYK inhibition [339, 516]. Metastatic disease is detected in approximately 
50% of patients at diagnosis, with bone and bone marrow being the major metastatic 
sites [359]. Studies in a preclinical prostate cancer model demonstrated that SYK 
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supported bone metastasis formation whereas SYK depletion by knockdown and 
overexpression of a kinase dead SYK variant reduced the metastatic burden [517]. 
Consequently, further studies (both in vitro and in vivo) are needed to determine the 
specific functions of SYK in the neuroblastoma microenvironment and the efficacy of 
SYK inhibition both alone and in combination with conventional therapies.  
The tumor microenvironment is composed of tumor cells, immune cells, 
stromal cells, and the ECM whose complex interactions evolve constantly to support 
the growing tumor [8, 10]. Inflammation is an indispensable defense mechanism 
against harmful stimuli and an essential factor of antitumor immunity [140]. However, 
chronic inflammatory processes in the TME can essentially support all stages of tumor 
growth and can be considered a hallmark of cancer [137, 139]. A thorough 
understanding of the inflammatory processes in the TME is therefore required to 
target excessive tumor-promoting inflammation while supporting inflammatory 
processes essential to anti-tumor immunity, basically walking a tightrope. In paper I 
and III we investigated the chemerin/CMKLR1 axis and the IL-17 family with the aim 
to expand the knowledge on inflammatory mediators and pathways in the 
neuroblastoma microenvironment. 
Chemerin is a versatile chemoattractant protein with context-dependent 
functions, and both tumor-promoting and tumor-suppressing functions of chemerin 
have been described [299]. Chemerin undergoes extensive post-secretory processing 
resulting in isoforms with varying activity [293]. In paper I we demonstrated that 
chemerin is secreted by neuroblastoma cells, however, we did not determine the 
presence of specific chemerin isoforms. To our knowledge, there are to date no 
isoform-specific chemerin antibodies commercially available. However, mass 
spectrometric analyses could be performed to determine chemerin isoforms and/or 
the presence of specific proteases that may mediate chemerin cleavage. Chemerin 
binds to three G protein-coupled receptors (CMKLR1, GPR1, and CCRL2) [294-296]. 
While CMKLR1 is the most studied chemerin receptor, functions for GPR1 and CCRL2 
in the TME are emerging. Recently GPR1 was implicated in migration and invasion of 
gastric cancer cells [321]. Furthermore, CCRL2 (and CMKLR1) have been demonstrated 
to mediate a chemerin-induced downregulation of IL-6 and GM-CSF and to reduce 
MDSC infiltration in hepatocellular carcinoma [307]. In paper I we describe the 
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presence of CMKLR1 and GPR1 protein in neuroblastoma cell lines and tumor tissues 
as well as CCRL2 mRNA in neuroblastoma cell lines. However, further studies are 
necessary to determine whether the observed chemerin functions are mediated by 
CMKLR1 and/or GPR1 and if CCRL2 protein is present and functional in neuroblastoma. 
As a chemoattractant, chemerin’s function in the TME is often not only associated 
with its direct effects on tumor cells but also effects on immune cells and stromal cells 
[299]. For example, anti-tumorigenic effects of chemerin have been linked to the 
recruitment of NK cells in melanoma and also NK cells and CD8+ T cell in breast cancer 
[309, 518]. Furthermore, chemerin promotes proliferation and migration of 
endothelial cells and vessel formation [287, 519]. In paper I we investigated the effect 
of CMKLR1 inhibition on tumor growth in a neuroblastoma xenograft model. However, 
further studies, particularly in immunocompetent mice are warranted to determine 
potential functions of chemerin and its receptors on the neuroblastoma 
microenvironment with focus on immune cell infiltration and angiogenesis. In our 
studies, we observed that IL-1β promotes chemerin secretion. A pilot study in paper III 
indicates increased levels of IL-1β in tumors and serum of tumor-bearing TH-MYCN 
transgenic mice. A possible in vivo link between IL-1β and chemerin could, therefore, 
be investigated using the TH-MYCN murine model. Of note, recent work by Fultang et 
al. demonstrates increased IL-1β expression in stage 4 compared to stage 1 
neuroblastomas and a correlation between high IL1B expression and a poor overall 
survival [520]. In their work, macrophages were identified as the source of IL-1β and 
TNFα [520]. 
The IL-17 family consist of six cytokines with important functions in immunity 
and host defense but also autoimmunity and cancer [200]. In paper III we examined 
the expression and prognostic implications of the IL-17 cytokines A-F and their 
receptors RA-RE. Furthermore, we aimed to gain insight into potential functions in 
neuroblastoma tumorigenesis. However, considering the multifunctional nature of 
the IL-17 family, we hardly scratched the surface. The most intensely studied family 
member IL-17A, which occurs as IL-17A homodimers and IL-17A/F heterodimers, was 
discovered over 25 years ago and is a versatile cytokine with highly context dependent 
functions [209, 521, 522]. In paper III we demonstrate the expression of the IL-17A 
receptors RA and RC in neuroblastoma cell lines and tumor tissue. We observed 
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modest effects of IL-17A or the IL-17A/F heterodimer on the cell viability of certain 
neuroblastoma cell lines. Furthermore, we found that IL-17A could modulate HGF 
secretion and in vitro cell migration. Interestingly, the effect of IL-17A and IL-17A/F 
differed between cell lines and more extensive studies are needed to investigate the 
cell-line specific effects in depth. It has previously been noted in different cell systems 
that while the in vitro effects of IL-17A can be relatively modest more pronounced in 
vivo effects occur [200]. IL-17A has strong immunomodulatory effects and both pro-
tumorigenic and anti-tumorigenic functions of IL-17A have been linked to immune cell 
recruitment (e.g. T cells, NK cells, DCs neutrophils, and MDSCs) and their functional 
activation or impairment [217]. Furthermore, IL-17 can promote tumor cell 
proliferation, migration, angiogenesis, and metastasis [217]. In vivo studies are 
therefore necessary to obtain a more complete picture of IL-17A functions in the 
neuroblastoma TME.  
Recently, IL-17RD was identified as an additional functional receptor for IL-17A 
indicating there might be receptor-ligand combinations that have so far not been 
discovered [207]. Of note, we observed IL17RD mRNA in the majority of 
neuroblastoma cell lines and the presence of IL-17RD protein and its functions could 
be an interesting subject for a new study especially with respect to the positive 
correlation between IL17RD and MYCN expression we observed in paper III.  
Differentiation therapy using 13-cis-retinoic acid (isotretinoin) is part of the 
maintenance regimen for high-risk neuroblastomas [461]. In recent work in pancreatic 
ductal adenocarcinoma, it was demonstrated that retinoic acid produced by DCs as 
well as other cells in the TME, modulates the balance between Tregs and IL-17A-
producing helper cells and that ATRA (all-trans retinoic acid) attenuates IL-17A and 
IFN-γ secretion [523]. Various immune modulatory functions have been described for 
retinoic acid [524]. In the context of neuroblastoma, it has previously been established 
that retinoids sensitize tumor cells to lysis by CTLs [525]. Further studies could be of 
interest to investigate the effect of retinoids on the neuroblastoma TME especially 
with respect to IL-17A. 
The COX-2/mPGES/PGE2 axis is a well-established contributor to 
neuroblastoma tumorigenesis [420, 421, 433, 434, 436, 437]. Interestingly, PGE2 can 
modulate Th17 differentiation and IL-17A secretion [526-529]. Furthermore, IL-17A 
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has been shown to upregulate COX-2 in cancer cell lines [530]. In addition, PGE2 can 
stimulate IL-23 production in, among other, breast cancer cells and dendritic cells 
[531-534]. A potential link between PGE2, IL-23, and IL-17 in the neuroblastoma TME 
may, therefore, be examined. In paper II we investigated SYK as a potential 
therapeutic target in neuroblastoma. Interestingly, SYK has been described as a 
mediator of IL-17A signaling in keratinocytes and multiple myeloma cells [535, 536]. 
IL-17A and IL-17F are cytokines at the crossroads of innate and adaptive 
immunity as they are produced by adaptive immune cells (Th17), innate immune cells 
(ILC3, NK cells) and cells associated with both innate and adaptive immunity (NKT, γδ T 
cells) [212]. γδ T cells can target cells without co-stimulation and MHC-restriction 
suggesting they have an application in cancers with low mutational loads, such as 
many pediatric malignancies including neuroblastoma [60, 347]. The efficacy of γδ T 
cell-mediated neuroblastoma cell killing in combination with anti-GD2 or 
Zolendronate has been demonstrated in vitro and in immunodeficient mouse models 
[537-540]. Although no effect was observed on the production of a panel of cytokines, 
including IL-17A, in a co-culture study of neuroblastoma cell lines and different γδ T 
cell subsets, potential effects on cytokine production in the TME were not evaluated 
[537, 538]. Furthermore, in a recent study GD2 CAR γδ T cells (vδ1 and vδ2) displayed 
specific neuroblastoma cell lysis [541]. However, further studies are required to 
determine the efficacy of GD2 CAR γδ T cells and potential microenvironmental effects 
in vivo. A phase 1 study by Pressey et al. evaluated the safety of γδ T cell expansion 
using Zolendronate and IL-2 in four refractory neuroblastoma patients [542]. Of note, 
when compared to healthy controls γδ T cell levels were significantly decreased in 
neuroblastoma patients. Although the treatment was well tolerated only a slight 
increase in γδ T cells was observed. In addition, an increase in Tregs was also seen. 
However, the small number of heavily treated patients made it difficult to observe 
clear trends and the article does not indicate whether cytokine analyses were 
performed. Furthermore, a recent study by Zoine et al. demonstrated the efficacy of 
neuroblastoma patient-derived and ex vivo expanded γδ T cells against 
neuroblastoma cells, which was further increased by the addition of dinutuximab 
[540]. In a neuroblastoma xenograft model, a combination of γδ T cells, dinutuximab 
and temozolomide reduced tumor growth significantly compared to untreated tumors 
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or either monotherapy [540]. However, the article did not indicate whether IL-17 
expression was examined in the study. 
Although the remaining IL-17 family members have to date been less 
extensively studied, cancer-related functions have been described for all of them. The 
IL-17B/RB axis has been demonstrated to promote tumor cell survival, migration, 
metastasis, and chemokine expression [238-243]. In paper III we observed that high 
expression of IL17B and IL17RB correlated with a reduced overall survival probability 
in neuroblastoma. We detected the presence of IL-17RB protein in neuroblastoma cell 
lines and tissue and of IL17B RNA in neuroblastoma cell lines. IL-17B promoted the cell 
viability of neuroblastoma cell lines, the in vitro migration of SK-N-BE(2) cells, and 
reduced HGF secretion from SK-N-AS cells. Our data indicates the presences of a 
functional IL-17B/RB axis in neuroblastoma cells whose role in tumorigenesis should 
be further explored.  
IL-17C can promote tumor cell survival, angiogenesis, and the recruitment of 
TANs [247, 248]. Interestingly, neurotrophic effects have been described for IL-17C in 
the peripheral nervous system where it promotes neurite growth and branching and 
has a protective effect during virus reactivation [543]. In paper III we noticed that high 
IL17C expression correlates with a lower overall survival probability in neuroblastoma 
and that IL17RC mRNA was present in some of the examined neuroblastoma cell lines. 
Furthermore, expression of the IL-17C receptors IL-17RA (mRNA and protein) and 
IL17RE (mRNA) was observed in the majority of neuroblastoma cell lines. Of note, high 
expression of IL17RE correlated with a higher overall survival probability. Further 
studies are warranted to determine potential functions of the IL-17C/IL-17RA/RE axis 
in neuroblastoma especially with respect to the previously described neurotrophic 
effect of IL-17C.  
Although the receptor for IL-17D is not yet identified, IL-17D has been 
demonstrated to promote NK cell recruitment and tumor rejection in preclinical 
glioma and prostate cancer models [251]. In our study, we observed that high IL17D 
expression correlates to a higher neuroblastoma overall survival and that IL17D mRNA 
was present in the majority of the examined neuroblastoma cells. IL-17D knockdown 
or overexpression studies could give indications toward IL-17D functions in 
neuroblastoma even though the receptor is to date unknown.  
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IL-17E was given a different name, IL-25, to emphasize its distinct functions in 
promoting type II immunity [200]. Opposing functions of IL-25 and other IL-17 family 
members have previously been described [237, 259]. For example, while IL-25 
promoted colon inflammation and allergic asthma, IL-17B displayed anti-
inflammatory effects [237]. Moreover, IL-17B reduced IL-25-induced IL-6 expression 
likely by blocking their shared receptor IL-17RB [237]. In our work, we observed that 
high concentrations of IL-25 impaired the cell viability of neuroblastoma cells lines, in 
particular of SK-N-DZ cells after 72h. Furthermore, we noted that while low 
concentrations of IL-17A, IL-17B, and IL-25 reduced HGF secretion, high 
concentrations of IL-17A stimulated the secretion of HGF in contrast to IL-17B and 
IL-25. Furthermore, we found that IL-25 had opposite effects on Dkk-1 secretion in 
SK-N-AS and SK-N-BE(2) cells.  
IL-17F is mainly co-produced with IL-17A and functional redundancy is often 
observed [212, 544]. However, differences in activity and distinct functions have also 
been described [212]. Recently, co-culture studies demonstrated that malignant 
T cell-derived IL-17F promoted sprouting and tube formation in HUVEC cells [545]. In 
paper III we observed that high IL17F expression correlated with a reduced overall 
survival probability in neuroblastoma and that recombinant IL-17A/F moderately 
promoted the cell viability of certain neuroblastoma cell lines. 
Our data indicate overlapping but also distinct effects of IL-17 family members 
in neuroblastoma that are likely cell-type and context dependent. Additional work is 
necessary to explore cytokine- and cell type- specific effects further, and evaluate the 
presence of reoccurring patterns. 
Studies of autoimmune disorders indicate that the functions of the 
IL-23/IL-17A axis are complex, fine-tuned, and highly context dependent [173]. While 
the blockade of IL-17A or IL-17RA alleviates the symptoms of psoriasis patients, 
blockade of IL-17A can exacerbate Crohn’s disease [173, 212]. Furthermore, work in a 
colitis murine model demonstrated that the blockade of IL-23 improved symptoms 
while the IL-17A blockade worsened the disease [546]. IL-17A contributes to the 
maintenance of barrier integrity in the gut and following acute injury, the production 
of IL-17A by γδ T cells is IL-23-independent [214]. In this context, Teng et al. suggested 
that IL-23 blockade may eliminate excessive disease-related IL-17A while not affecting 
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protective IL-17A in the gut [189]. These findings underline that the presence and 
function of IL-23 should be taken into consideration when studying IL-17A (and IL-17F) 
in any specific context. 
IL-23 stabilizes Th17 populations and promotes the secretion of IL-17A from 
Th17, γδ T cells, ILC3, NKT and NK cells [212]. Recently, lung cancer cell-derived IL-23 
was shown to convert ILC1 to ILC3 cells promoting IL-17A production and subsequent 
IL-17-dependent tumor cell proliferation [193]. Furthermore, cervical fibroblasts 
stimulate IL-23 production in cervical cancer-educated DCs consequently promoting 
Th17 expansion [196]. These examples demonstrate the complexity of the IL-23/IL-17 
axis in the TME. In paper III we demonstrate the presence of IL-23p19 in 
neuroblastoma cell lines and tumor tissue. However, in vivo studies are indispensable 
to investigate the role of IL-23/IL-17 in the neuroblastoma microenvironment. In a 
pilot study, we observed the presence of IL-23 in myeloid cells and tumor-stroma cells 
in the TH-MYCN mouse model, indicating this model may be suitable to study IL-23 
function in neuroblastoma using IL-23-specifc antibodies to block its function. 
With a median age of 18 months at diagnosis, neuroblastoma is a malignancy 
of early childhood [354]. Children are not small adults and potential differences in 
immunological and inflammatory processes during tumorigenesis should be 
considered when studying embryonal and pediatric malignancies. System 
immunology studies have expanded our knowledge on immune system changes in 
early life. After birth, the immune system undergoes dramatic changes. For example, 
high MDSC and Breg numbers that are abundantly observed in cord blood after birth 
decrease quickly and in addition, a slow reduction of neutrophils is observed whereas 
CD4+ and CD8+ T cells gradually increase [547]. Moreover, the first three months of 
life are important for B cells, NK cells, and DCs as adult-like phenotypes are developing 
[547]. Tregs are observed early in the thymus during fetal development and can be 
detected in the blood of newborns [548]. Interestingly, cord blood-derived γδ T cells 
express more diverse combinations of Vγ and Vδ TCR chains and while Vδ1+ T cells are 
the predominant subset in early life Vγ9Vδ2+ T cell are the main subset in adult blood 
and Vδ1+ T cells occur in skin and mucosa [60, 549]. In addition, it has been suggested 
that γδ T cell function compensates for the relative immaturity of the αβ compartment 
at birth as they display stronger functional responsiveness including IFN-γ production 
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[550]. Furthermore, the T helper cell response is skewed towards Th2 in newborns 
[548, 551]. This may in part be attributed to decreased IL-12 levels, resulting from 
reduced transcription of the p35 subunit in DCs [552, 553]. In consequence, cord 
neonatal innate immune cells secrete less IL-12, IFN-α, and IFN-γ (Th1 polarizing 
cytokines) and more IL-6, IL-1β, and IL-23 (Th17 polarization) as well as IL-10 in 
response to TLR engagement [554]. Vanden Eijnden et al. demonstrated that neonatal 
DCs secrete functional IL-23 in response to TLR-ligands and that LPS-stimulated DCs 
induced IL-17 production in neonatal CD8+ T cells [555]. In conclusion, the authors 
suggested that “a functional IL-23/IL-17 axis might compensate a suboptimal 
IL-12/IFN-γ pathway in early life”. Moreover, Olin et al. observed elevated levels of 
IL-17A and IL-12B (IL-12p40) in stage 4 and 5; distinct developmental stages where 
stage 5 corresponds to 3 months of age [547]. Collectively, these studies suggest that 
the IL-23/IL-17 axis may have important functions in early life immunity. Interestingly, 
IL-12 has previously been demonstrated to promote anti-tumor immunity in 
neuroblastoma mouse models [556-558]. Considering that IL-12 and IL-23 can exert 
opposing effects in tumorigenesis [194] more research on the IL-23/IL-17 axis and 




Despite continuing therapeutic advances, the survival of high-risk neuroblastoma 
patients remains poor. Neuroblastoma is a malignancy of early childhood and 
survivors often experience severe chronic health conditions later in life. The aim of 
neuroblastoma therapy is, therefore, to improve the survival of neuroblastoma 
patients while reducing treatment-related morbidities to ensure a high and lasting 
quality of life. 
A thorough understanding of the neuroblastoma microenvironment and associated 
inflammatory pathways contributes to the understanding of the disease and can 
thereby lead to the discovery of novel therapeutic approaches and the improvement 
of existing therapies. The tumor microenvironment is a complicated jigsaw puzzle and 
only when we turn around enough pieces and fit them together a clear picture will 
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ABSTRACT
Pro-inflammatory cells, cytokines, and chemokines are essential in promoting a 
tumor supporting microenvironment. Chemerin is a chemotactic protein and a natural 
ligand for the receptors CMKLR1, GPR1, and CCRL2. The chemerin/CMKLR1 axis is 
involved in immunity and inflammation, and it has also been implicated in obesity 
and cancer.
In neuroblastoma, a childhood tumor of the peripheral nervous system we 
identified correlations between high CMKLR1 and GPR1 expression and reduced overall 
survival probability. CMKLR1, GPR1, and chemerin RNA and protein were detected in 
neuroblastoma cell lines and neuroblastoma primary tumor tissue. Chemerin induced 
calcium mobilization, increased MMP-2 synthesis as well as MAP-kinase- and Akt-
mediated signaling in neuroblastoma cells. Stimulation of neuroblastoma cells with 
serum, TNFα or IL-1β increased chemerin secretion. The small molecule CMKLR1 
antagonist α-NETA reduced the clonogenicity and viability of neuroblastoma cell 
lines indicating the chemerin/CMKLR1 axis as a promoting factor in neuroblastoma 
tumorigenesis. Furthermore, nude mice carrying neuroblastoma SK-N-AS cells as 
xenografts showed impaired tumor growth when treated daily with α-NETA from day 
1 after tumor cell injection.
This study demonstrates the potential of the chemerin/CMKLR1 axis as a 
prognostic factor and possible therapeutic target in neuroblastoma.
INTRODUCTION
Neuroblastoma is a malignancy of the sympathetic 
nervous system occurring in early childhood and 
accounting for 7% of all pediatric cancers [1]. While the 
prognosis for low and intermediate risk neuroblastoma 
patients is favorable, the long-term event-free survival 
rate for high-risk patients remains less than 50%, despite 
intensive treatment [1, 2].
Chronic inflammation is an important modulator of 
the tumor microenvironment (TME). Pro-inflammatory 
cells, cytokines, and chemokines present in the TME 
promote tumor development, progression, and metastasis 
in various cancers [3, 4]. Recently, a subset of high-
risk, therapy-resistant neuroblastomas was demonstrated 
to be inflammation-driven indicating the importance 
of inflammation in neuroblastoma [5]. A thorough 
understanding of the neuroblastoma TME and the 
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inflammatory processes involved in tumorigenesis may 
lead to new therapy approaches and the discovery of novel 
prognostic markers [6–9].
Chemerin (also known as TIG-2 or RARRES2) 
is an adipokine and chemoattractant factor associated 
with obesity, inflammatory diseases and cancer [10–
20]. Synthesized as a 163 amino acid preproprotein, 
this chemerin precursor is N-terminally cleaved and 
secreted as prochemerin with low activity. Following 
secretion, prochemerin can be C-terminally cleaved by 
a variety of extracellular proteases, resulting in several 
chemerin isoforms with varying length, receptor affinity, 
and biological activity [21]. Proteases associated with 
inflammation such as cathepsin G and neutrophil elastase 
respectively cleave prochemerin into chemerin 21-156 
and 21-157. These are the most active forms, whereas 
prochemerin processed with mast cell chymase or protease 
3 results in the inactive or low activity chemerin 21-154 and 
21-155 variants, respectively [22, 23]. During inflammation 
initiation, maintenance and resolution the different 
chemerin isoforms may exert pro- and/or anti-inflammatory 
functions [24, 25]. Chemerin is a natural ligand for the 
G-protein-coupled receptors CMKLR1 (or ChemR23), 
GPR1, and CCRL2. CMKLR1 is expressed by different cell 
types including macrophages as well as immature dendritic 
cells and mediates the majority of the described chemerin 
functions [10, 24, 26–29]. Besides the involvement in 
various inflammatory diseases, the chemerin/CMKLR1 axis 
has been shown to play a role in different malignancies. 
While there is evidence that chemerin and CMKLR1 
support tumorigenesis in glioblastoma, gastric cancer, 
squamous esophageal cancer and squamous cell carcinoma 
of the oral tongue [16-18, 20], an anti-tumorigenic effect 
has been suggested in melanoma, hepatocellular carcinoma 
and non-small cell lung cancer [15, 30, 31].
GPR1 functions are so far less understood, but it 
has recently been found to contribute to the regulation of 
glucose homeostasis in obese mice [32]. At present, no 
active signaling has been detected following chemerin 
binding to CCRL2. However, CCRL2 is known to increase 
local chemerin concentrations [33] and its expression has 
been linked to rheumatoid arthritis and liver metastasis 
in colorectal cancer [34, 35]. The aim of the present 
study was to investigate the functional significance of 
chemerin, CMKLR1 and GPR1 in the neuroblastoma 
microenvironment and assess their potential as prognostic 
factors and therapeutic targets.
RESULTS
High CMKLR1 and GPR1 expression 
predict poor overall survival probability in 
neuroblastoma
To investigate CMKLR1 and GPR1 gene expression 
in neuroblastoma we used the publically available R2: 
Genomics analysis and visualization platform http://
r2.amc.nl. Examining two neuroblastoma gene expression 
cohorts, we found a correlation between high expression 
of CMKLR1 (Figure 1A and 1B) and GPR1 (Figure 1D 
and 1E) and a decrease in overall survival probability. 
Furthermore, CMKLR1 expression was higher in 
neuroblastoma cohorts compared to benign neurofibroma 
and neural crest cells (Figure 1C). However, no difference 
was found comparing GPR1 expression in the different 
cohorts (Figure 1F).
Additionally, we observed that expression 
of chemerin receptor CCRL2 was elevated in the 
neuroblastoma cohorts compared to neurofibroma and 
neural crest, and that high expression of CCRL2 correlated 
with a poor survival prognosis (Supplementary Figure 1D-
1F). While chemerin (RARRES2) expression was higher 
in the neuroblastoma cohorts compared to the neural 
crest, no difference was seen in comparison with benign 
neurofibroma. Furthermore, no clear correlation between 
high expression of RARRES2 and a decrease in overall 
survival probability was apparent due to conflicting results 
in the selected data sets (Supplementary Figure 1A-1C).
Neuroblastoma cell lines express chemerin, 
CMKLR1 and GPR1
We examined different neuroblastoma cell lines 
for the expression of CMKLR1, GPR1 and chemerin. 
Using RT-PCR (Figure 2A) and western blot (Figure 
2B) we demonstrated expression of CMKLR1, GPR1 
and chemerin mRNA and protein at varying levels 
in all neuroblastoma cell lines tested. No correlation 
was apparent between CMKLR1, GPR1 or chemerin 
expression levels and specific cell line characteristics such 
as MYCN amplification, 1p deletion, 11q deletion or multi-
drug resistance phenotype.
HepG2 cells were included in the western blots as 
a positive control. They are known to express and secrete 
chemerin and several antibody suppliers recommended 
them as a control cell line for CMKLR1.
Furthermore, we examined the expression levels 
of RARRES2 (chemerin), CMKLR1 and GPR1 in a panel 
of neuroblastoma cell lines using the publically available 
R2: Genomics analysis and visualization platform 
http://r2.amc.nl. We observed that all three genes are 
expressed at varying levels in the neuroblastoma cell 
lines included in this panel (Supplementary Figure 2A-
2C). In addition we compared their expression to known 
neuroblastoma promoting cytokines, chemokines, growth 
factors and their receptors and found GPR1 and CMKLR1 
expression in the range of FPR1, IL6R and PDGFRA. 
While RARRES2 (chemerin) expression is lower than 
VEGFA, it is comparable to CCL2 and CCL5 expression 
(Supplementary Figure 2D and 2E).
Immunofluorescence staining demonstrated the 
cellular distribution of CMKLR1 (Figure 2C) and GPR1 
(Figure 2D) in the neuroblastoma cell line SH-SY5Y. 
Both receptors were localized at the cell membrane 
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and in the cytoplasm. Comparable staining pattern for 
CMKLR1 was observed in other neuroblastoma cell lines 
using additional primary antibodies for confirmation 
(Supplementary Figure 3A and 3B). No apparent staining 
was observed in cells incubated with an isotype control 
antibody instead of the primary antibody (Supplementary 
Figure 3C).
TNFα, IL-1β and serum increase chemerin 
secretion in neuroblastoma cells
To investigate the effect of the pro-inflammatory 
cytokines TNFα and IL-1β as well as serum components 
on chemerin expression and secretion, chemerin 
concentrations were measured by ELISA. Exposure to 
IL-1β, TNFα as well as 10% serum for 24h increased the 
level of chemerin in the supernatant of SK-N-AS cells 
(Figure 2E).
CMKLR1, GPR1 and chemerin are expressed in 
neuroblastoma primary tumors
To confirm the presence of CMKLR1, GPR1 and 
chemerin in neuroblastoma primary tumors, IHC and 
IF-P were performed. A total of 27 neuroblastoma tissue 
samples from all clinical stages and biological subsets 
[36] were stained with antibodies detecting chemerin, 
CMKLR1 and GPR1. All tumor samples investigated 
demonstrated a significant expression of chemerin and its 
receptors. Figure 3 presents a representative labeling with 
CMKLR1 (Figure 3A), GPR1 (Figure 3B) and chemerin 
(Figure 3C) specific antibodies showing a clear staining of 
both the receptors and chemerin in neuroblastoma primary 
tumors. Fluorescence labeling of CMKLR1 (green) and 
chemerin (red) displayed the membranous and cytoplasmic 
localization of CMKLR1 whereas chemerin was detected 
both in intra- and extracellular compartments (Figure 
Figure 1: High CMKLR1 and GPR1 expression predicts poor survival in neuroblastoma patients. Expression data was 
analyzed using the R2 database http://r2.amc.nl. Kaplan-Meier survival estimates were used to evaluate the prognostic value of CMKLR1 
(A, B) and GPR1 (D, E) expression in two patient data sets (A and D: Versteeg n=88; B and E: Seeger n=102). The Kaplan-Meier scanning 
tool was used to determine the CMKLR1 and GPR1 mRNA expression in neuroblastoma. All expression data were scanned to find the 
most optimal cut-off between high and low gene expression and the log-rank test that gave the lowest p-value was calculated to search for 
significant differences between tumor samples expressing high and low CMKLR1 and GPR1 mRNA levels, respectively. The expression of 
CMKLR1 (C) and GPR1 (F) was compared between neural crest (Etchevers n=5), benign neurofibroma (Miller n=86) and 4 neuroblastoma 
cohorts (cohort 1: Versteeg n=88, cohort 2: Delattre n=64, cohort 3: Hiyama n=51, cohort 4: Lastowska n=30).
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3D-3F) indicating chemerin secretion in neuroblastoma 
primary tumor tissue. For both, IHC and IF-P, no apparent 
staining was observed in sections incubated with isotype 
control antibodies instead of the primary antibodies 
(Supplementary Figure 3D-3F).
Chemerin induces calcium mobilization 
and promotes MAPK and Akt signaling in 
neuroblastoma cell lines
Chemerin has been previously shown to stimulate 
intracellular calcium mobilization in immature DCs 
and macrophages as well as MAPK and Akt signaling 
in human chondrocytes and endothelial cells through 
CMKLR1 [14, 24, 37]. GPR1-mediated calcium 
mobilization and ERK1/2 phosphorylation following 
chemerin binding has been demonstrated to be much 
weaker [38, 39]. Recently, both CMKLR1 and GPR1 
were found to signal through the RhoA/Rock pathway in 
HEK293A and gastric carcinoma cells [40].
To determine the effect of chemerin in 
neuroblastoma, we studied calcium mobilization, MAPK, 
and Akt signaling in neuroblastoma cell lines. Chemerin 
stimulation caused a rapid, but transient increase in 
intracellular calcium in SK-N-SH cells (Figure 4A and 
4B) in comparison to vehicle treatment. Furthermore, 
prior incubation with the calcium chelator EDTA showed 
no inhibitory effect (Figure 4B) indicating calcium release 
from intracellular compartments.
The addition of chemerin to SK-N-AS cells induced 
a rapid and dose-dependent phosphorylation of MEK1/2, 
ERK1/2 and Akt (Figure 4C) indicating the activation 
of MAPK and Akt signaling. Similar phosphorylation 
patterns were observed in SK-N-BE(2) cells (data not 
shown).
Chemerin increases MMP-2 synthesis in 
neuroblastoma cells
Chemerin is known to stimulate MMP-2 and 
MMP-9 expression and activity [37, 41]. Using real-time 
zymography, we could follow the degradation of gelatin 
by MMP-2 and MMP-9 in real-time. We observed a dose-
dependent increase in MMP-2 synthesis in both SK-N-
Figure 2: CMKLR1, GPR1 and chemerin are expressed in neuroblastoma cell lines and TNFα, IL-1β, and serum 
stimulate chemerin secretion. (A) RT-PCR analysis demonstrating the expression of chemerin, CMKLR1 and GPR1 mRNA in all 
neuroblastoma cell lines investigated. NTC, no template control. The expression of chemerin, CMKLR1, and GPR1 protein was confirmed 
by western blot (B). HepG2 cells were used as a positive control. The images are representative of three independent experiments. 
Immunofluorescence labeling shows the presence of CMKLR1 (C) and GPR1 (D) in SH-SY5Y cells (green). The nuclei (blue) were stained 
with Hoechst 33342, scale bar 20μm. (E) Chemerin concentrations were measured in cell supernatants of SK-N-AS cells after treatment 
with 10 or 50ng/ml TNFα, IL-1β or 10% FBS for 12 or 24h, respectively. The supernatants of 10 independent samples were pooled and 
concentrated 10x prior to ELISA measurement. The standards and samples were measured in duplicates and the data is presented as mean 
and range. Statistical analysis was performed using a two-way ANOVA P<0.001 for both stimulation and incubation time followed by 
Dunnett’s post-test control vs. treatment * P<0.05, *** P<0.001.
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AS and to a lesser extent in SK-N-BE(2) cells after 6, 12, 
24 and 48h stimulation with active chemerin (Figure 5). 
No effect on MMP-9 synthesis was observed under these 
conditions.
CMKLR1 inhibition reduces the cell viability 
and clonogenicity of neuroblastoma cells
The effect of CMKLR1 inhibition on 
neuroblastoma cell lines was studied using the recently 
described CMKLR1 inhibitor α-NETA [42]. Increasing 
concentrations of α-NETA reduced the cell viability of 
four neuroblastoma cells lines after 72h of treatment with 
IC50 values ranging between 3.87-7.49μM (Figure 6A 
and 6B). No effect (IC50 values >10μM) was observed 
on human fibroblasts (MRC-5) and endothelial cells 
(HUVEC). A dose-dependent inhibition of clonogenicity 
was observed in SK-N-BE(2) cells (Figure 6C) as well 
as SK-N-AS, SK-N-DZ, and SH-SY5Y cells (Figure 6D). 
The colony forming ability was completely inhibited using 
5μM α-NETA.
Early and prolonged CMKLR1 inhibition 
impairs neuroblastoma growth in vivo
The therapeutic effect of CMKLR1 inhibition was 
examined in a SK-N-AS xenograft model. A significant 
prolongation (p=0.015, Log rank test) of survival (defined 
as time needed for the animals to grow a macroscopic 
tumor with a volume >1.5ml) was observed in the pre-
treatment group, where the animals were treated s.c. 
with α-NETA continuously from day 1 after tumor cell 
injection, compared to the control group (Figure 7). 
In addition, when comparing tumor growth rates for 
individual tumors, the tumors from the pre-treated mice 
grew significantly slower than the tumors in the control 
group (p=0.0061, one way ANOVA with Bonferroni post-
test, control vs. pre-treatment p=0.049, Supplementary 
Figure 4). However, no effect was seen in the treatment 
group, where α-NETA s.c. injections were initiated after 
the tumor reached a volume of ≥ 0.15ml, compared to 
the control group. No signs of toxicity were observed at 
the used concentrations of α-NETA. In the pre-treatment 
Figure 3: CMKLR1, GPR1 and chemerin are expressed in neuroblastoma primary tumors. Immunoperoxidase staining 
demonstrates specific expression of (A) CMKLR1, (B) GPR1 and (C) chemerin in neuroblastoma primary tumor tissue. Immunofluorescence 
labeling (D-F) displays CMKLR1 (green) and chemerin (red) localization in neuroblastoma tissue. The nuclei were stained with DAPI 
(blue). (E and F) are higher magnifications of (D) to illustrate the colocalization of CMKLR1 and chemerin. The displayed images are 
representative stainings from a panel of neuroblastoma tumors.
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group, a hardening of the skin was seen at the later stages 
of the experiment probably due to the daily s.c. injection 
over a prolonged period. All mice gained weight over the 
course of the experiment.
DISCUSSION
Neuroblastoma is a malignancy with only a few 
identified key genetic events. Besides amplification 
of the MYCN oncogene (in approximately 20% of 
neuroblastomas), ALK mutations and amplifications 
occur in 9% and 2-3%, respectively. Other affected genes 
include ODC, NTRK2/TrkB, FOXR1, PTPN11, ATRX, 
CADM1, and ARID1A/B [2, 43]. For the discovery of 
potential new therapeutic targets, understanding of the 
neuroblastoma TME is of great importance. Chemokines 
and chemoattractant factors are essential regulators of cell 
trafficking during immune response and inflammation. 
Furthermore, they are involved in all stages of cancer 
development: tumor establishment, neovascularization, 
and metastasis [44, 45].
Several chemokine receptors and their ligands 
have been identified as contributors to neuroblastoma 
angiogenesis, metastasis, and communication between 
tumor cells and cells of the TME [6, 46]. CMKLR1 
is a chemoattractant receptor present on immune cells 
such as immature DCs, macrophages and NK cells [47]. 
Recently, CMKLR1 was found to be expressed in a 
subset of myeloid-derived suppressor cells (MDSCs) in 
hepatocellular carcinoma [48].
Chemerin, a ligand for CMKLR1 possesses a wide 
variety of characteristics attributed to tumor growth such 
as chemotaxis and cell adhesion, as well as cell survival 
and proliferation [21, 41, 47]. In ECs, CMKLR1 was 
Figure 4: Chemerin induces intracellular calcium mobilization and stimulates MAPK and Akt signaling in 
neuroblastoma cells. Intracellular calcium mobilization was measured in SK-N-SH cells with confocal laser scanning microscopy 
following the stimulation with 10nM chemerin without (A) and with (B) the prior addition of the calcium chelator EDTA. The arrow 
indicates the time point when chemerin was added. (C) Chemerin stimulates the phosphorylation of Akt, ERK1/2 and MEK1/2 in SK-N-AS 
cells in a dose-dependent manner. The cells were serum-starved for 24h prior to stimulation and samples were taken 5, 10, 20 and 30min 
after stimulation. Densitometric analysis of the protein bands was performed and the ratios between p-ERK1/2 and total ERK1/2, p-Akt 
and total Akt as well as p-MEK1/2 and β-actin were calculated. The values are displayed relative to the control=1. The experiments were 
performed three times with similar results.
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found to be upregulated by the pro-inflammatory cytokines 
TNFα, IL-1β and IL-6. Furthermore, chemerin stimulation 
induced MMP production and angiogenesis [37]. Recent 
work by Chua et al. demonstrates that hypoxia promotes 
chemerin expression in human coronary artery endothelial 
cells as well as migration and tube formation, supporting 
previous findings on the role of chemerin in angiogenesis 
[49]. However, the function of the chemerin/CMKLR1 
axis in malignancies is probably tumor specific as both 
tumor promoting and tumor suppressing roles have been 
reported [15-18, 20, 30, 31].
In the present study, we investigated the role of 
chemerin and its receptors CMKLR1 and GPR1 in 
neuroblastoma tumorigenesis. Using publically available 
gene expression datasets (http://r2.amc.nl) we observed 
that high CMKLR1 and GPR1 expression correlates with 
a reduced overall survival probability in the two datasets 
we examined. We did not find any relationship between 
genetic characteristics of neuroblastoma, such as MYCN 
expression, and CMKLR1, GPR1 or chemerin expression. 
Our findings indicate that CMKLR1 and/or GPR1 could 
potentially be used as independent prognostic factors.
Tumor-associated macrophages (TAMs) have 
been shown to promote neuroblastoma tumorigenesis 
[6], and CMKLR1 expression in macrophages can be 
stimulated by mammary and lung carcinoma cells [50]. 
Asgharzadeh et al. [7] described the prognostic value of 
a TAM gene expression signature (CD33, CD16, IL6R, 
IL10, FCGR3) in metastatic neuroblastoma. Examining 
publically available neuroblastoma gene expression 
datasets (R2: Genomics Analysis and Visualization 
Platform http://r2.amc.nl) we observed a significant 
correlation between expression of CMKLR1 and the 
TAM markers (Supplementary Figure 5). IHC labeling 
of the macrophage marker CD68 as well as double IF-P 
staining of CD68 and CMKLR1 in neuroblastoma tissue 
demonstrated that while the majority of CMKLR1 is 
expressed by the tumors cells, CD68+ cells in the TME 
also express CMKLR1 (Supplementary Figure 6).
Additionally, CMKLR1 is expressed at high levels 
in monocytic MDSCs in hepatocellular carcinoma 
[48]. Therefore, the expression of CMKLR1 on tumor 
promoting immune cells could also play a significant role 
in the tumorigenesis process.
Figure 5: Chemerin stimulates MMP-2 synthesis in neuroblastoma cells. Typical real-time gelatin zymography of supernatants 
from SK-N-AS and SK-N-BE(2) cells untreated (control) or treated with increasing concentrations of chemerin (0.1-100 nM) or TNFα (10 
ng/ml) for 6h, 12h, 24h and 48h. Prior to stimulation, the cells were serum-starved for 24h. For each zymogram the supernatants of three 
independent samples were pooled and analyzed. The shown zymograms were taken after optimal incubation time (for SK-N-AS 15h, 10h, 
13h and 13h and for SK-N-BE(2) 15h, 10h, 5h and 4h) in assay buffer after the removal of SDS from the gels. The standard (st) comprised 
a mixture of proMMP-9 monomer (92 kDa), active MMP-9 (83 kDa), proMMP-2 (72 kDa) and active MMP-2 (62 kDa).
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A recent study demonstrated that chemerin secreted 
by esophageal squamous cancer-associated myofibroblasts 
stimulates the migration of cancer cells, indicating a role 
in invasion. Blockage of the chemerin/CMKLR1 axis 
inhibited invasion [41]. In addition, Kaur et al. determined 
a mitogenic effect of chemerin on human macro- and 
microvascular endothelial cells through activation of 
CMKLR1 [37]. Therefore, a potential role of chemerin/
CMKLR1 in neuroblastoma angiogenesis could be 
hypothesized. Collectively, these findings indicate that 
targeting CMKLR1 expressed on stromal cells in addition 
to the tumor cells could be of therapeutic interest.
In the present study, active chemerin induced 
both calcium mobilization and the activation of MAPK 
and Akt signaling. PI3K/Akt- and MAPK-mediated 
signaling are known to contribute to neuroblastoma 
tumorigenesis [51–54]. Furthermore, we demonstrated 
that the pro-inflammatory cytokines TNFα and IL-1β as 
well as serum components stimulate chemerin secretion by 
neuroblastoma cells. Both cytokines have been previously 
found to regulate CMKLR1 and chemerin expression 
in human endothelial cells, keratinocytes (IL-1β), and 
other cell types [37, 55]. Additionally, we observed 
that chemerin stimulated MMP-2 synthesis in a dose-
dependent manner. MMP-2 is a member of the matrix 
metalloproteinase family with important functions in 
tumorigenesis. Through processing of extracellular matrix 
and non-matrix proteins, MMP-2, and other members of 
the MMP family, contribute to cell invasion, metastasis 
and neovascularization [56]. Increased MMP-2 expression 
in neuroblastoma has been associated with increased 
angiogenesis, advanced stage, and poor clinical outcome 
[57, 58]. Our results indicate that chemerin may contribute 
to an increased MMP-2 synthesis in neuroblastoma.
Figure 6: The CMKLR1 antagonist α-NETA reduces the cell viability and clonogenicity of neuroblastoma cell lines. 
Cell viability was determined after 72h of incubation with α-NETA (0.313-10μM). A dose-dependent decrease in cell viability was observed 
in the neuroblastoma cell lines but not in MRC-5 and HUVEC cells (A). Data is presented as mean ± SEM from three experiments. The 
IC50 values are given with 95% confidence intervals in (B). The mean of log IC50s in neuroblastoma cell lines was significantly lower than 
the hypothetical log IC50 of the investigated normal cell lines (one sample t-test, p=0.029; means: 0.726 vs 1). The CMKLR1 antagonist 
α-NETA reduces the clonogenicity of SK-N-BE(2) cells (C; 1.25 and 2.5μM, n=3) and other neuroblastoma cell lines (D; 0.313-2.5μM, 
n=3) in a dose-dependent manner after 72h treatment. Data is presented as mean ± SD from a representative experiment. The experiment 
was repeated twice more with similar results. Statistical testing was performed using a two-way ANOVA P<0.001 for both stimulation and 
between cell lines followed by Dunnett’s post-test control vs. treatment * P<0.05, *** P<0.001.
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In our work, we observed that α-NETA, a small 
molecule inhibitor for CMKLR1, reduced the cell viability 
and clonogenicity of neuroblastoma cell lines. Initially 
identified as a choline acetyltransferase inhibitor, α-NETA 
was recently found to be a more potent inhibitor of 
CMKLR1 [42]. In an in vivo xenograft study, we observed 
that continuous, long-term treatment with α-NETA 
resulted in impaired tumor growth. However, no effect 
was observed when α-NETA injections were initiated 
after the tumor had reached a volume of 0.15ml. These 
results indicate that CMKLR1 function might be of greater 
importance during the early stages of tumor growth as well 
as tumor recurrence and relapse in neuroblastoma patients. 
However, SK-N-AS xenograft tumors grow very fast once 
the tumor has been established therefore providing only a 
narrow treatment window. In order to achieve a significant 
effect, a longer treatment window as given in the pre-
treatment group might be necessary. The results from the 
in vitro studies indicate a role of CMKLR1 during clone 
formation. Inhibiting CMKLR1 at a stage where the tumor 
has reached a certain size might therefore have a smaller 
impact. Since α-NETA has only recently been described 
as a CMKLR1 inhibitor, potential off-target effects are not 
fully studied. Concerning bioavailability and stability of 
α-NETA in vivo only limited data is available, hampering 
dose estimation. Hence, the concentration used in this 
study might have been too low to sufficiently abrogate 
CMKLR1 function in established tumors. Further studies 
are therefore necessary to determine the appropriate 
concentrations for α-NETA in vivo. Additionally, the 
results should be confirmed using CMKLR1 knockout 
neuroblastoma cell lines. Although we made several 
attempts to knock down/out CMKLR1 in neuroblastoma 
cell lines using both shRNA and the CRISPR/Cas9 system, 
we have established to date only one SK-N-AS cell line 
with a marked CMKLR1 downregulation (Supplementary 
Figure 7). Since this cell line grows very slowly and is 
unable to form distinct colonies in clonogenicity assays 
we have been unable to utilize it in functional in vitro or in 
vivo studies. While these findings, taken together with the 
results from the inhibitor studies, indicate that CMKLR1 
may contribute to colony formation and tumorigenesis we 
have been unable to confirm these findings with additional 
knock down clones.
GPR1 is an additional active chemerin receptor 
expressed in the central nervous system, skeletal 
muscle, and adipose tissue [47]. In this work, we also 
demonstrate the expression of GPR1 mRNA and protein 
in neuroblastoma cell lines and primary tumor tissue. 
While most of the known chemerin functions have 
been connected to CMKLR1-mediated signaling, we 
cannot exclude that chemerin mediated signaling in 
neuroblastoma cell lines is not at least partly mediated by 
GPR1. However, GPR1 mediated calcium mobilization 
and ERK1/2 phosphorylation has been demonstrated 
to be much weaker compared to CMKLR1 [38, 39]. 
Recently, chemerin was found to activate RhoA/Rock 
signaling through CMKLR1 and GPR1 [40]. The Rho/
Rock pathway is involved in actin rearrangement, hence 
suggesting a potential role of the chemerin/CMKLR1/
GPR1 axis in migration and metastasis.
CCRL2, the third known chemerin receptor is present 
on myeloid cells, mast cells and CD34+ bone marrow 
precursors [47]. While not actively signaling, it was found 
Figure 7: Early and prolonged CMKLR1 inhibition with α-NETA impairs tumor growth in vivo. Kaplan-Meier survival 
plots of nude mice (n=11 in control group and in pre-treatment group, n=10 in treatment group) injected daily s.c. with 20mg/kg α-NETA 
after the tumor reached 0.15ml (treatment group), 10mg/kg α-NETA from the day after tumor cell injection and 20mg/kg when the tumor 
reached 0.15ml (pre-treatment group) or 10% Captisol® (control group). Survival, defined as time needed for the animals to grow a 
macroscopic tumor (volume >1.5ml), was significantly prolonged in the pre-treatment group (log rank test P=0.015, control vs. pre-
treatment P= 0.019 and control vs. treatment P=0.51).
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to increase local chemerin levels suggesting that CCRL2 
presents chemerin to CMKLR1 or GPR1 on neighboring 
cells [33]. Akram et al. recently identified a role of CCRL2 
in colorectal cancer liver metastases [35]. Although we 
were able to detect CCRL2 mRNA in neuroblastoma cell 
lines (data not shown), the role of CCRL2 in neuroblastoma 
was not addressed in the present study.
Our results demonstrate, for the first time, the 
presence of a fully active and functional chemerin/
CMKLR1 axis in childhood neuroblastoma. Neuroblastoma 
cells produce chemerin that can promote survival in an 
autocrine manner. Inhibition of the chemerin/CMKLR1 axis 
impaired neuroblastoma cell growth in vitro and in vivo. 
Our findings provide new insight into the pathobiology of 
neuroblastoma. Pharmacological interventions targeting the 
chemerin/CMKLR1 signaling pathway may be an important 
adjuvant therapy for children with neuroblastoma, but 
further preclinical in vivo studies are warranted.
MATERIALS AND METHODS
Microarray gene expression analysis
Gene expression analysis was performed using 
the publicly available R2: Genomics Analysis and 
Visualization Platform (http://r2.amc.nl).
Antibodies and reagents
The antibodies used in this study are listed in Table 
1. Recombinant human IL-1β was purchased from Cell 
Guidance Systems Ltd. (Cambridge, UK). Recombinant 
human TNFα and chemerin were obtained from R&D 
Systems, Inc. (Minneapolis, USA) and α-NETA was from 
Santa Cruz Biotechnology, Inc. (Dallas, USA).
Cell lines and human tissue samples
The human neuroblastoma cell lines SK-N-
AS, SK-N-SH, SK-N-DZ, SK-N-FI, SH-EP1, Kelly, 
SH-SY5Y, and IMR-32 as well as the hepatocellular 
carcinoma cell line HepG2 were purchased from the 
ATCC (American Type Culture Collection), and SK-
N-BE(2) cells were bought from DSMZ (Deutsche 
Sammlung von Mikroorganismen und Zellkulturen). 
The cells were cultivated in RPMI-1640 medium 
containing L-glutamine and sodium bicarbonate 
(Sigma-Aldrich Norway AS, Oslo, Norway) 
supplemented with 10% heat-inactivated FBS (Thermo 
Fisher Scientific Inc.) at 37°C in humidified air with 
5% CO2. The human fibroblast cell line MRC-5 and 
human umbilical vein endothelial cells (HUVEC) were 
purchased from the ATCC and cultivated in EGM-2 
BulletKit with 2% FBS (Lonza, Basel, Switzerland) 
Table 1: Antibodies used in the study
Antibody Application Source
Anti-ChemR23 WB, IHC #STJ92262, St John’s Laboratory
Anti-Human ChemR23 IF-P, ICC #MAB362, R&D Systems
Anti-GPCR GPR1 WB #ab157209, abcam
Anti-GPCR GPR1 ICC #ab121315, abcam
Anti-GPCR GPR1 IHC #ab188977, abcam
Anti-TIG2 Antibody (K-15) WB, IF-P #sc-47482, Santa Cruz Biotechnology
Anti-Human Chemerin IHC #MAB2324, R&D Systems
Anti-beta Actin WB #ab8227, abcam
Anti-p44/42 MAPK (Erk1/2) WB #4695, Cell Signaling Technology
Anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) WB #4370, Cell Signaling Technology
Anti-Akt WB #9272, Cell Signaling Technology
Anti-Phospho-Akt (Ser473) (D9E) WB #4060, Cell Signaling Technology
Anti-Phospho-MEK1/2 (Ser217/221) WB #9121, Cell Signaling Technology
Goat Anti-Rabbit IgG H&L (HRP) WB #ab6721, abcam
Swine Anti-Goat Ig's, HRP WB #ACI0404, Thermo Fisher Scientific
Goat anti-Rabbit IgG (H+L), Alexa Fluor 488 ICC # A-11008, Thermo Fisher Scientific
Donkey anti-Goat IgG (H+L), Alexa Fluor 594 IF-P #A-11058, Thermo Fisher Scientific
Rabbit anti-Mouse IgG (H+L), Alexa Fluor 488 IF-P # A-11059, Thermo Fisher Scientific
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and MEM supplemented with 2mM L-glutamine, 1% 
non-essential amino acids and 10% FBS, respectively. 
Mycoplasma tests were regularly performed using the 
MycoAlert™ PLUS Mycoplasma Detection Kit (Lonza, 
Basel, Switzerland).
Neuroblastoma tumor tissue was obtained from 
the Karolinska University Hospital according to the 
ethical approval from the Stockholm Regional Ethical 
Review Board and the Karolinska University Hospital 
Research Ethics Committee (approval ID 2009/1369-
31/1 and 03-736). Informed consent (written or verbal) 
was provided by the parents or guardians for the use 
of tumor samples in research. Samples were collected 
during surgery, snap-frozen in liquid nitrogen and stored 
at -80°C until further use. Twenty-seven neuroblastoma 
samples derived from children of different ages and all 
clinical stages, including different biological subsets [36] 
were analyzed.
RNA isolation and reverse transcriptase PCR
Total RNA was isolated using the RNeasy® Mini Kit 
(Qiagen Norge, Oslo, Norway) according to the provided 
manual. The RNA quantity and quality was determined 
using the NanoDrop 1000 (Thermo Fisher Scientific 
Inc.). One μg RNA was used for cDNA synthesis with 
the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories 
AB, Oslo, Norway). PCR was performed in a 25μl 
reaction mix containing 2μl cDNA, 12.5μl AccuStart™ 
II GelTrack PCR SuperMix (Quanta Biosciences, 
Gaithersburg, USA), 400 nM of each primer and 10.1μl 
of ultra-pure H2O (Biochrom GmbH, Berlin, Germany). 
The PCR run was performed in a T100™ Thermal 
Cycler (Bio-Rad Laboratories AB, Oslo, Norway) as 
follows: 2min at 94°C and 35 cycles of 94°C for 20s, 
62°C for 30s and 72°C for 90s. The sequences for the 
PCR primers were the following: APRT (housekeeping) 
5’-CCCGAGGCTTCCTCTTTGGC-3’ (sense) and 
5’-CTCCCTGCCCTTAAGCGAGG-3’ (antisense) [59], 
CMKLR1 5'-GCCAACCTGCATGGGAAAATA-3’ 
(sense) and 5’-GTGAGGTAGCAAGCTGTGATG-3’ 
(antisense), GPR1 5’-CAATCTAGCCATTGCGG 
ATTTCA-3’ (sense) and 5’-CCGATGAGATA 
AGACAGGATGGA-3’ (antisense), chemerin 
5’-AGAAACCCGAGTG CAAAGTCA-3’ (sense) and 
5’-AGAACTTGGGTCTCTATGGGG-3’ (antisense) 
(Primer bank ID 215272316c3, 148228828c3 and 
218931208c1 http://pga.mgh.harvard.edu/primerbank/
index.html).
PCR products were analyzed by gel electrophoresis. 
The 1.8% SeaKem® LE Agarose gel (Lonza) was stained 
with GelRed™ (Biotium, Inc., Hayward, USA) and 
visualized under UV light in the BioDoc-It™ Imaging 
System (UVP, LLC, Upland, USA). The PCR results for 
CMKLR1, GPR1 and chemerin were confirmed with a 
second, independent primer set (data not shown).
Western blot
Cultured cells were washed briefly with phosphate-
buffered saline (PBS, Biochrom GmbH) and harvested 
in RIPA Lysis and Extraction Buffer containing Halt™ 
Protease and Phosphatase Inhibitor Cocktail (Thermo 
Fisher Scientific Inc.). Following sonication, the 
protein concentration was determined using a Protein 
Quantification Assay (MACHEREY-NAGEL GmbH 
& Co. KG, Düren, Germany). The protein lysates were 
supplemented with NuPAGE® LDS Sample Buffer (4X) 
(Thermo Fisher Scientific Inc.) as well as 100mM DTT 
(Sigma-Aldrich Norway AS) and incubated for 10min 
at 70°C. Equal amounts of protein were separated on 
NuPAGE™ Novex™ 4-12% Bis-Tris Protein Gels (Thermo 
Fisher Scientific Inc.) and transferred onto a 0.45μm 
PVDF Membrane (Merck Life Science AS, Oslo, Norway) 
according to the XCell SureLock Mini-Cell technical guide 
(Thermo Fisher Scientific Inc.). The membranes were 
blocked in TBS-T (Tris-buffered saline (TBS) with 0.1% 
Tween-20; Sigma-Aldrich Norway AS) containing 5% 
(w/v) skimmed milk powder. Incubation with the primary 
antibody was performed overnight at 4°C according to 
antibody supplier recommendation in either blocking buffer 
or 5% BSA (AppliChem, Darmstadt, Germany) in TBS-T. 
Following three washes in TBS-T, the membranes were 
incubated in the appropriate secondary antibody solution 
for 1h at room temperature. After four washes, detection 
and visualization were performed using SuperSignal™ 
West Pico Chemiluminescent Substrate (Thermo Fisher 
Scientific Inc.) and the ImageQuant LAS 4000 imager (GE 
Healthcare, Oslo, Norway). MagicMark™ XP Western 
Protein Standard (Thermo Fisher Scientific Inc.) was used 
to estimate the molecular mass of the detected proteins. 
Densitometry was performed using Fiji software [60].
ICC
For immunocytochemistry, cells were grown on 
8-well μ-Slide (ibidi GmbH, Munich, Germany) for 
24h. Cells were then rinsed briefly with PBS and fixed 
with 4% formaldehyde for 20min. After three washes 
with PBS, unspecific binding sites were blocked with 
1% BSA in PBS containing 0.3% Triton-X-100 (Sigma-
Aldrich Norway AS) for 45min. The cells were incubated 
with primary antibodies diluted in blocking solution at 
4°C overnight. After three washes with PBS, the cells 
were incubated with the secondary antibodies diluted in 
blocking solution for 1h at room temperature, protected 
from light. Following three washes with PBS, the nuclei 
were stained with Hoechst 33342 (ImmunoChemistry 
Technologies, LLC, Bloomington, USA) for 10min. 
The cells were washed 2x with PBS and covered with 
Mounting Medium for fluorescence microscopy (ibidi 
GmbH). The cells were subsequently examined with a 
Leica TCS SP5 or Zeiss LSM780 confocal microscope.
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IHC
Formalin-fixed and paraffin-embedded tissue 
sections were deparaffinized in xylene and graded 
alcohols, hydrated and washed in PBS. After antigen 
retrieval in a sodium citrate buffer (pH 6) in a microwave 
oven, the endogenous peroxidase was blocked by 0.3% 
H2O2 for 15min. Sections were incubated overnight at 4°C 
with the primary antibody. As a secondary antibody, the 
anti-rabbit-HRP SuperPicTure Polymer detection kit (87-
9663, Zymed-Invitrogen, San Francisco, USA) or anti-
mouse EnVision-HRP (Dako, Agilent Technologies, Inc., 
Santa Clara, USA) was used. A matched isotype control 
was used as a control for nonspecific background staining.
For immunofluorescence histology studies (IF-P), 
the sections were treated as described above and stained 
sequentially with the primary and secondary antibody 
sets. Alexa Fluor® 488 and Alexa Fluor® 594 conjugated 
secondary antibodies were used to visualize positive 
staining.
The fluorescence labeled tissue sections were 
examined using the Zeiss LSM780 confocal microscope 
and the immunoperoxidase stained sections using the 
Leica DMI6000B microscope.
Calcium mobilization assay
SK-N-SH cells were seeded into an 8-well μ-Slide 
(ibidi GmbH) and incubated overnight in RPMI containing 
10% FBS. The following day the cells were washed and 
preloaded with 20μM Cal-520 (AATBio, Sunnyvale, USA) 
in Hanks' Buffer with 20mM Hepes (HHBS) with 0.04% 
Pluronic® F-127 (AATBio). After 90min of incubation 
at 37°C, the dye solution was replaced with HHBS and 
the cells were subsequently examined with a Leica TCS 
SP5 confocal microscope in the presence or absence 
2mM EDTA. Before the addition of 10nM of chemerin, 
a baseline measurement was taken. Images were then 
obtained and analyzed using the Leica LAS AF software.
Stimulation of cells with chemerin
Cells were seeded in 35mm cell culture dishes 
(Corning, Corning, USA) and incubated overnight in 
complete growth medium. The cells were serum starved 
for 24h prior to stimulation with recombinant human 
chemerin (0.1-10 nM) for 5, 10, 20 and 30min.
Chemerin ELISA
SK-N-AS cells were seeded in 96-well culture 
plates. The following day, the medium was removed 
and the cells were serum starved (0.1% FBS) overnight. 
The cells were then stimulated with either 10% FBS or 
10 ng/ml, 50 ng/ml TNFα, or IL-1β in serum reduced 
medium (0.1% FBS) for 12 and 24h. After incubation, 
supernatants from 10 parallels were pooled and spun 
for 5min at 200xg to pellet floating cells. The cell 
supernatant was concentrated 10x using Amicon Ultra-0.5 
Centrifugal Filter Unit (Merck Life Science AS). The 
chemerin quantity was assayed by ELISA according to the 
manufacturer’s instructions (Human Chemerin Quantikine 
ELISA, R&D Systems, Inc).
Real-time zymography
SK-N-AS and SK-N-BE(2) cells were seeded 
in 96-well plates (Corning, Corning, USA) and left to 
attach overnight. The medium was replaced with Opti-
MEM and the cells were serum-starved for 24h. The cells 
were thereafter exposed to chemerin (0.1-100 nM) for 6, 
12, 24 and 48h, using Opti-MEM serum-free medium. 
TNFα (10ng/ml) was used as a positive control. After 
the incubation, the medium from three independent 
samples was pooled, centrifuged at 200xg for 5min at 
4°C, and made 10 and 100mM with respect to CaCl2 
and Hepes (pH 7.5). Undiluted samples were analyzed 
for the expression of gelatin degrading enzymes using 
real-time zymography. Zymography was performed as 
described previously [61] with the exception that 0.1% 
(w/v) 2-methoxy-2,4-diphenyl-3(2H)-furanone (MDPF)-
fluorescent labeled gelatin was incorporated in the 7.5 % 
SDS-PAGE separating gel instead of 0.1% (w/v) unlabeled 
gelatin. Gelatin (Sigma-Aldrich Norway AS) was labeled 
with the fluorescent dye 2-methoxy-2,4-diphenyl-3(2H)-
furanone (Sigma-Aldrich Norway AS) to give MDPF-
gelatin as described previously [62]. The main difference 
between normal gelatin zymography and real-time gelatin 
zymography is that in real-time zymography the gel is not 
stained and hence it is possible to follow the degradation 
of the gelatin in real time without staining. In the present 
work, each gel was monitored continuously and a picture 
of the gel was taken approximately every second hour 
for fifteen hours or more. Gelatinase activity was evident 




diphenyltetrazolium bromide (MTT) viability assay [63] 
was employed to assess the effect of α-NETA on the 
viability of neuroblastoma cell lines as well as MRC-5 
and HUVEC. The cells were seeded in 96-well plates in 
full growth media. After 24h the cells were washed once 
with Opti-MEM (Thermo Fisher Scientific Inc.) before 
being incubated with 313nM-10μM α-NETA (dissolved 
in dimethylsulfoxide, DMSO) in Opti-MEM for 72h. 
Control cells received DMSO corresponding to the highest 
concentration present in the α-NETA treated cells. The MTT 
solution (20μl of 5mg MTT, Sigma-Aldrich Norway AS, 
per ml phosphate buffered saline) was added to each well. 
After 2-3h additional incubation 150μl of solution were 
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carefully removed from each well and 100μl isopropanol 
containing 0.04M HCl were added and mixed thoroughly. 
To further facilitate formazan crystal solubilizing, the plates 
were placed on an orbital shaker for 1h at room temperature. 
The absorbance was measured with a CLARIOstar plate 
reader (BMG LABTECH, Ortenberg, Germany) at 590 nm. 
The experiment was repeated three times with at least three 
parallels per treatment and the cell viability was calculated as 
the ratio of the mean OD of treated cells over vehicle treated 
control cells (100% living cells). The IC50s were calculated 
from log concentration curves using non-linear regression 
analysis in GraphPad Prism.
Clonogenic assay
SK-N-AS, SK-N-BE(2), SK-N-DZ, and SH-SY5Y 
cells were seeded in 6 well plates and allowed to attach 
to the surface overnight. The cells were washed and the 
medium was replaced with Opti-MEM containing 313 
nM-5μM α-NETA dissolved in DMSO. The control cells 
received DMSO corresponding to the highest concentration 
present in the α-NETA treated cells. After 72h the medium 
was replaced with regular growth medium containing 10% 
FBS. When the cell colonies reached ≥ 50 cells, the plates 
were briefly rinsed with PBS (Thermo Fisher Scientific 
Inc.), fixed in 4% formaldehyde (Merck Life Science 
AS), and stained with Giemsa (Merck Life Science AS). 
Colonies containing at least 50 cells were counted.
In vivo xenograft study
All animal experiments were approved by the local 
ethical committee (approval ID: N231/14) appointed 
by the Swedish Board of Agriculture and conducted in 
accordance with the local guidelines and the European 
Directive 2010/63/EU.
Female, immunodeficient nude mice (NMRI-nu/nu, 
Taconic) were used for the xenograft studies. The animals 
were housed in cages containing 2–6 mice with ad libitum 
access to food and sterile water. The cages contained 
environmental enrichment (a house, nest material and 
gnawing sticks) and the mice were kept on a 12h day/
night cycle.
Each mouse was anaesthetized (Isoflurane 
4% induction and 2% maintenance) and injected 
subcutaneously (s.c.) on the right flank with 1x107 SK-N-
AS cells. After 24h, 11 animals were randomly selected for 
the pre-treatment group and received 10 mg/kg α-NETA 
s.c. daily. α-NETA was dissolved in 10% Captisol® 
(Ligand Pharmaceuticals, Inc., La Jolla, USA). The mice 
were weighed and tumors were measured every other 
day. The tumor volume was calculated with the following 
formula: length × (width)2 × 0.44. When tumors reached 
a volume of ≥ 0.15ml the mice were randomized to either 
treatment group (20 mg/kg α-NETA, daily s.c. injections, 
n=11 in pre-treatment group and n=10 in treatment group) 
or control group (vehicle, daily s.c. injections, n=11). 
When the tumors from the pre-treatment group were ≥ 
0.15ml the α-NETA dose was increased to 20 mg/kg.
The mice were closely monitored for weight loss 
and other signs of toxicity. In accordance with the ethical 
guidelines the animals were sacrificed when tumors 
reached a volume of 2ml, or a diameter over 2cm, and 
the tumors were resected. Hence, survival was defined as 
time needed for the animals to grow a macroscopic tumor 
(volume >1.5ml). Smaller parts of the tumors were fixed 
in formaldehyde or frozen.
Tumor volume growth was analyzed using rate-
based comparison. By fitting each tumor’s growth curve 
to an exponential model (by correlating the logarithm of 
the tumor volume measurements to the time), the slope, as 
an estimate for the tumor growth, for each tumor’s growth 
could be determined [64].
Statistics
SigmaPlot and GraphPad Prism software was used 
for the statistical analysis and the graphs. Differences 
between several groups were assessed with one-way 
ANOVA and Bonferroni post-test or two-way ANOVA 
and Dunnett’s post-test. One sample t-test was used to 
compare differences between one group and a hypothetical 
mean. The survival analysis on tumor growth in vivo was 
performed using the Kaplan-Meier method and statistical 
differences between groups were performed using log-
rank test.
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Inhibition of chemerin/CMKLR1 axis in neuroblastoma cells 
reduces clonogenicity and cell viability in vitro and impairs 
tumor growth in vivo
SUPPLMENTARY MATERIALS
Supplementary Figure 1: Expression data was analyzed using the R2 database http://r2.amc.nl. Kaplan-Meier survival 
estimates were used to evaluate the prognostic value of RARRES2 (chemerin) (A, B) and CCRL2 (D, E) expression in two patient data sets 
(A and D: Versteeg n=88; B and E: Seeger n=102). The Kaplan-Meier scanning tool was used to determine the RARRES2 (chemerin) and 
CCRL2 mRNA expression in neuroblastoma. All expression data were scanned to find the most optimal cut-off between high and low gene 
expression and the log-rank test that gave the lowest p-value was calculated to search for significant differences between tumor samples 
expressing high and low RARRES2 (chemerin) and CCRL2 mRNA levels, respectively. The expression of RARRES2 (chemerin) (C) and 
CCRL2 (F) was compared between neural crest (Etchevers n=5), benign neurofibroma (Miller n=86) and 4 neuroblastoma cohorts (cohort 
1: Versteeg n=88, cohort 2: Delattre n=64, cohort 3: Hiyama n=51, cohort 4: Lastowska n=30).
www.impactjournals.com/oncotarget/  Oncotarget, Supplementary Materials 2017
Supplementary Figure 2: CMKLR1 (A), RARRES2 (B) and GPR1 (C) expression was analyzed using the Russel neuroblastoma cell 
line panel (transcript) in the R2 database http://r2.amc.nl. Cell lines used in this study were marked with an asterisk. The expression of 
CMKLR1 and GPR1 was compared to the previously in neuroblastoma cell lines described receptors FPR1, IL6R and PDGFRA (D). 
Chemerin expression was compared to CCL2, CCL5 and VEGFA (E).
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Supplementary Figure 3: Immunofluorescence CMKLR1 staining using SK-N-AS, SK-N-BE(2), SH-SY5Y and SK-N-SH cells and 
two different antibodies: STJ92262 from St. John’s laboratory (A) and LS-B12924 from LSBio (B). The used secondary antibody was 
Goat anti-Rabbit IgG (H+L), Alexa Fluor 488 (A-11008, Thermo Fisher Scientific) and the nuclei were stained with Hoechst 33342 
(ImmunoChemistry Technologies). Isotype control staining for IF and IHC. (C) SH-SY5Y cells were incubated with rabbit isotype antibody 
instead of primary antibody. Immunoperoxidase labeled tissue sections where the primary antibodies were replaced with rabbit (D) or 
mouse (E) isotype antibodies. Neuroblastoma tissue sections were incubated with mouse and goat isotype antibodies prior to fluorescence 
staining (F).
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Supplementary Figure 4: The tumor growth rate in neuroblastoma bearing mice was significantly lower in the α-NETA 
pre-treatment group compared to the control group (one-way ANOVA P=0.0061, Bonferroni post-test, control vs. 
pre-treatment P=0.049). Growth rate in the different treatment groups was illustrated as the slope from curves over individual mice 
log tumor volume versus time. Goodness of curve fitting was assessed with R2 (R2 mean 0.97; range 0.875-0.999). The line represents 
mean slope in each treatment group (A). Individual tumor growth in (B) control mice (daily s.c. injections with 10% Captisol®), (C) pre-
treatment group (daily s.c. injections with 10 mg/kg α-NETA from the day after tumor cell injection and 20 mg/kg when the tumor reached 
0.15ml) and (D) treatment group (daily s.c. injections with 20 mg/kg α-NETA after the tumor reached 0.15ml).
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Supplementary Figure 5: Expression data was analyzed using the R2 database http://r2.amc.nl. The Asgharzadeh 
neuroblastoma cohort n=249 was used to correlate the expression of previously identified TAM markers (CD33, CD14, IL6R, IL10, 
FCGR3) to CMKLR1 expression.
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Supplementary Figure 6: Immunoperoxidase staining of the macrophage marker CD68 using M0814 from Dako (A, B) and CMKLR1 
using STJ92262 from St. John’s laboratory (C) in neuroblastoma primary tumor tissue demonstrates while the majority of cells in the TME 
are positive for CMKLR1 only few are positive for CD68. Double immunofluorescence labeling (D, E) of CMKLR1 (green) and CD68 
(red) confirms this observation. The used secondary antibodies were Goat anti-Rabbit IgG (H+L), Alexa Fluor 488 (A-11008, Thermo 
Fisher Scientific) and Donkey anti-Mouse IgG (H+L), Alexa Fluor 594 (A-21203, Thermo Fisher Scientific). The nuclei were stained with 
DAPI (blue). Isotype control staining is displayed in panel (F).
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Supplementary Figure 7: SK-N-AS cells were transfected with sgRNA/Cas9 targeting all variants for human CMKLR1 
or scrambled sgRNA control plasmids (GeneCopoeia, Inc., Rockville, USA) using jetPRIME® transfection reagent 
(Polyplus-transfection®, Illkirch, France) according to the provided manual. Forty-eight hours post transfection the cells 
were seeded as single cells into 96-well plates. After clonal expansion, the clones were screened for CMKLR1 expression using western 
blot and RT-PCR. Western blot of SK-N-AS wild-type (wt), scramble control (scr control) and CMKLR1 knockdown (CMKLR1 kd) using 
two different antibodies targeting CMKLR1 (A, STJ92262, St. John’s laboratory and (B) ab64881, abcam) showing a clear reduction 
in CMKLR1 protein in the knockdown clone. RT-PCR analysis demonstrating a downregulation of CMKLR1 transcripts using two 
different primer sets (C). In clonogenicity assays (D-H) slower growth and the formation of indistinct colonies was observed in CMKLR1 
knockdown cells. While small but distinct colonies were observed 6 days after cell seeding in the wild-type (D) and scramble control (E) the 
CMKLR1 knock down cells multiplied slower and were only loosely connected (F). After completion of the assays macroscopic colonies 
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Abstract: Neuroblastoma is a malignancy arising from the developing sympathetic nervous system
and the most common and deadly cancer of infancy. New therapies are needed to improve
the prognosis for high-risk patients and to reduce toxicity and late effects. Spleen tyrosine
kinase (SYK) has previously been identified as a promising drug target in various inflammatory
diseases and cancers but has so far not been extensively studied as a potential therapeutic target
in neuroblastoma. In this study, we observed elevated SYK gene expression in neuroblastoma
compared to neural crest and benign neurofibroma. While SYK protein was detected in the majority
of examined neuroblastoma tissues it was less frequently observed in neuroblastoma cell lines.
Depletion of SYK by siRNA and the use of small molecule SYK inhibitors significantly reduced the
cell viability of neuroblastoma cell lines expressing SYK protein. Moreover, SYK inhibition decreased
ERK1/2 and Akt phosphorylation. The SYK inhibitor BAY 61-3606 enhanced the effect of different
chemotherapeutic drugs. Transient expression of a constitutive active SYK variant increased the
viability of neuroblastoma cells independent of endogenous SYK levels. Collectively, our findings
suggest that targeting SYK in combination with conventional chemotherapy should be further
evaluated as a treatment option in neuroblastoma.
Keywords: pediatric cancer; neuroblastoma; tyrosine kinase; combination therapy
1. Introduction
Tyrosine kinases are important mediators of cellular functions such as proliferation, differentiation,
metabolism, and survival. As tyrosine kinases are frequently deregulated in e.g. inflammatory diseases
and cancer they are among the most attractive drug targets [1–3]. Spleen tyrosine kinase (SYK) is a
72 kDa non-receptor tyrosine kinase consisting of two SRC homology 2 (SH2) domains and a kinase
domain joined by two linker regions, interdomains A and B [4]. A shorter SYK splice variant lacking
23 amino acids in the linker region B (SYK(S) or SYK B) has also been described in various cell
types [5–7].
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SYK is a multifunctional protein. It mediates inflammatory responses by linking immune cell
receptors to various intracellular signaling networks and exhibits, for example, a pivotal role in B-cell
development [4,8,9]. Among its various functions, SYK promotes, in concert with PKCδ, the expression
of anti-apoptotic Mcl-1 in B-cell chronic lymphocytic leukemia (CLL) [10] and regulates actin filament
assembly and dynamics through phosphorylation of cortactin and cofilin in ovarian cancer, thereby
promoting migration and invasion [11]. Furthermore, phosphorylated SYK has been observed in specific
cell types and areas of the developing nervous system and diverse functions have been described [12–14].
Widely expressed in hematopoietic cells [15,16], SYK is a promising therapeutic target in
inflammatory diseases (including rheumatoid arthritis, allergies, systemic lupus erythematosus,
and chronic immune thrombocytopenia) [17–19] as well as in different hematological malignancies
such as CLL [10,20,21], non-Hodgkin lymphoma [22], and acute myeloid leukemia (AML) [23].
However, SYK expression is not restricted to hematopoietic cells and its presence has been
described, among others, in epithelial, endothelial, and neuronal cells as well as in different solid
tumors [24,25]. The role of SYK in the tumorigenesis of both hematological and solid malignancies is
highly complex, tumor-specific and cell type-dependent, as both tumor promoting and suppressing
functions have been described [25].
A tumor-suppressing role for SYK has been demonstrated in e.g. breast cancer [26], pancreatic
cancer [27], melanoma [28], hepatocellular carcinoma [29] as well as childhood pro-B-ALL [30].
In contrast, SYK has been shown to be pro-tumorigenic in prostate cancer [31], small-cell lung
cancer [32], ovarian cancer [11,33], glioma [34], pediatric retinoblastoma [35], and Ewing sarcoma [36].
Of note, distinct functions of the two SYK splice variants have also been demonstrated. While the
longer SYK variant suppressed breast cancer invasiveness, the shorter variant SYK B did not [37].
Neuroblastoma is a malignancy of early childhood with 90% of patients diagnosed below the
age of 10 [38]. Worldwide, neuroblastoma accounts for 12.5% of cancer cases in children of age 0 to
4 years [39]. Arising from the developing sympathetic nervous system, the majority of primary tumors
occur in the adrenal gland [38]. About 50% of neuroblastomas are classified as low- and very-low-risk
with a very good prognosis and receive minimum therapy [38]. In contrast, the treatment of high-risk
neuroblastomas remains a challenge. Despite intensive therapy, about 50% of patients are refractory to
first-line treatment or relapse within two years [40].
With the increasing understanding of neuroblastoma biology and the identification of druggable
protein kinase targets such as ALK and Aurora A kinase as well as the MAPK and PI3K/mTOR/Akt
signaling pathways targeted therapies, both alone and in combination with conventional drugs,
provide new promising treatment options [41]. The aim of the present study was to investigate the
expression of SYK in neuroblastoma tumor tissues as well as neuroblastoma cell lines and to evaluate
its use as a potential therapeutic target.
2. Results
2.1. SYK Is Expressed in Neuroblastoma Tissue
We examined SYK gene expression using the publicly available R2: Genomics analysis and
visualization platform (http://r2.amc.nl) and observed that SYK expression was higher in four different
neuroblastoma cohorts compared to neural crest cells and benign neurofibroma (Figure 1A).
Furthermore, we evaluated the presence of SYK protein in neuroblastoma and ganglioneuroma
using immunohistochemistry (IHC). Supplementary Table S1 displays the clinical features of
the neuroblastoma tumors used in this study. SYK was present at varying levels in 40 out of
42 neuroblastomas and 3 out of 3 ganglioneuromas (Table 1). Figure 1B,C display a representative
staining of SYK in non-MYCN-amplified and MYCN-amplified tumors, respectively. In both,
the cytoplasm and the nucleus, a positive SYK staining was observed. SYK-positive tumor cells
were present in 31 out of 32 non-MYCN-amplified neuroblastomas and in 9 out of 10 MYCN-amplified
tumors (Table 1).
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Figure 1. SYK is expressed in neuroblastoma tissue. Gene expression data were analyzed using the 
R2 database http://r2.amc.nl. (A) The expression of SYK was compared between neural crest 
(Etchevers n = 5), benign neurofibroma (Miller n = 86) and 4 neuroblastoma cohorts (cohort 1: Versteeg 
n = 88, cohort 2: Delattre n = 64, cohort 3: Hiyama n = 51, cohort 4: Lastowska n = 30). The presence of 
SYK protein (B and C) and phosphorylation at Tyr525 (D and E) were determined in neuroblastoma 
primary tissue using immunoperoxidase staining. (B) and (D) display a staining of a non-MYCN-
amplified tumor and (C) and (E) show a MYCN-amplified tumor. Images were captured at a 
magnification of 900×. The displayed images are representative stainings from a panel of 
neuroblastoma tumors. 
Table 1. Presence of SYK and p-SYK (Tyr525) in neuroblastoma tumor tissue. 
Neuroblastoma Subgroups SYK Positive (Sections Examined) 
p-SYK Positive 
(Sections Examined) 
Neuroblastoma 40 (42) 38 (40) 
Non-MYCN-amplified 31 (32) 29 (31) 
MYCN amplified 9 (10) 9 (9) 
* Treated tissue 11 (13) 10 (11) 
* Untreated tissue 26 (26) 25 (26) 
Ganglioneuroma 3 (3) 3 (3) 
* For three tumor tissue samples the information concerning prior treatment was unavailable. 
Using Fisher’s exact test we determined that there was no significant difference in the presence 
of SYK protein between MYCN-amplified and non-amplified tumors (p = 0.4239). However, 
examining different neuroblastoma datasets in the R2: Genomics analysis and visualization platform, 
we observed a significant negative correlation between MYCN and SYK expression (Supplementary 
Figure S1A displaying a representative dataset). In contrast, we found a significant positive 
correlation between SYK and MYC expression (Supplementary Figure S1B). Furthermore, we 
evaluated whether there was a difference in the presence of SYK in tumors that were treated with 
chemotherapy prior to surgery compared to untreated tumors. All 26 untreated tumor samples and 
11 out of 13 treated tumor samples were SYK-positive. This difference was however not significant 
(Fisher’s exact test p = 0.1053). Of note, surgery was performed after at least 10–14 days of washout. 
Hence, no acute chemotherapy-induced regulation of genes should be expected. 
Additionally, the presence of SYK phosphorylated at Tyr525, located within the activation loop 
of the kinase domain, was examined as an indication for active SYK [8,42]. Figure 1D,E display a 
representative staining of p-SYK in non-MYCN-amplified and MYCN-amplified tumors. A strong 
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tissue using imm noperoxidase staining. (B,D) display a staining of a non-MYCN-amplified tumor and
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Table 1. Presence of SYK and p-SYK (Tyr525) in neuroblastoma tumor tissue.
Neuroblastoma Subgroups SYK Positive (Sections Examined) p-SYK Positive (Sections Examined)
Neuroblastoma 40 (42) 38 (40)
Non-MYCN-amplified 31 (32) 29 (31)
MYCN amplified 9 (10) 9 (9)
* Treated tissue 11 (13) 10 (11)
* Untreated tissue 26 (26) 25 (26)
Ganglioneuroma 3 (3) 3 (3)
* For three tumor tissue samples the information concerning prior treatment was unavailable.
Using Fisher’s exact test we determined that there was no significant difference in the presence of
SYK protein between MYCN-amplified and non-amplified tumors (p = 0.4239). However, examining
different neuroblastoma datasets in the R2: Genomics analysis and visualization platform, we observed
a significant negative correlation between MYCN and SYK expression (Supplementary Figure S1A
displaying a representative dataset). In contrast, we found a significant positive correlation between
SYK and MYC expression (Supplementary Figure S1B). Furthermore, we evaluated whether there was
a difference in the presence of SYK in tumors that were treated with chemotherapy prior to surgery
compared to untreated tumors. All 26 untreated tumor samples and 11 out of 13 treated tumor samples
were SYK-positive. This difference was however not significant (Fisher’s exact test p = 0.1053). Of note,
surgery was erformed after at least 10–14 days of washout. Hence, no acute chemotherapy-induced
regulati n of genes should be expected.
Additionally, the presence of SYK phosphorylated at Tyr525, located within the activation loop
of the ki ase domain, was examined as an indication for active SYK [8,42]. Figure 1D,E display a
representa ve staining of p-SYK in non-MYCN-amplified and MYCN-amplified tumors. A str ng
nuclear staining, as well as some cytoplasmic staining, was obs rved. Phospho-SYK was present in
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29 out of 31 non-MYCN-amplified tumors, 9 out of 9 MYCN-amplified tumors, 25 out of 26 untreated
tumors, and 10 out of 11 treated tumors (Table 1).
Examples for SYK- and p-SYK-negative tumors are displayed in Supplementary Figures S2A
and S2B. To ensure the specificity of the labeling, a corresponding isotype control antibody was used
instead of the primary antibodies with which no apparent staining was observed (Supplementary
Figure S2C).
2.2. SYK mRNA and to a Lesser Extend SYK Protein Are Present in Neuroblastoma Cell Lines
Using RT-PCR, western blot and immunocytochemistry (ICC) we examined the presence of
SYK mRNA and protein in neuroblastoma cell lines. The majority of the neuroblastoma cell
lines express SYK mRNA at varying levels (Figure 2A). However, SYK protein was detected
by western blotting in only two of 10 neuroblastoma cell lines, even after long exposure times
(Figure 2B). Interestingly, we noticed that the cell lines with absent or very low SYK mRNA levels are
MYCN-amplified cell lines (SK-N-BE(2), SK-N-DZ, Kelly and IMR-32).
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Figure 2. SYK mRNA and to a lesser extend SYK protein are expressed in neuroblastoma cell lines. 
(A) RT-PCR analysis demonstrating the expression of both SYK mRNA variants in different 
neuroblastoma cell lines. U937 cells were used as a positive control (PC). NTC, no template control. 
(B) Expression of SYK protein was determined by western blot. THP-1 cells were used as a positive 
control. Immunofluorescence labeling of SYK (green) in SH-SY5Y (C), LAN-6 (D) and SK-N-BE(2) 
cells (E). The nuclei (blue) were stained with Hoechst 33342. Panels (F–H) display isotype controls for 
SH-SY5Y (F), LAN-6 (G) and SK-N-BE(2) cells (H). 
The shorter SYK splice variant SYK B has previously been detected in different cell types [5–
7,37]. We observed that SH-SY5Y, LAN-6 and SK-N-FI cells concomitantly express both splice 
variants of SYK mRNA at similar levels whereas SH-EP1, SK-N-SH, and IMR-32 exhibit 
predominantly the short SYK B variant. The monocytic cell lines U937 and THP-1 with known SYK 
expression were used as positive controls for RT-PCR and western blot, respectively [43].  
ICC was used to confirm the presence of SYK protein in SH-SY5Y and LAN-6 cells. A clear SYK 
labeling was observed in the cytoplasm of SH-SY5Y (Figure 2C) and LAN-6 cells (Figure 2D). The 
SYK signal appears to be localized mainly in the cytoplasm, with an increased intensity in patch-like 
structures. However, a faint staining was also observed in SK-N-BE(2) cells (Figure 2E). This could 
most likely be attributed to some moderate non-specific binding of the antibody. No staining was 
apparent in cells incubated with an isotype control antibody (Figure 2F–H).  
2.3. SYK Is Phosphorylated in Neuroblastoma Cell Lines  
SYK activity is tightly controlled by its (auto)phosphorylation and important regulatory 
functions are associated with particular tyrosine residues, such as tyrosine 323, 352, 525, and 526 [8]. 
To determine whether SYK exhibits basic activity in neuroblastoma cell lines, we performed SYK 
immunoprecipitation followed by western blot with different phosphotyrosine-specific SYK 
antibodies in SH-SY5Y cell lysates and THP-1 cells, serving as a positive control. We detected 
phosphorylation of tyrosine 352 and tyrosine 323 in both cell types (Figure 3A).  
The presence of phosphorylated tyrosine 525/526 was examined by immunocytochemistry. 
Phospho-525/526 SYK was detected in the cytoplasm and close to the cell membrane in both SH-SY5Y 
cells (Figure 3B) and LAN-6 cells (Figure 3C). A weak nuclear staining was also noticeable. Variations 
in staining intensity were observed among the cells. As no prior synchronization or stimulation of 
the cells was performed, this may be attributed to the dynamic regulation of SYK-phosphorylation 
[8]. A very weak staining, most probably caused by non-specific background binding of the antibody, 
was observed in SK-N-BE(2) cells (Figure 3D) with no apparent SYK expression (Figure 2A,B). 
 
Figure 2. SYK mRNA and to a lesser extend SYK protein are expressed in neuroblastoma cell
lines. (A) RT-PCR analysis demonstrating the expression of both SYK mRNA variants in different
neuroblastoma cell lines. U937 cells were used as a positive control (PC). NTC, no template control.
(B) Expression of SYK protein was determined by western blot. THP-1 cells were used as a positive
control. Immunofluorescence labeling of SYK (green) in SH-SY5Y (C), LAN-6 (D) and SK-N-BE(2)
cells (E). The nuclei (blue) were stained with Hoechst 33342. Panels (F–H) display isotype controls for
SH-SY5Y (F), LAN-6 (G) and SK-N-BE(2) cells (H).
The shorter SYK splice variant SYK B has previously been detected in different cell types [5–7,37].
We observed that SH-SY5Y, LAN-6 and SK-N-FI cells concomitantly express both splice variants of
SYK mRNA at similar levels whereas SH-EP1, SK-N-SH, and IMR-32 exhibit predominantly the short
SYK B variant. The onocytic cell lines U937 and THP-1 with known SYK expression were used as
positive controls for RT-PCR and western blot, respectively [43].
ICC was used to confirm the presence of SYK protein in SH-SY5Y and LAN-6 cells. A clear SYK
labeling was observed in the cytoplasm of SH-S 5Y (Figure 2C) and LAN-6 cells (Figure 2D). The S
signal appears to be localized mainly in the cytoplasm, with an increased intensity in patch-like
structures. However, a faint staining was also observed in SK-N-BE(2) cells (Figure 2E). This could
most likely be attributed to some moderate non-specific binding of the antibody. No staining was
apparent in cells incubated with an isotype control antibody (Figure 2F–H).
2.3. SYK Is Phosphorylated in Neuroblastoma Cell Lines
SYK activity is tightly controlled by its (auto)phosphorylation and important regulatory functions
are associ ted with particular tyrosine res dues, suc as ty osine 323, 352, 525, and 526 [8].
To determine whether SYK exhibits basic activity in neuroblastoma cell lines, we performed SYK
immunoprecipitation followed by western blot w h different phosphotyrosine-specific SYK antibodies
n SH-SY5Y ell lysates and THP-1 cells, serving as a positive control. We detected phosphorylation of
tyrosine 352 and tyrosine 323 in both cell types (Figure 3A).
T e prese ce of phosphorylated tyrosine 525/526 was examined by immunocytochemistry.
Phosp o-525/526 SYK was detected in the cytoplasm and close to the c ll membrane in both SH-SY5Y
cells (Figure 3B) and LAN-6 c lls (Figure 3C). A weak nuclear taining was also noticeable. Variations in
staining intensity were observed among the cells. As no prior sy chroniz tion r stimulation of the
cells was performed, this may be attributed to the dynamic regulation of SYK-phosphorylation [8].
A very we k staining, most proba ly caused by non-specific background binding of the antibody,
was observed in SK-N-BE(2) cells (Figure 3D) with ap arent SYK expression (Figure 2A,B).
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SH-SY5Y and LAN-6, but not SK-N-BE(2) cells, we observed a significant decrease in cell viability 72 
h post-transfection with two different SYK targeting siRNAs compared to scramble control siRNA 
(scr.) (Figure 4A). The decreased cell viability corresponded to reduced SYK protein levels in 
SH-SY5Y and LAN-6 cells (Figure 4B). Using densitometry, we calculated the downregulation of SYK 
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2.4. Downregulation of SYK Reduces the Cell Viability of SYK Expressing Neuroblastoma Cell Lines
Using siRNA, we assessed the consequences of SYK knockdown on the cell viability of
SYK-positive SH-SY5Y and LAN-6 as well as SK-N-BE(2) cells that show no apparent SYK expression.
In SH-SY5Y and LAN-6, but not SK-N-BE(2) cells, we observed a significant decrease in cell viability
72 h post-transfection with two different SYK targeting siRNAs compared to scramble control siRNA
(scr.) (Figure 4A). The decreased cell viability corresponded to reduced SYK protein levels in SH-SY5Y
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and LAN-6 cells (Figure 4B). Using densitometry, we calculated the downregulation of SYK protein.
In SH-SY5Y cells the downregulation was approximately 5-fold with 18.1% (siRNA 1) and 21.3%
(siRNA 2) of SYK protein remaining compared to the scrambled siRNA control (=100%). In LAN-6 cell
the downregulation was less effective with 45.2% (siRNA 1) and 40.7% (siRNA 2) remaining SYK
protein compared to the scrambled siRNA control.
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SYK catalytic inhibition on the cell viability of SYK-positive SH-SY5Y and SYK-negative SK-N-BE(2) 
cells. Figure 5 displays the cell viability (MTT assay) after 48 h incubation with the SYK inhibitors 
BAY 61-3606 (Figure 5A), R406 (Figure 5B), PRT062607 (=P505-15; Figure 5C) and GS-9973 
(=entospletinib; Figure 5D). The results of 24 h incubation with these inhibitors are shown in 
Supplementary Figure S3 and comparable tendencies could be observed. A statistically significant 
difference (control vs. treatment) in the cell viability of SH-SY5Y and SK-N-BE(2) cells was observed 
upon exposure to multiple inhibitor concentrations (marked by asterisks in the graphs). SH-SY5Y 
cells expressing high SYK levels were significantly more sensitive to the SYK inhibitors in comparison 
to SK-N-BE(2) cells expressing very low or no SYK (Figure 5). All four inhibitors significantly reduced 
the cell viability of both cell lines in a dose-dependent matter suggesting that at higher inhibitor 
Figure 4. SYK downregulation reduces the cell viability of SYK expressing neuroblastoma cell lines.
SYK-positive SH-SY5Y and LAN-6 cells, as well as SYK-negative SK-N-BE(2) cells, were transfected
with 5 pmol SYK specific or scrambled (scr.) siRNA. The medium was replaced after 4 h. After 72 h,
the cell viability l t assay (A). The scr. control was et as 100% viable c lls. Data are
presented as mean ± SD from thre independent experi e ts. l c arisons were made
using two-way ANOVA and a significant e fect was observed for the siRNA treatment p < 0. 01 and
betw en lines p = 0.003. The Dunnett’s multiple comparison test was used to evaluate the diff rence
between scr. siRNA vs. SYK specific siRNA: ** p < 0.01, ** p < .001. (B) SYK expression levels were
determin d by west rn blot.
2.5. SYK Activity Inhibition Decreases the Cell Viability of Neuroblastoma Cells
Four commercially available, pharmacological SYK inhibitors were used to evaluate the effect of
SYK catalytic inhibition on the cell viability of SYK-positive SH-SY5Y and SYK-negative SK-N-BE(2)
cells. Figure 5 displays the cell viability (MTT assay) after 48 h incubation with the SYK inhibitors BAY
61-3606 (Figure 5A), R406 (Figure 5B), PRT062607 (=P505-15; Figure 5C) and GS-9973 (=entospletinib;
Figure 5D). The results of 24 h incubation with these inhibitors are shown in Supplementary
Figure S3 and comparable tendencies could be observed. A statistically significant difference (control
vs. treatment) in the cell viability of SH-SY5Y and SK-N-BE(2) cells was observed upon exposure to
multiple inhibitor concentrations (marked by asterisks in the graphs). SH-SY5Y cells expressing high
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SYK levels were significantly more sensitive to the SYK inhibitors in comparison to SK-N-BE(2) cells
expressing very low or no SYK (Figure 5). All four inhibitors significantly reduced the cell viability
of both cell lines in a dose-dependent matter suggesting that at higher inhibitor concentrations the
decrease in cell viability of SK-N-BE(2) is SYK-independent and caused by off-target effects.
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for BAY 61-3606, 0.8–1 µM fo R406, and 1 µM fo b th PRT062607 and GS-9973. Because BAY
61-3606 displayed the most prominent diffe ences between the two cell lin s, it was used in
subsequent experiments.
2.6. Inhibition of SYK Activity Reduces ERK1/2 and Akt Phosphorylation in Neuroblastoma Cells
Active SYK is known to affect various downstream targets including MAPK, PI3K/Akt and
NFκB signaling pathways [4,8,36]. Hence, we evaluated the consequences of SYK inhibition on
ERK1/2 and Akt phosphorylation under the same experimental conditions used for the cell viability
studies. As compared to vehicle alone, a significant and lasting reduction of ERK1/2 phosphorylation
(Figure 6A,B) and Akt phosphorylation (Figure 6A,C) was observed for three out of four inhibitors
(BAY 61-3606, R406, and PRT062607) after 4 h and 24 h. In contrast, GS-9973 treatment did not affect
ERK1/2 or Akt phosphorylation at the investigated time points.
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2.7. The Selective SYK Inhibitor BAY 61-3606 Enhances the Effect of Chemotherapeutic Drugs on
Neuroblastoma Cells
To determine whether SYK inhibition could increase the efficacy of chemotherapeutic agents to
inhibit neuroblastoma cell growth, we combined BAY 61-3606 with the drugs paclitaxel, cisplatin,
doxorubicin, and temozolomide, respectively. We investigated the effect of single vs. combined
treatment on PARP cleavage (indicating apoptosis) and cell viability (MTT assay) in SYK-positive
SH-SY5Y and SYK-negative SK-N-BE(2) cells (Figure 7A and Table 2). After 24 h, we observed an
increase in cleaved PARP in SH-SY5Y cells for the combination of 0.4 µM BAY 61-3606 with paclitaxel,
cisplatin, and temozolomide compared to single drug treatment (Figure 7A). For the combination of
0.4 µM BAY 61-3606 with paclitaxel or cisplatin this effect was sustained after 48 h (Supplementary
Figure S4A).
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Of note, after 24 h incubation with BAY 61-3606, paclitaxel or the combination temozolomide-BAY
61-3606 increased SYK protein levels could be observed (Figure 7A). This effect was not sustained after
48 h (Supplementary Figure S4A). However, after 48 h a clear reduction in SYK protein levels could be
detected in cells treated with a combination of BAY 61-3606 and chemotherapeutic drugs compared to
treatment with drugs alone (Supplementary Figure S4A).
After 48 and 72 h incubation, a significant decrease in cell viability was evident for all drugs in
combination with BAY 61-3606 in SH-SY5Y cells as compared to the chemotherapeutic drugs alone
(Table 2).
In SK-N-BE(2) cells the apparent increase in cleaved PARP after combined treatment with BAY
61-3606 and paclitaxel was accompanied by a decrease in cell viability after 48 h and 72 h (Table 2).
Comparing the combinations to treatment with BAY 61-3606 alone, a significant difference was
observed for paclitaxel and cisplatin but not doxorubicin and temozolomide after 48 h and 72 h in
SH-SY5Y cells, indicating that monotherapy with 0.4 µM BAY 61-3606 is comparable to a combination
of temozolomide or doxorubicin and BAY 61-3606.
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Bliss independence model and the response additivity, and effect are specified for each combination. 
Figure 7. The selective SYK inhibitor BAY 61-3606 e a ces the effect of chemotherapeutic drugs in
neuroblastoma cells. (A) PARP cleavage and SYK expression were determined by western blot after
24 h monotherapy or combinations of 0.4 µM BAY 61-3606, 20 nM paclitaxel, 5 nM doxorubicin, 100 µM
temozolomide and cisplatin (1 µM or 3 µM for SH-SY5Y and SK-N-BE(2), respectively). Illustration of
drug combination effects for 0.4 µM BAY 61-3606 and paclitaxel (B) as well as 0.4 µM BAY 61-3606 and
cisplatin (C) in SH-SY5Y and SK-N-BE(2) cells after 48 h and 72 h treatment. The continuous horizontal
line indicates the effect of the highest single agent, the dashed line denotes expected additive effect
calculated by the Bliss independence model, and the dotted line shows expected additive effect
calculated by response additivity. Combination index (CI), given from the Bliss independence model
and the response additivity, and effect are specified for each combination.
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Table 2. Cell viability of SH-SY5Y and SK-N-BE(2) after treatment with 0.4 µM BAY 61-3606, chemotherapeutic drugs or combinations of both.
SH-SY5Y SK-N-BE(2)
Treatment Cell viability (%)Mean ± SD
p value Drug vs.
combination




p value Drug vs.
combination
p value BAY vs.
combination
48 h
0.4 µM BAY 79.01 ± 6.26 94.04 ± 7.72
Paclitaxel 87.71 ± 7.83 90.89 ± 7.86
Paclitaxel + BAY 54.65 ± 3.26 <0.001 <0.001 72.98 ± 9.33 <0.001 <0.001
Cisplatin 82.33 ± 9.01 98.94 ± 6.48
Cisplatin + BAY 62.47 ± 5.82 <0.001 <0.001 90.49 ± 7.46 0.052 >0.999
Doxorubicin 100.5 ± 9.59 102 ± 9.68
Doxorubicin + BAY 77.97 ± 8.01 <0.001 >0.999 93.69 ± 8.78 0.121 >0.999
Temozolomide 107 ± 11.17 107.7 ± 3.65
Temozolomide + BAY 76.81 ± 4.82 <0.001 >0.999 100 ± 4.36 0.132 0.181
72 h
0.4 µM BAY 80.20 ± 7.62 96.97 ± 6.89
Paclitaxel 84.53 ± 4.60 88.29 ± 5.19
Paclitaxel + BAY 36.79 ± 3.14 <0.001 <0.001 59.48 ± 8.81 <0.001 <0.001
Cisplatin 73.38 ± 5.89 73.99 ± 2.95
Cisplatin + BAY 56.25 ± 5.72 <0.001 <0.001 73.53 ± 5.94 >0.999 <0.001
Doxorubicin 102.2 ± 8.37 101.3 ± 7.56
Doxorubicin + BAY 78.57 ± 7.16 <0.001 >0.999 93.99 ± 9.68 0.053 >0.999
Temozolomide 107.7 ± 6.13 102.7 ± 4.28
Temozolomide + BAY 74.21 ± 5.99 <0.001 0.217 99.74 ± 6.68 >0.999 >0.999
Cell viability was measured by MTT assay after 48 and 72 h. The control was set as 100% viable cells. Data are presented as mean ± SD from at least three independent experiments.
Using two-way ANOVA, a significant effect was observed for both treatment and between cell lines p < 0.001; Bonferroni’s multiple comparison test was used to evaluate differences
between treatments, and p values < 0.05 were considered as statistically significant.
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Using Bliss independence and response additivity calculations, we determined whether the
chemotherapeutic drug-BAY 61-3606 combination was synergistic, additive or antagonistic in regard
to cell viability. The combinations of BAY 61-3606 and doxorubicin or temozolomide could not be
analyzed with these methods due to the limited effects of these drugs as single agents at concentrations
used in this study. A synergistic effect was determined for paclitaxel in combination with BAY
61-3606 in both SH-SY5Y and SK-N-BE(2) cells after 48 and 72 h (Figure 7B). Additionally, cisplatin in
combination with BAY 61-3606 displayed a mainly additive effect in SH-SY5Y and SK-N-BE(2) cells
after 48 and 72 h (Figure 7C).
A 24 h treatment with a higher BAY 61-3606 concentration (0.8 µM) in combination with any of
the drugs resulted in a more pronounced increase in cleaved PARP in SH-SY5Y cells but not in the
SYK-negative SK-N-BE(2) cells (Supplementary Figure S5A) after 24 h. However, after 48 h higher
levels of PARP were observed in the combinations compared to treatment with chemotherapeutic drugs
alone for the majority of drugs in SH-SY5Y and to a lesser extent in SK-N-BE(2) cells (Supplementary
Figure S4B). Furthermore, a significant decrease in cell viability was observed for both cell lines
comparing chemotherapeutic drug vs. combination with BAY 61-3606 after 48 and 72 h (Supplementary
Table S2). However, when comparing the combinations to treatment with BAY 61-3606 alone,
a significant difference in cell viability occurred for combinations of BAY 61-3606 with paclitaxel,
cisplatin and temozolomide in SH-SY5Y cells after 48 h, and paclitaxel as well as cisplatin after
72 h. In SYK-negative SK-N-BE(2) cells combination of paclitaxel, cisplatin or doxorubicin and BAY
61-3606 after 72 h and paclitaxel as well as cisplatin after 48 h demonstrated a significant difference
compared to monotherapy with BAY 61-3606.
A synergistic effect was determined for paclitaxel in combination with 0.8 µM BAY 61-3606 in both
SH-SY5Y and SK-N-BE(2) cells after 48 and 72 h (Supplementary Figure S5B). Additionally, cisplatin
in combination with 0.8 µM BAY 61-3606 displayed a less consistent effect, the combinational effects
were mainly additive in SH-SY5Y and SK-N-BE(2) cells after 48 and 72 h (Supplementary Figure S5C)
but some of the combinations were classified as synergistic or antagonistic using Bliss independence
and response additivity calculations.
2.8. Transfection with an Active SYK Variant Increases the Cell Viability of Neuroblastoma Cells Independent of
Endogenous SYK Levels
To further explore the effect of SYK on neuroblastoma cell viability, we transfected SH-SY5Y,
SK-N-BE(2), and SK-N-AS cells with expression vectors encoding different FLAG-tagged SYK variants
(SYK wt = SYK wild type, SYK B = short SYK splice variant B, SYK Y130E = constitutive active SYK,
SYK K402R = kinase dead SYK, SYK RR42/195KK = SYK with inactive SH2 domains). After 48 h,
we measured the cell viability and confirmed transfection efficiency by evaluating exogenous SYK
expression levels using western blot (Figure 8). SYK overexpression that exceeded the endogenous SYK
levels was evident. Constitutive active SYK Y130E increased cell viability of all three neuroblastoma
cell lines in comparison to transfection with the empty vector independent of the presence/absence
of endogenous SYK (Figure 8A). Transfection with SYK wt significantly increased the cell viability
of SK-N-AS cells and SYK RR42/195KK increased the cell viability of SH-SY5Y cells. A minor,
reproducible reduction in cell viability after transfection with the kinase dead SYK mutant was
observed in SH-SY5Y and SK-N-BE(2) cells, which was however not statistically significant.
Following transfection, all SYK variants were detected in the three cell lines by western blot
although SYK RR42/195K was expressed at somewhat lower levels (Figure 8B).
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comparison test was used to evaluate the difference between empty vector and different SYK variants: 
* p < 0.05, *** p <0.001. Western blot analysis was used to evaluate the presence of SYK following 
transfection, ensuring sufficient transfection efficiency (B). SYK wt = SYK wild type, SYK B = short 
SYK splice variant B, SYK Y130E = constitutive active SYK, SYK K402R = kinase dead SYK, SYK 
RR42/195KK = SYK with inactive SH2 domains. 
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3. Discussion
There is a need for further advancements in the treatment of neuroblastoma to improve the
survival of high-risk patients and reduce acute and long-term toxic effects in neuroblastoma survivors.
Targeted therapies exhibit great potential used either alone or more particularly in combination with
conventional drugs [41,44].
In two other pediatric cancers, retinoblastoma and Ewing sarcoma, SYK promotes tumor cell
survival and SYK inhibition, using small molecule inhibitors, was identified as a promising treatment
option for these diseases [35,36].
In the present study, we observed that SYK expression was higher in four different neuroblastoma
cohorts compared to neural crest cells and benign neurofibroma. Moreover, we demonstrate that SYK
is present in neuroblastoma tissues and to a lesser extent in neuroblastoma cell lines. Inhibition of
SYK using small molecule inhibitors alone or in combination with chemotherapeutic drugs as well
as knockdown of SYK by siRNA impaired the cell viability of SYK expressing neuroblastoma cells.
Additionally, SYK inhibition decreased phosphorylation of Akt and ERK1/2 indicating Akt and MAPK
signaling as potential downstream targets of SYK in neuroblastoma. Furthermore, constitutive active
SYK increased neuroblastoma cell viability independent of endogenous SYK expression. Taken together,
our findings indicate a tumorigenic involvement of SYK in neuroblastoma.
We observed the presence of SYK protein in the majority of neuroblastoma tissues analyzed in this
study. A positive staining of SYK and p-SYK was observed in both the cytoplasm and the nucleus with
a more pronounced nuclear staining for p-SYK. The presence of SYK in different cellular compartments
(cytoplasm, nucleus, membrane) has previously been described [37,45,46].
Furthermore, we compared the presence of SYK protein in MYCN-amplified and
non-MYCN-amplified tumor tissue and did not observe differences between the two groups. Of note,
by examining publicly available gene expression datasets, we detected a negative correlation between
MYCN and SYK in neuroblastoma. In contrast, a positive correlation between SYK and MYC
was discerned. MYCN-amplification occurs in about 20% of neuroblastomas and is associated
with aggressive tumors and poor survival [47–49]. Furthermore, MYC has also been identified as
an independent prognostic marker for poor survival in neuroblastoma [50] and is predominantly
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expressed by non-MYCN-amplified tumors [51]. A link between SYK and MYC has been previously
demonstrated in Ewing sarcoma and hematopoietic cells [36,52]. Therefore, a potential connection
between SYK and MYC in neuroblastoma is highly interesting and warrants further investigation.
In contrast to neuroblastoma tumor tissue, SYK protein was only detected in two out of ten
neuroblastoma cell lines by western blot. This is in accordance with previous findings by Alaminos
et al. reporting more frequent methylation of the SYK promoter in neuroblastoma cell lines (60%)
compared to tumor tissue (11%) [53]. In subsequent work by Margetts et al. and Grau et al. no
aberrant hypermethylation of the SYK promoter was observed in tumor tissue or highly infiltrated
bone marrow [54–56]. Yu et al. recently demonstrated that EGF stimulates SYK-mediated migration
and invasion in ovarian cancer cells. The authors suggested that SYK function might be regulated
by environmental stimuli [11]. Therefore, one could speculate that the absence of a specific stimulus,
which is present in the tumor microenvironment, could lead to the downregulation of SYK expression
in neuroblastoma cells lines. However, additional studies are necessary to determine if known factors,
such as specific cytokines and chemokines, present in the neuroblastoma tumor microenvironment
may affect SYK expression and function.
Complex phosphorylation events on tyrosine residues are required for the regulation of SYK
functions by mediating conformational changes and creating docking stations for other proteins [8,57,58].
Phosphorylation of Tyr352 and/or Tyr348 (Tyr346 and Tyr342 in mouse SYK) provides binding sites
for various proteins such as phospholipase Cγ, Vav-1 and 2 as well as Akt, and ERK, linking SYK
to different signaling pathways and cellular functions [8,59–62]. Furthermore, Tyr352 has been linked
to constitutive SYK activation [63]. The Tyr525/526 residues are located in the SYK activation loop.
These phosphorylation sites likely provide important docking sites for other proteins thereby mediating
intracellular signaling. However, mutations in these sites affect the in vitro catalytic activity only
marginally [8,64,65]. Phosphorylation of Tyr323 in SYK promotes binding of Cbl protein family members
causing ubiquitination and possibly degradation of SYK. However, Tyr323 is also an important binding
site for PI3K indicating multiple functions of this phosphorylation site (reviewed in [8]).
We determined the status of these three well-established SYK phosphorylation sites (Tyr352,
Tyr525/526, and Tyr323) and found that all were phosphorylated under normal growth conditions in
the SYK expressing SH-SY5Y neuroblastoma cells, suggesting the presence of catalytically active SYK.
We observed a weaker nuclear staining of both total SYK and p-SYK in neuroblastoma cell lines
as compared to neuroblastoma tissue. It has previously been demonstrated that SYK splice variants
display differences in cellular localization and function [37,66,67] and that EGF can modulate SYK
splicing pattern [66]. These findings indicate that the cellular localization of SYK may be affected by
environmental stimuli and changes in splicing pattern. Therefore, the presence of specific stimuli in
the neuroblastoma tumor microenvironment as well potential differences/changes in SYK splicing
pattern compared to neuroblastoma cell lines may contribute to the observed differences in staining
pattern. In our study, we observed that siRNA-mediated SYK downregulation reduced neuroblastoma
cell growth. However, we did not achieve a complete SYK knockdown. Since SYK is a protein
kinase, residual SYK protein could provide an explanation for the significant, but modest effect on the
cell viability.
Therefore, we investigated the effects of commercially available SYK inhibitors BAY 61-3606 [68],
R406 [69], PRT062607 (P505-15) [70] and GS-9973 [71] on neuroblastoma survival. Using increasing
inhibitor concentrations, we compared the effect on cell viability in neuroblastoma cells with and
without detectable SYK protein levels (SH-SY5Y and SK-N-BE(2), respectively). We determined at least
one concentration for each inhibitor at which a significant reduction in cell viability was observed in
SH-SY5Y but not SK-N-BE(2) cells, indicating an effect on cell viability that can likely be attributed to
specific SYK inhibition.
PRT062607 and GS-9973 significantly reduced the viability of SH-SY5Y but not SK-N-BE(2)
cells at a concentration of 1 µM. This is in line with recent work by Sun et al. where 1 µM
PRT062607 and GS-9973 significantly impaired clonogenicity and cell viability of Ewing sarcoma
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cell lines [36]. A dose-dependent impairment of cell viability as well as increased caspase-3 activity
has been previously reported in retinoblastoma cells after treatment with BAY 61-3606 and R406 [35].
We observed that these inhibitors significantly decreased SH-SY5Y cell viability as compared to
SK-N-BE(2) cells at concentrations of 0.1–0.6 µM and 0.8–1 µM, respectively.
Of note, inhibitor concentrations >1 µM also significantly reduced the cell viability of SK-N-BE(2)
cells that exhibit no apparent SYK expression suggesting off-target effects for all four inhibitors when
used at higher concentrations. Kinase inhibitors commonly display off-target effects that can be
beneficial but need to be carefully evaluated at the mechanistic level. For example, the SYK inhibitor
BAY 61-3606 has been reported to inhibit JNK [72]. JNK inhibition has previously been demonstrated
to reduce the apoptotic effect of chemotherapeutic drugs such as doxorubicin in SH-SY5Y cells [73].
Therefore, off-target effects of BAY 61-3606 on JNK could potentially impair doxorubicin function
and not display a potentiating effect as seen in our studies. Furthermore, work by Colado et al.
demonstrated that GS-9973 and R406 can impair T-cell function via off-target effects on the SYK
homolog ZAP-70 [74]. We screened the neuroblastoma cell lines used in this study for ZAP-70 presence
and found it expressed at protein level only in SK-N-DZ cells (Supplementary Figure S6). Since this
cell line was not used in the inhibitor studies, potential off-target effects on ZAP-70 can be excluded.
However, these are just two of many potential proteins that may be the target of non-selective inhibition.
Various downstream targets for SYK have been described in health and disease [4,8]. ERK- and
Akt-mediated signaling is known to be affected by SYK inhibition in CLL and Ewing sarcoma [20,36].
We observed that Akt and ERK1/2 phosphorylation was decreased by the SYK inhibitors BAY 61-3606,
R406 and PRT062607, but not GS-9973. A possible explanation could be differences in the kinetics
of GS-9973 mediated SYK inhibition. Since we only examined two time points, (4 h and 24 h) rapid
and transient effects might not have been detected. PI3K/Akt- and MAPK-mediated signaling was
previously shown to promote neuroblastoma tumorigenesis [75–79]. Therefore, a decrease in Akt and
ERK1/2 phosphorylation and activity could contribute to the impaired cell viability.
Yu et al. demonstrated an increased expression of SYK in paclitaxel-resistant ovarian cancer
cells and that paclitaxel in combination with the SYK inhibitor R406 increased apoptosis in vitro
and impaired tumor growth in vivo [33]. Paclitaxel is a chemotherapeutic drug that is rarely used
for the treatment of neuroblastoma. It was, however, included in this study to determine if the
additive effect seen in ovarian cancer cells [33] could also be observed in neuroblastoma cell lines.
We furthermore analyzed the effect of three drugs used in first-line treatment and/or refractory and
relapsed neuroblastoma: cisplatin, doxorubicin, and temozolomide.
We compared the cell viability of neuroblastoma cells treated with cytostatic drugs alone or
in combination with the pharmacological SYK inhibitor BAY 61-3606. Synergetic and additive
effects were observed in SYK expressing SH-SY5Y cells for paclitaxel- BAY 61-3606 and cisplatin-
BAY 61-3606 combination, respectively. Furthermore, 0.4 µM BAY 61-3606 potentiated the effects of
doxorubicin and temozolomide in SH-SY5Y cells. Interestingly, a synergetic effect of BAY 61-3606 in
combination with paclitaxel was also observed in SK-N-BE(2), a cell line without significant expression
of SYK protein. Although BAY 61-3606 concentrations applied in this study are rather low, off-target
effects are likely the cause for the observed effect.
Furthermore, we observed increased amounts of cleaved PARP in the SYK-positive SH-SY5Y cells
after treatment with BAY 61-3606 (0.4 and 0.8 µM) in combination with the tested drugs after 24 h,
particularly when 0.8 µM BAY 61-3606 was used. We propose that the decrease in cell viability in
SH-SY5Y cells may be attributed to an increase in apoptosis, whereas the decrease in cell viability in
SYK-negative SK-N-BE(2) cells might rather be due to reduced proliferation than increased apoptosis.
However, further experiments are required to determine the detailed mechanisms.
In addition, we also demonstrate that transient transfection with a constitutively active SYK
variant increased the cell viability of neuroblastoma cell lines independent of endogenous SYK
expression. This suggests that SYK has tumor-promoting functions in neuroblastoma. Previous work
reported a tumor-suppressing role for SYK in breast cancer, among others. Transfection of breast cancer
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cells with a wild-type SYK encoding vector suppressed invasive outgrowth in Matrigel and impaired
tumor growth and metastasis in mice [26]. We did, however, not observe any inhibitory effect on the
cell viability of transfected neuroblastoma cell lines expressing exogenous SYK. Taken together, this
suggests that SYK functions as a tumor-promoting molecule in neuroblastoma rather than having a
tumor-suppressing effect.
To further evaluate the potential therapeutic use of SYK inhibitors in neuroblastoma both as a
single agent and in combination with existing chemotherapeutic drugs, in vivo studies are necessary.
Since SYK is widely expressed by hematopoietic cells, potential negative effects on the immune cells of
the tumor microenvironment have to be carefully evaluated using immunocompetent neuroblastoma
animal models. Recent work in glioma demonstrated that SYK inhibition impaired the mobility and
infiltration of B cells and CD11b+ leukocytes in addition to reducing proliferation and migration of
tumor cells [34].
4. Materials and Methods
4.1. Microarray Gene Expression
Gene expression analysis was performed using the MegaSampler feature of the publicly available
R2: Genomics Analysis and Visualization Platform (http://r2.amc.nl).
4.2. Reagents and Antibodies
The selective SYK inhibitors GS-9973 (Entospletinib) and R406 were purchased from Selleck
Chemicals Europe (Munich, Germany). BAY 61-3606 and PRT062607 were obtained from
Calbiochem/Merck (Merck Life Science AS, Oslo, Norway) and ApexBio (Houston, TX, USA),
respectively. Paclitaxel, cisplatin, doxorubicin, and temozolomide were bought from Sigma-Aldrich
Norway AS (Oslo, Norway). The antibodies used in this study are listed in Table 3.
Table 3. Antibodies.
Antibody Application Source
Anti-SYK WB, IP #1240, Santa Cruz Biotechnology
Anti-SYK WB #13198, Cell Signaling Technology
Anti-SYK ICC/IHC #HPA001384, Sigma
Anti-Phospho-ZAP-70 (Tyr319)/SYK (Tyr352) WB #2701, Cell Signaling Technology
Anti-Phospho-SYK (Tyr323) WB #2715, Cell Signaling Technology
Anti-Phospho-SYK (Tyr525/526) ICC #2710, Cell Signaling Technology
Anti-Phospho-SYK (pTyr525) IHC #SAB4503839, Sigma
Anti-PARP WB #9542, Cell Signaling Technology
Anti-Phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204) WB #4370, Cell Signaling Technology
Anti-p44/42 MAPK (Erk1/2) WB #4695, Cell Signaling Technology
Anti-Phospho-Akt (Ser473) (D9E) WB #4060, Cell Signaling Technology
Anti-Akt WB #9272, Cell Signaling Technology
Anti-GAPDH WB #47724, Santa Cruz Biotechnology
Goat Anti-Rabbit IgG H&L (HRP) WB #6721, Abcam
Rabbit Anti-Mouse IgG H&L (HRP) WB #97046, Abcam
Goat anti-Rabbit IgG (H+L), Alexa Fluor 488 ICC # A-11008, Thermo Fisher Scientific
4.3. Human Tissue Samples and Cell Lines
Human tissue samples were obtained, with informed consent (written or verbal) provided by
the parents or guardians for the use of tumor samples in research, in accordance with the ethical
approval from the Stockholm Regional Ethical Review Board and the Karolinska University Hospital
Research Ethics Committee (approval ID 2009/1369-31/1 and 03-736). Neuroblastoma tumor tissue
was collected at the Karolinska University Hospital, snap-frozen in liquid nitrogen and stored at
−80 ◦C until further use.
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The human cell lines SK-N-AS, SK-N-SH, SK-N-DZ, SK-N-FI, SH-EP1, Kelly, SH-SY5Y,
and IMR-32 as well as THP-1, Jurkat E6.1, and U937 cells were obtained from the ATCC (American
Type Culture Collection, LGC Standards GmbH, Wesel, Germany). SK-N-BE(2) cells were purchased
from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen, Braunschweig, Germany).
The cell lines were cultivated in RPMI-1640 medium containing L-glutamine and sodium bicarbonate
(Sigma-Aldrich Norway AS, Oslo, Norway) supplemented with 10% heat-inactivated fetal bovine
serum (FBS; Thermo Fisher Scientific Inc., Waltham, MA, USA). LAN-6 cells were a kind gift from
Deborah Tweddle, Newcastle University and were grown in Iscove’s Modified Dulbecco’s Medium
(Sigma-Aldrich Norway AS, Oslo, Norway) supplemented with GlutaMAX™ and 10% heat-inactivated
FBS. All cell lines were cultivated at 37 ◦C in humidified air with 5% CO2 and mycoplasma tests
were performed regularly using the MycoAlert™ PLUS Mycoplasma Detection Kit (Lonza, Basel,
Switzerland). The identity of the human neuroblastoma cell lines was confirmed by STR-profiling
performed at the Centre of Forensic Genetics, University of Tromsø, Norway.
4.4. Immunohistochemistry (IHC)
Formalin-fixed, paraffin-embedded tissue sections were deparaffinized using xylene (VWR
International, Oslo, Norway) and a series of graded alcohols (Sigma-Aldrich Norway AS, Oslo,
Norway) followed by rehydration and washing in phosphate buffered saline (PBS, Biochrom GmbH,
Berlin, Germany). Antigen retrieval was performed in sodium citrate buffer (pH 6) in a microwave oven.
After blocking of endogenous peroxidase with 0.3% H2O2 for 15 min, unspecific antibody binding sites
were blocked with 5% BSA in PBS (AppliChem, Darmstadt, Germany) for 45 min. The sections were
incubated with the primary antibody overnight at 4 ◦C. The following day sections were thoroughly
washed in PBS and incubated with SignalStain®Boost IHC Detection Reagent, HRP, Rabbit (Cell
Signaling Technology, Leiden, Netherlands) and kept for 1 h at room temperature. Following washes
in PBS, the sections were incubated with Liquid DAB+ Substrate solution (Dako, Agilent Technologies,
Inc., Santa Clara, CA, USA). A matched isotype control was used as a control for nonspecific staining.
The sections were examined with a BX43 microscope (Olympus, Tokyo, Japan) and images were
acquired with an Olympus DP26 camera.
4.5. RNA Isolation and RT-PCR
Total RNA was isolated using the NucleoSpin®TriPrep Kit (MACHEREY-NAGEL GmbH &
Co. KG, Düren, Germany) and RNA quantity and quality was determined with a NanoDrop™
2000 spectrometer (Thermo Fisher Scientific Inc.). One µg RNA was used as input for cDNA synthesis
with the iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories AB, Oslo, Norway).
PCR was set up as a 25 µl reaction mix containing 2 µL cDNA, 12.5 µL AccuStart™ II GelTrack
PCR SuperMix (Quanta Biosciences, Gaithersburg, MD, USA), 400 nM of each primer (Sigma-Aldrich
Norway AS, Oslo, Norway) and 10.1 µL of ultra-pure H2O (Biochrom GmbH, Berlin, Germany).
The PCR run was performed in a T100™ Thermal Cycler (Bio-Rad Laboratories AB) as follows: 2 min
at 94 ◦C and 35 cycles of 94 ◦C for 20 s, 61 ◦C for 30 s and 72 ◦C for 90 s. The following intron
spanning primer sets were used: APRT (housekeeping) 5′ CCCGAGGCTTCCTCTTTGGC 3′ (sense)
and 5′ CTCCCTGCCCTTAAGCGAGG-3′ (antisense) [80], SYK 5′ CATGTCAAGGATAAGAACATCAT
AGA 3′ (sense) and 5′ AGTTCACCACGTCATAGTAGTAATT 3′ (antisense) [26], SYK L/S 5′
TTTTGGAGGCCGTCCACAAC ‘3 (sense) and 5′ ATGGGTAGGGCTTCTCTCTG 3′ (antisense) [37].
All primer sets used in this study were intron-spanning to avoid false positive signals caused by
amplification of residual traces of genomic DNA. PCR products were analyzed by gel electrophoresis.
The 2% SeaKem®LE Agarose gel (Lonza) was stained with GelRed™ (Biotium, Inc., Hayward, CA, USA)
and visualized under UV light in the BioDoc-It™ Imaging System (UVP, LLC, Upland, CA, USA).
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4.6. Immunocytochemistry (ICC) and Western Blot
Cells were grown in 8-well µ-Slide dishes (iBidi GmbH, Munich, Germany) until they reached
approximately 70% confluence. Following a brief rinse with PBS the cells were fixed with 4%
formaldehyde (Alfa Aesar, VWR International, Oslo, Norway) for 20 min. After three washes with
PBS, unspecific binding sites were blocked with 5% goat serum (Sigma-Aldrich Norway AS) in PBS
containing 0.3% Triton-X-100 (Sigma-Aldrich Norway AS) for 1 h. The cells were incubated with
primary antibodies diluted in 1% bovine serum albumin (BSA; AppliChem, Darmstadt, Germany)
in PBS containing 0.3% Triton-X-100 overnight at 4 ◦C. After three washes with PBS, the cells were
incubated with the secondary antibodies diluted in 1% bovine serum albumin in PBS containing 0.3%
Triton-X-100 for 1 h at room temperature, protected from light. Following three washes with PBS,
the nuclei were stained with Hoechst 33342 (ImmunoChemistry Technologies, LLC, Bloomington,
IN, USA) for 10 min. The cells were washed 3x with PBS and covered with Mounting Medium
for fluorescence microscopy (iBidi GmbH). Subsequently, the cells were examined using a Zeiss
LSM780 confocal microscope (Carl Zeiss AG, Oberkochen, Germany). Images were taken with the
same microscope settings (laser intensity, gain etc.) and identical image processing parameters were
applied to allow comparison between the cell lines. Western blots were performed as previously
described [81].
4.7. Immunoprecipitation (IP)
Cells were washed twice with cold PBS and lysed by addition of lysis buffer containing 50 mM
Tris-HCl (pH 8.0), 150 mM NaCl, 0.1% Triton X-100, 1 mM DTT and 1 mM EDTA (Sigma-Aldrich
Norway AS, Oslo, Norway) as well Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher
Scientific Inc.). Following sonication and centrifugation, the protein concentration was determined
using a Protein Quantification Assay (MACHEREY-NAGEL GmbH & Co. KG). A sample of the
supernatant was taken as “input control”, supplemented with NuPAGE®LDS Sample Buffer (4X)
(Thermo Fisher Scientific Inc.) as well as 100 mM DTT (AppliChem, Darmstadt, Germany) and
incubated for 10 min at 70 ◦C. Cell lysate containing approximately 800 µg protein was pre-cleared
with an irrelevant IgG2a antibody (same class as the SYK antibody used for IP) to reduce unspecific
binding. Afterwards, the samples were incubated with the anti-SYK antibody (1 µg) rotating at
4 ◦C overnight followed by incubation with 80 µl of a 50% Sepharose G beads/lysis buffer solution
(GE Healthcare, Oslo, Norway) for 1 h rotating at 4 ◦C. The beads were washed three times with
lysis buffer and two times with 50 mM Tris-HCl, pH 8.0. Afterwards, the beads were incubated in
sample buffer containing NuPAGE®LDS Sample Buffer (4×), ultrapure H2O as well as 100 mM DTT
for 10 min at 70 ◦C. The samples were subsequently used for western blot analysis.
4.8. siRNA-Mediated SYK Silencing
Two pre-designed SYK siRNAs were used in this study: ID-s13679 (siRNA 1) and ID-s13681
(siRNA 2) as well as a scramble control #1 siRNA (cat# 4392420 and 4390843, Ambion, Thermo Fisher
Scientific Inc.). Cells were seeded into 24- and 6-well plates for cell viability assay and western
blot analysis, respectively. After 24 h, the cells were transfected with the different siRNAs using
Lipofectamine RNAiMAX reagent (Thermo Fisher Scientific Inc.) according to the manufacturer’s
specifications. Briefly, cells were incubated with 5 pmol (24-well plate) or 30 pmol siRNA (6-well plate)
per well in Opti-MEM (Thermo Fisher Scientific Inc.) for 4 h followed by the removal of the transfection
mix and addition of fresh Opti-MEM. After 72 h the cell viability was assessed and cells were harvested
for western blot analysis. Densitometry was performed using Fiji software [82].
4.9. Cell Viability Assay
To assess the effect of the commercially available SYK inhibitors BAY 61-3606, R406, GS-9973
(Entospletinib) and PRT062607 alone as well as BAY61-3606 in combination with paclitaxel, cisplatin,
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doxorubicin and temozolomide on the cell viability of SH-SY5Y and SK-N-BE(2) neuroblastoma
cells the colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazodium bromide)-assay was
used [83]. The cells were seeded in 96-well plates in full growth media. As an exception, cells treated
with GS-9973 and PRT062607 were seeded in Opti-MEM to reduce cell viability variations attributed to
residual serum. After 24 h, the cells were washed once with Opti-MEM before incubation with SYK
inhibitors alone for 24 and 48 h or a combination of chemotherapeutic drugs with BAY61-3606 for
48 and 72 h. Control cells received the corresponding drug vehicle at the highest concentration present
in the drug-treated cells. BAY 61-3606 and doxorubicin were dissolved in water, R406, GS-9973,
PRT062607, and temozolomide in DMSO, paclitaxel in ethanol, and cisplatin in 0.9% saline. After 24,
48 or 72 h the MTT solution (10 µL of 5 mg MTT, Sigma-Aldrich Norway AS, per ml phosphate
buffered saline) was added to each well and incubated for additional 3 h. To facilitate formazan
crystal solubilizing, 70 µL of the solution were carefully removed from each well, 100 µL isopropanol
containing 0.04 M HCl were added and mixed thoroughly. In addition, the plates were placed on an
orbital shaker for 1 h at room temperature. The absorbance was measured with a CLARIOstar plate
reader (BMG LABTECH, Ortenberg, Germany) at 590 nm. The experiment was performed at least
three times with at least three parallels per treatment. The cell viability was calculated as the ratio of
the mean OD of treated cells over vehicle treated control cells (100% living cells). The cell viability
assay for the siRNA and SYK plasmid studies were performed in 24-well plates. The amounts of MTT
solution and acidic isopropanol were adjusted correspondingly.
4.10. Cell Signaling Study
To investigate the effect of commercially available SYK inhibitors on MAPK- and Akt- mediated
signaling SH-SY5Y cells were seeded in 6-well plates in full growth medium. The next day, the cells
were washed in Opti-MEM and treated with BAY 61-3606, R406, GS-9973 (entospletinib), PRT062607 or
corresponding vehicle controls (water for BAY 61-3606 and DMSO for R406, GS-9973, and PRT062607)
for 4 or 24 h. Following incubation, the cells were washed with PBS and harvested in RIPA Lysis
and Extraction Buffer containing Halt™ Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher
Scientific Inc.) and analyzed by western blot. Densitometry was performed using Fiji software.
Phosphorylated and total protein were normalized to their respective GAPDH loading control
(pERK/GAPDH, ERK/GAPDH, pAkt/GAPDH, Akt/GAPDH). Ratios of pERK/ERK and pAkt/Akt
were calculated using the normalized values. The respective vehicle control was set as 1 and the ratios
were calculated.
4.11. Transfection with SYK Plasmids
The following, previously described FLAG-tagged plasmids were used in this study:
pCAF1 empty expression vector, SYK wt = SYK wild type, SYK B = short SYK splice variant B, SYK
Y130E = constitutive active SYK, SYK K402R = kinase dead SYK, SYK RR42/195KK = SYK with inactive
SH2 domains [26,46]. Cells were seeded in 24- (cell viability assay) or 6-well plates (western blot) in
full growth media. The following day the cells were transfected using jetPRIME®transfection reagent
(Polyplus-transfection®, Illkirch, France) according to the provided manual (1 µg DNA per well in
a 6-well plate and 0.25 µg DNA per well in a 24-well plate). After 5 h, the media containing the
transfection mix was removed and fresh media was added. After 48 h, cell viability was determined
and cells were harvested for western blot.
4.12. Drug Combination Analysis
To determine whether the chemotherapeutic drug-SYK inhibitor combinations displayed a
synergistic or additive effect, highest single agent, response additivity and Bliss independence
calculations were performed on the cell viability data as described in [84]. Highest single agent
method proves the superiority of the drug combination compared to its single agents and was assessed
with statistical testing (two-way ANOVA). Response additivity and the Bliss Independence model
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both compares the observed drug combination effect to the expected additive effect and thereby
calculates a combination index. For Response additivity the expected additive effect is calculated as
following: E(A) + E(B) and for the Bliss Independence: E(A) + E(B) − E(A)*E(B) where E is the effect
produced by drug A and B. A combination index <0.9 was defined as synergistic, 0.9–1.1 as additive
and >1.1 as antagonistic.
4.13. Statistical Analysis
GraphPad Prism software (versions 7 and 8, GraphPad Inc., San Diego, CA, USA) was used for
statistical analysis and graph design. Fisher’s exact test was used to test the statistical significance of
the association between two categories. Two-way ANOVAs and Dunnett or Bonferroni post-tests were
applied to assess two independent variables (differences between cell lines and the effect of treatment).
Two-tailed one sample t-tests were used for the statistical analysis of the cell signaling studies.
5. Conclusions
Our findings demonstrate the presence of functional SYK in neuroblastoma tissue as well
as certain neuroblastoma cell lines and indicate that pharmacological SYK inhibition may be
a potential therapeutic approach that can be used to support conventional chemotherapy in
SYK-expressing neuroblastomas.
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Table S1. Clinical features of neuroblastoma tumors. 
 Number (%)  
Age  
<18 month 22 (52%) 
>18 month 20 (48%) 
Gender  
Female 22 (52%) 
Male 20 (48%) 
INSS Stage  
1 10 (24%) 
2 9 (21%) 
3 11 (26%) 
4 10 (24%) 
4s 2 (5%) 
MYCN amplification 10 (24%) 
1p deletion 9 (21%) 
11q deletion 3 (7%) 
17q gain 7 (17%) 
Treated tissue 13 (31%) 
Untreated tissue 26 (62%) 
Information not available 3 (7%) 
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Table 2. Cell viability of SH-SY5Y and SK-N-BE(2) after treatment with 0.8 μM BAY 61-3606, chemotherapeutic drugs or combinations of both. 
 
 SH-SY5Y SK-N-BE(2) 
Treatment 
Cell viability (%) 







Cell viability (%) 








0.8μM BAY 51.26 ± 7.83   82.4 ± 8.79   
Paclitaxel 87.71 ± 7.83   90.89 ± 7.86    
Paclitaxel + BAY 31.63 ± 2.23 <0.001 <0.001 54.61 ± 4.12 <0.001 <0.001 
Cisplatin 82.33 ± 9.01   98.94 ± 6.48   
Cisplatin + BAY 42.53 ± 2.96 <0.001 0.001 73.21 ± 5.16 <0.001 <0.001 
Doxorubicin 100.5 ± 9.59   102 ± 9.68   
Doxorubicin + BAY 49.15 ± 6.39 <0.001 >0.999 76.06 ± 8.81 <0.001 0.167 
Temozolomide 107 ± 11.17   107.7 ± 3.65   
Temozolomide + BAY 44.56 ± 3.83 <0.001 0.018 76.81 ± 3.85 <0.001 0.304 
72 h 
0.8μM BAY 45.38 ±7.87    82 ± 9.05   
Paclitaxel 84.53 ± 4.6   88.29 ± 5.19   
Paclitaxel + BAY 21.79 ± 1.28 <0.001 <0.001 38.07 ± 4.55 <0.001 <0.001 
Cisplatin 73.38 ± 5.89   73.99 ± 2.95   
Cisplatin + BAY 36.68 ± 4.99 <0.001 <0.001 61.53 ± 4.99 <0.001 <0.001 
Doxorubicin 102.2 ± 8.37    101.3 ± 7.56   
Doxorubicin + BAY 47.36 ± 6.6 <0.001 >0.999 75.18 ± 8.05 <0.001 0.008 
Temozolomide 107.7 ± 6.13   102.7 ± 4.28   
Temozolomide + BAY 40.55 ± 2.79 <0.001 0.997 80.87 ± 6.6 <0.001 >0.999 
Cell viability was measured by MTT assay after 48 and 72 h. The control was set as 100% viable cells. Data are presented as mean ± SD from at least three independent 
experiments. Using two-way ANOVA, a significant effect was observed for both treatment and between cell lines p < 0.001; Bonferroni’s multiple comparison test 
was used to evaluate differences between treatments and p values < 0.05 were considered as statistically significant.
 S3 of S6 
 
 
Figure S1. The expression of SYK is negatively correlated to MYCN but positively to MYC in neuroblastoma tissue. Gene expression data were analyzed using the 
R2 database http://r2.amc.nl. (A) Correlation of SYK and MYCN expression in neuroblastoma tissue using the SEQC dataset (n = 498). (B) Correlation of SYK and 
MYC expression in neuroblastoma tissue using the SEQC dataset (n = 498).
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Figure S2. IHC of neuroblastoma tumors negative for SYK and p-SYK. Representative images of 
immunoperoxidase labeled tumor sections negative for SYK (A) and p-SYK (B). (C) Isotype control, 
where the primary antibody was replaced with the appropriate rabbit isotype antibody. Images were 
captured at a magnification of 900. 
 
Figure S3. Inhibition of SYK decreases the cell viability of neuroblastoma cells. Cell viability was 
measured in SH-SY5Y and SK-N-BE(2) cells by MTT assay after 24 h incubation with increasing 
concentrations of the SYK inhibitors BAY 61-3606 (A) R406 (B) PRT 062607 (C) GS-9973 (D). The 
control was set as 100% viable cells. Data are presented as mean ± SD from three independent 
experiments. Using two-way ANOVA, a significant difference between cell lines and significant effect 
of the inhibitor p < 0.001 was seen. Dunnett’s multiple comparison test was used to evaluate the 
difference between vehicle treated control cells and the various inhibitor concentrations* p < 0.05  
** p< 0.01 *** p < 0.001. 
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Figure S4. Combination of chemotherapeutic drugs and the selective SYK inhibitor BAY 61-3606 
promotes PARP cleavage in neuroblastoma cells. PARP cleavage and SYK expression were 
determined by western blot after 48 h monotherapy or combinations of 0.4 µM (A) or 0.8 µM (B) BAY 
61-3606, 20 nM paclitaxel, 5 nM doxorubicin, 100 µM temozolomide and cisplatin (1 µM or 3 µM for 
SH-SY5Y and SK-N BE(2), respectively). 
 
Figure 5. The selective SYK inhibitor BAY 61-3606 enhances the effect of chemotherapeutic drugs in 
neuroblastoma cells. (A) PARP cleavage and SYK expression were determined by western blot after 
24 h monotherapy or combinations of 0.8 µM BAY 61-3606, 20 nM paclitaxel, 5 nM doxorubicin,  
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100 µM temozolomide and cisplatin (1 µM or 3 µM for SH-SY5Y and SK-N-BE(2), respectively). 
Illustration of drug combination effects for 0.8 µM BAY 61-3606 and paclitaxel (B) as well as 0.8 µM 
BAY 61-3606 and cisplatin (C) in SH-SY5Y and SK-N-BE(2) cells after 48 h and 72 h treatment. The 
continuous horizontal line indicates the effect of the highest single agent, the dashed line denotes 
expected additive effect calculated by the Bliss independence model, and the dotted line shows 
expected additive effect calculated by response additivity. Combination index (CI), given from the 
Bliss independence model and the response additivity, and effect are specified for each combination. 
 
Figure S6. ZAP70 is expressed in at least one neuroblastoma cell line. Expression data were analyzed 
using the R2 database http://r2.amc.nl. (A) The expression of ZAP70 was compared between neural 
crest (Etchevers n = 5), benign neurofibroma (Miller n = 86) and 4 neuroblastoma cohorts (cohort 1: 
Versteeg n = 88, cohort 2: Delattre n = 4, cohort 3: Hiyama n = 51, cohort 4: Lastowska n = 30). (B) RT-
PCR analysis demonstrating the expression ZAP70 mRNA in some of the examined neuroblastoma 
cell lines. Jurkat cells were used as a positive control (PC). NTC, no template control. (C) western blot 
of ZAP70 with Jurkat cells as a positive control. 
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